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1INTRODUCTION 
End-stage renal disease (ESRD) is a public health problem. The incidence of 
ESRD is increasing worldwide at an annual growth rate of 8%, far in excess of the 
population growth rate of 1.3% (1). The number of elderly ESRD patients (defined 
as aged > 65 years) keeps growing rapidly. According to recent data from the Dutch 
renal replacement system (REgistratie NIerfunktievervanging NEderland, RENINE), 
the number of elderly ESRD patients receiving renal replacement therapy (RRT, i.e., 
hemodialysis and peritoneal dialysis) almost doubled from 2005 to 2015 (https://
www.renine.nl/). As a group, the elderly have a higher prevalence of comorbidities 
including serious infections, which reduce life expectancy and impaired quality of life 
(2, 3). In the United states, 10% of patients of 65–79 years of age die within the first 
3 months after dialysis initiation and the 1-year survival rate after dialysis initiation for 
all patients of at least 80 years is 54% (2). RRT also includes  kidney transplantation 
(KT) which offers patients a better 5-year life expectancy than dialysis in elderly 
ESRD patients (4). All kidney transplant recipients including these elderly patients 
are on standard immunosuppression to prevent rejection of the transplanted organ 
(5).
Immune status of ESRD patients 
Loss of renal function causes retention of uremic toxins and cytokines, leading to 
increased oxidative stress and inflammatory cytokines (6). This contributes to the 
pro-inflammatory environment in ESRD patients (7), which is marked by chronic 
immune deficiency and systemic inflammation (8). Immune deficiency leads to a 
decreased vaccination efficacy (9-12),  an increased susceptibility for infection (3, 
13, 14) and a higher risk for developing tumors (15-18) while systemic inflammation 
contributes to atherosclerosis and cardiovascular disease (1, 19, 20). Together these 
abnormalities account for the large proportion of morbidity and mortality in ESRD 
patients (21, 22). 
T cells represent a major component of adaptive immune system and play a central 
part in cell-mediated immunity. T cells develop after clonal T cell receptor (TCR) 
selection in the thymus. Upon emigrating the thymus, naive T cells carry specific 
TCR that recognise epitopes. In response to corresponding antigens, multiple signal 
pathways induce naive T cells to proliferate and differentiate into effector cells. The 
majority of effector cells migrate to peripheral tissues and inflamed sites to facilitate 
destruction of infected targets (23, 24). Following antigen clearance, most of the 
effector cells die and only a small pool of T cells ultimately remains as long-lived 
memory T cells (25). Recently, the concept of premature immunological ageing has 
proposed/introduced to explain the uremia-associated defective T cell-mediated 
immune system (26, 27). The immunological age of ESRD patients is increased by 
20-30 years compared with the chronological age-matched healthy individuals (HI), 
based on less thymic output, altered T cell composition towards a more differentiated 
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phenotype and shorter telomeres (28). A proper in depth understanding of the 
uremia-induced defective T cell-mediated immune system is warranted to facilitate 
individualized immunosuppressive regimens to prevent over-immunosuppression 
and  its associated complications.
The ageing immune system
Ageing is associated with a decline in immune function and affects various cells types 
of both the innate and adaptive immune system(29). The decline in T cell number and 
function appear to be key features of immune cell ageing. This is due to a decreased 
capacity of aged hematopoietic stem cells to generate lymphoid progenitor cells, 
from which T cells originate, and an age-related atrophy of the thymus, in which T 
cells develop further (30-32). During ageing, naive T cell number, T cell receptor Vβ 
-repertoire diversity, expression of co-stimulatory molecules and proliferative capacity 
of T cells decrease (33-36); in contrast, numbers of memory and effector T cells 
increase, clones of effector T cells expand (33, 34) and especially an upregulation of 
the low-grade chronic systemic pro-inflammation occurs (37). It is characterized by 
raised levels of pro-inflammatory cytokines interleukin (IL)-1, IL-6 and tumor necrosis 
factor (TNF) (38). This age-related inflammation (“inflammageing”) is supposed to be 
caused by a cumulative lifetime exposure to antigenic load and environmental free 
radicals (39). This induces inflammatory responses, tissue damage and production 
of reactive oxygen species. Then consequent oxidative damage as well as an 
additional release of pro-inflammatory cytokines occurs (40). This results in a vicious 
cycle, driving immune system remodeling and favoring a chronic pro-inflammatory 
state (37). Age-related changes of the immune system contribute to the increased 
susceptibility of elderly persons to infectious diseases, a decline in vaccination 
efficacy,  and an increased risk for development of autoimmune diseases and cancer 
(41-45). 
Traditional T-cell ageing parameters
Several assays have already been used to assess/evaluate T-cell ageing. Below the 
main features of T-cell ageing are described as well as their corresponding assays 
for evaluating these T-cell ageing characteristics.
Thymic output
One of the most important features of ageing of T cells is a consequence of involution 
of the thymus, leading to a decline in functional thymic tissue with increasing age. 
As a result of thymic involution, thymic output declines with increasing age (46-
48). T cell receptor excision circle (TREC), is a product formed upon TCR gene 
rearrangement during intrathymic T cell maturation. These TRECs are not replicated 
during T cell proliferation and only passed on to one daughter cell (49). TREC 
content can be measured using qPCR (50). Another method for evaluating thymic 
output is by determining frequencies of recent thymic emigrants within the circulation 
by flow cytometry. CD31 (platelet/endothelial cell adhesion molecule-1, PECAM-1) 
is expressed on a variety of cell types, including T cells (51). Naive T cells that have 
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recently left the thymus co-express CD31 and possess the highest TREC content 
(52, 53). With increasing age, a decrease in absolute counts and frequencies of 
CD31-expressing naive T cells is observed (46, 47). Thus measuring both TREC-
content and frequencies or absolute numbers of CD31-expressing naive T cells can 
be used to quantify thymic output (48, 54, 55). 
T cell differentiation status 
Another characteristic feature of T-cell ageing is the shift occurring from naive to 
memory T cells, the T cell differentiation status can be assessed by fl ow cytometry. As 
shown in Fig. 1, elderly people display a decline in naive T cell number in peripheral 
blood; in contrast, the proportion of highly differentiated memory T cells increases 
markedly (56-58).  Naive and memory T cells within the peripheral blood can be 
distinguished based on CD45RO (isoform of CD45 expressed by memory T cells) 
and CCR7 (C-C motif receptor 7, a chemokine receptor facilitating T cells homing 
to lymph nodes) expression (Fig. 1). Naive T cells are CD45RO-CCR7+. Central 
memory (CM) T cells (CD45RO+ CCR7+) have the potential to home to secondary 
lymphoid tissues, produce high amounts of interleukin (IL)-2 but low levels of other 
effector cytokines (e.g. IL-4, IL-5 and IFNγ) (59); while effector memory (EM) T cells 
have rapid effector function and potential to home to peripheral tissues, produce high 
levels of IL-4 and IL-5 (CD4+ T cells only), and/or IFN-γ (both CD4+ and CD8+ T cells), 
and have granules containing perforin and granzyme B for immediate cytotoxicity 
(part of CD4+ T cells and CD8+ T cells) (59). Terminally differentiated effector memory 
CD45RA+ (EMRA, CD45RO-CC7-) T cells are generally negative for CD28 (a T cell 
co-stimulatory molecule that with increasing differentiation of T cells gets lost from 
the cell surface) (60). CD4+ CD28- T cells are highly cytotoxic as they secrete large 
amounts of IFN-γ, and possess  perforin- and granzyme B-containing granules, (61, 
62). Both CD4+CD28- and CD8+CD28- T cells represent a heterogeneous population 
                  
Fig. 1. Age-related effects on CD4+ T cell subsets from healthy individuals (HI). Naive, 
central memory (CM), effector memory (EM), terminally differentiated effector memory 
(EMRA) can be distinguished based on differential expression of CD45RO and CCR7. A shift 
from naive T cell subset towards memory subset occurs during ageing. 
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composed of various functionally competing (cytotoxic and immunosuppressive) 
subsets (63). The cytotoxic CD8+CD28- T cells also produce high amounts of  IFN-γ 
and tumor necrosis factor-α (TNF-α) (64), while immunosuppressive CD8+CD28- T 
cell subsets secrete IL-10 (65). Accumulation of CD28- T cells  may be related to 
anti-viral immunity directed to for example cytomegalovirus (CMV) (66, 67), or self-
antigen directed immune responses (68, 69).
Telomere length 
Loss of telomere length, associated with proliferative history of T cells, occurs with 
increasing age and can be visualized using flow cytometry. Telomere length differs 
between naive and memory T cells (70). Telomeres are the repetitive nucleotides 
at the ends of chromosomes, which protects the end of the chromosome from 
deterioration or from fusion with neighboring chromosomes (70). In the absence of 
a compensatory mechanism, dividing cells undergo gradual telomere erosion until 
a critical degree of shortening results in chromosomal abnormalities and cell death 
or senescence (71). Assessment of telomere length can be used as a reflection of 
replicative history. Elderly individuals with shorter telomeres have a much higher rate 
of mortality than those with longer telomeres (72). 
New approaches to evaluate the T cell immune status in more detail
In recent years, new assays have become available, allowing for a more detailed 
analysis of the T cell immune status,  evaluating phenotypic aspects, like TCR 
-repertoire diversity as well as functional characteristics (signaling pathways) upon 
TCR-mediated activation of T cells and relating this to T-cell ageing.
T cell receptor -repertoire diversity 
A diverse (polyclonal) T cell receptor (TCR) -repertoire capable of recognizing 
a broad range of foreign antigens is key to an effective T-cell-mediated immune 
response (73). Contraction of TCR Vβ-repertoire has been reported to occur during 
ageing (74). Naive T cells expressing CD31 possess the broadest TCR -repertoire 
(i.e. polyclonal TCR -repertoire) (75). Memory T cells that develop upon encountering 
of an antigen have a repertoire that is skewed towards particular specificities (76) 
(Fig. 2). 
Most TCRs consist of an α and a β chain and each chain is composed of a variable 
(V) region and a constant (C) region. In the thymus, the V region of the TCR α and 
β chain is generated by random gene rearrangement of variable (V) and joining (J) 
genes or V, diversity (D) and J genes, respectively. The TCR Vβ-repertoire can be 
assessed using several approaches such as gene scan spectratyping via a DNA 
based PCR (77), Vβ family phenotyping by flow cytometry (78, 79), and clonal 
diversity via next generation sequencing (NGS) (80). Gene scan spectratyping of 
the TCR Vβ-repertoire is a qualitative measurement. Both flow cytometry and NGS 
allow for a more quantitative evaluation of TCR Vβ-repertoire. As NGS is relatively 
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labor-intensive and requires sorting of highly pure T cells or their subsets, many 
researchers prefer to use fl ow cytometry.  Flow cytometry allows for measuring 
percentages of TCR Vβ families at the T cell subset level obviating the need for cell 
sorting. Tracking alloreactive TCR-repertoire prior to and following KT may provide 
a good biomarker predicting rejection and drug related side-effects leading to adapt 
the immunosuppressive regimen, prevent graft dysfunction, and improved graft 
survival (81).  
The TCR Vβ-repertoire diversity might also be affected by chronic antigenic 
stimulation (82-84). For example, CMV latency may also induce contraction of the 
TCR Vβ-repertoire as it results in a vast expansion of CMV-specifi c T cells exceeding 
4% of CD8+ T cells in immunocompetent donors (85) and these anti-CMV T cells 
clones are stably maintained for 5 years (86) (Fig. 2). 
 
Fig. 2. Age-related effects on TCR -repertoire diversity in healthy individuals (HI). The 
TCR -repertoire of naive and memory T cells  changes with age (circle size indicates clonal 
size). A diverse naive repertoire has been established in the young adult (left). The naive 
compartment decreases in  size and TCR diversity in elderly life (right). T cell clones specifi c 
for CMV (red circles) dominate the repertoire in the elderly and contribute to the contraction 
of diversity in the memory compartment. Adapted from Jörg J Goronzy & Cornelia M Weyand 
Nature Immunology 2013.
MAPK pathway during T cell activation (signal transduction)
T-cell ageing is associated with defective signaling pathways (87, 88). The 
mitogen-activated protein kinase (MAPK) pathway is one of the major pathways 
induced upon TCR stimulation (89) (Fig. 3). Activation of MAPK is mediated by 
phosphorylation of MAPK and downregulated by MAPK phosphatase resulting in 
inactive MAPK (90). In particular, the extracellular signal-regulated kinase (ERK) 
pathway is one of the important MAPK pathways. ERK activity controls the positive 
feedback loop in the TCR-induced activation cascade (91, 92), reduces sensitivity 
of cells to apoptosis and promotes T cell proliferation (93). Reduced ERK activity 
affects TCR-mediated signal strength, T cell activation and IL-2 production (94, 95). 
Dual-specifi city phosphate (DUSP) 6 is a cytoplasmic phosphatase with substrate 
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specificity to dephosphorylate pERK and decreased phosphorylation of ERK can 
be overcome by inhibiting DUSP6 (96). Recently it has been shown that decreased 
ERK phosphorylation in naive CD4+ T cells from elderly HI was associated with a 
lower sensitivity to TCR-mediated signals and more time to build up the required 
signaling strength compared to those from young HI (91). DUSP6 is one of the 
important regulators of the TCR activation threshold that controls the initial ERK 
phosphorylation and expression of DUSP6 increases with age (91) (Fig. 4). P38 is 
another pivotal protein in the MAPK pathway (97). Highly differentiated CD27-CD28-
CD4+ T cells have higher phosphorylation of P38 compared with CD27+CD28+ and 
CD27-CD28+CD4+ T cells and this could be driven by intracellular changes such as 
DNA-damage (98, 99). Phosphorylation of signaling proteins upon T cell activation 
may be used to  monitor the immune activation status in KT patients prior to and 
following transplantation (100). 
                                      
Fig. 3.  Mitogen-activated protein kinase (MAPK) pathway after T cell activation.  Anti-
CD3 (T cell receptor) and anti-CD28 (co-stimulator) stimulation promotes a number of 
signaling cascades including MAPK. Extracellular signal-regulated kinase (ERK) and P38 
belong to MAPK pathway and their activation is mediated by phosphorylation. Dual specificity 
phosphate (DUSP6) is a phosphatase that inhibits ERK activation. DNA damage can also 
cause p38 phosphorylation especially in highly differentiated T cells.    
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Fig. 4. T cell receptor (TCR) desensitization in the elderly. Phosphorylated ERK (pERK) is 
associated with TCR sensitivity to TCR-mediated signals. DUSP6 expression increases with 
age, resulting in a decline in pERK and desensitization of TCR-mediated activation. Adapted 
from Jörg J Goronzy & Cornelia M Weyand Nature Immunology 2013.
Cytomegalovirus infection in ESRD patients 
Depending on ethnicity and social-economic background, 65-100% of  elderly ESRD 
patients are CMV seropositive (101, 102). CMV may have a substantial impact on 
the composition and function of circulating T cells, resembling features of ageing 
of the immune system. Studies have shown that CMV significantly expands the 
number of circulating CD8+ T cells by almost twofold (103), promotes emergence of 
highly differentiated T cell subsets (104) and may decrease T cell telomere length 
(105) in immune competent individuals. In young to middle-aged ESRD patients, 
the additional effects of CMV latency on T cell ageing parameters were modest and 
mainly confined to CD8+ T cells (106). 
An infection with CMV is also one of the most common complications after kidney 
transplantation. In kidney transplant recipients, CMV infection and disease have been 
reported in 8-31% and 8% respectively (107), posing a critical challenge on both 
graft and patient survival (108, 109). In clinical practice, anti-CMV immunoglobulin 
(Ig) G is used for immune-risk stratification. CMV IgG-seronegative ESRD patients 
receiving kidneys from CMV IgG-seropositive donors are at high risk to develop 
CMV infection, but still a considerable proportion (30%-40%) of this group does not 
experience a CMV infection (110). CMV-specific T cell responses play an important 
role in controlling viral infection.  Furthermore, the production of neutralizing 
antibodies by CMV specific B-cells/plasma blasts depends on adequate help from 
CMV-specific CD4+ T cells (111-113). Effective cytotoxic CD8+ T cell (CTL) responses 
also contribute to control CMV infections (114, 115). 
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The aim and outline of this thesis 
Uremia-associated premature T-cell ageing contributes to a defective T cell-mediated 
immune system in ESRD patients.  A comprehensive more in depth evaluation of 
defective T cell-mediated immune system, taking functional aspects into account, 
in ESRD patients is crucial to identify patients at risk for infections, virus-related 
cancers, and decreased vaccination efficacy and allograft rejection. In this thesis, a 
more detailed assessment of the defective T-cell mediated immune system, studying 
both phenotypic as well as functional aspects, in ESRD patients is described. Special 
emphasis is put on the increasing population of elderly ESRD patients.
   
In chapter 1, the concept of several T-cell ageing parameters and the role of CMV 
infection in ESRD patients are introduced. Studies with respect to the defective T-cell 
mediated immune system in the rapidly growing elderly ESRD population are limited, 
hence in chapter 2, we evaluate the effect of uremia and CMV on T cells focusing on 
elderly ESRD patients to test whether the uremia-induced premature ageing remains 
in the elderly population. Although the composition of the circulating T cells may be 
profoundly altered in ESRD patients, it is not known whether this invariably leads to a 
change in TCR Vβ- repertoire diversity, therefore, in chapter 3, we measure the TCR 
Vβ-repertoire diversity in a qualitative way using DNA-based spectratyping in ESRD 
patients, also assessing the contribution of CMV and age on TCR Vβ-repertoire 
diversity. For a more detailed view of this ESRD-related effect on TCR Vβ- repertoire 
diversity, a quantitative measure is needed of the TCR Vβ-repertoire within T cell 
subsets, also taking into account effects of age and CMV. Therefore, we used a flow 
cytometry-based approach and antibodies to 24 Vβ families as described in chapter 
4. Upon unraveling the uremia-associated changes of T cell phenotype and DNA, 
described in previous chapters, we are also interested in the uremia-associated 
effects on more downstream events upon TCR-mediated activation of T cells (signal 
transduction pathways). In chapter 5, we examine the MAPK pathway including 
ERK and P38 phosphorylation following TCR stimulation and the role of DUSP6 
inhibition on ERK phosphorylation in ESRD patients. Assessing CMV-specific T 
cell-immunity may allow for a more accurate characterization of the immune risk 
for a CMV-infection in ESRD patients before transplantation. In chapter 6, CMV-
specific T cell-immunity is determined in CMV IgG-seronegative renal transplant 
recipients before transplantation and clinical relevance with respect to CMV viremia 
after transplantation is assessed. Finally in chapter 7, we summarize and discuss in 
depth the work of this thesis.
General introduction and outline of the thesis
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ABSTRACT
The number of elderly patients with end-stage renal disease (ESRD) has significantly 
increased over the last decade. Elderly ESRD patients are vulnerable to infectious 
complications because of an aged immune system. Additional immunological ageing 
effects may be derived from the uremic environment and cytomegalovirus (CMV) 
latency. Elderly patients may be affected by these factors in particular, but data 
in this age group are limited. To assess the degree of immunological ageing and 
proliferative capacity of T lymphocytes, 49 elderly ESRD patients (defined as aged 
≥65 years) on the renal transplantation waiting list were recruited and compared to 
44 elderly HI, matched for age and CMV serostatus. CMV latency was associated 
with more highly differentiated CD4+ and CD8+ T cells in both elderly HI and patients. 
Elderly CMV-seropositive ESRD patients showed a substantial reduction in the 
number of naive CD4+ and CD8+ T cells compared with age- and CMV-serostatus-
matched HI. Elderly ESRD patients also showed significantly decreased numbers 
of central memory CD4+ and CD8+ T cells compared with HI, independent of CMV 
serostatus. In addition, thymic output and relative telomere length of both CD4+ 
and CD8+ T cells were decreased in CMV-seropositive ESRD patients compared 
with HI. The proliferative capacity of T cells was similar for patients and HI. Elderly 
ESRD patients have an advanced aged T cell compartment when compared to age-
matched healthy controls, which is mainly driven by CMV latency.  
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INTRODUCTION
The number of elderly patients (defined as aged ≥65 years) suffering from end-
stage renal disease (ESRD) keeps growing rapidly (1).  In the USA, during 1994-
2004 patients aged more than 75 years increased by 67% compared to 24% for 
those aged between 5 and 74 years (2). According to recent data from the Dutch 
renal replacement system (REgistratie NIerfunktievervanging NEderland, RENINE), 
the number of elderly ESRD patients (aged >65 years) receiving renal replacement 
therapy (RRT) almost doubled from 2005 to 2015 (https://www.renine.nl/). Importantly, 
elderly ESRD patients are at high risk of developing serious infections (2-4) and show 
a poor response to vaccination (5, 6). Also after successful kidney transplantation, 
elderly ESRD patients are more susceptible to infectious complications (7, 8). T 
cells are key players in the immune response to foreign antigens, such as those 
encountered during an infection and after vaccination. 
With advanced ageing, the T-cell mediated immune system undergoes dramatic 
changes (9) and loss of renal function is associated  with a defective T-cell mediated 
immune system(10). We have demonstrated previously that ESRD-related 
defects in T cell-mediated immunity may be related to premature T-cell ageing, as 
assessment of T cell receptor excision circle (TREC) content, T cell differentiation 
status and relative telomere length revealed a discrepancy of 15-20 years between 
the immunological age of the patients’ T cells and their chronological age(11, 12).
Cytomegalovirus (CMV) may have a substantial impact on the composition and 
function of circulating T cells. Recent studies have shown that CMV latency expands 
the number of circulating CD8 T cells significantly by almost twofold (13), promotes 
the emergence of highly differentiated T cell subsets (14) and may decrease T cell 
telomere length (15) in immune competent individuals. Depending on the ethnicity, 
65-100% of all elderly ESRD patients are CMV-seropositive (16, 17).  In young to 
middle-aged ESRD patients, the additional effects of CMV latency on T cell ageing 
parameters are modest and confined mainly to the CD8+  T cells (18).
However, little is known with respect to the impact of ESRD and CMV latency on the 
immunological age of the peripheral T cell compartment in elderly (≥65 years of age) 
ESRD patients. In this study, we show that CMV latency appears to be a dominant 
factor for the observed advanced immunological ageing of T cells from elderly ESRD 
patients as compared to healthy age-matched individuals.
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MATERIALS AND METHODS
Study population
Forty-nine stable elderly (defined as ≥65 years) ESRD patients, defined as having a 
glomerular filtration rate of ≤15 ml/min with or without renal replacement therapy and 
44 elderly healthy individuals (HI) were included (study population characteristics are 
described in Table 1) from 1st November 2010 to 1st October 2013 at the outpatient 
clinic. Patients with any clinical or laboratory evidence of acute bacterial or viral 
infection, malignancy, immunosuppressive drugs treatment within 28 days prior to 
transplantation (except glucocorticoids) were excluded. Lithium-heparinized blood 
was drawn of ESRD patients and healthy kidney donors. All individuals included gave 
informed consent and the local medical ethical committee approved the study (METC 
number: 2012–022), which was conducted according to the principles of Declaration 
of Helsinki and in compliance with International Conference on Harmonization/Good 
Clinical Practice regulations.
Table 1. Clinical and demographic characteristics of patients with end-stage renal disease 
(ESRD) and healthy individuals (HI)
 ESRD patients HI P-value
Number of individuals 49 44
Age( years; median with range) 68; 65–79 70; 65–89 n.s.
Male (%) 69.4 45.5 0.022
CMV-IgG serostatus (% seropositive) 59.2 63.6 n.s.
Patients on dialysis (%) 55.1
        Haemodialysis (%) 76.9
        Peritoneal dialysis (%) 19.2
        Haemodialysis followed peritoneal     
        dialysis(%)
3.8
Patients with renal transplant history (%) 2.0
Underlying kidney disease
        Nephrosclerosis/atherosclerosis/
hypertensive nephropathy
28.6
        Primary glomerulopathy 10.2
        Diabetic nephropathy 28.6
        Reflux nephropathy 8.1
        Polycystic kidney disease 18.4
        Other 6.1   
CMV = cytomegalovirus; Ig = immunoglobulin; n.s. = not significant. 
Circulating T cell numbers and their differentiation status
Freshly drawn peripheral blood samples from 49 ESRD patients and 44 HI were 
stained and acquired on a fluorescence activated cell sorter (FACS) Canto II flow 
cytometer (BD Biosciences, Erembodegem, Belgium) to determine both absolute 
numbers and frequencies of the different T cell subsets, as described previously (11, 
19) . Data were analyzed using FACS Diva software version 6.1.2 (BD Biosciences). 
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PBMCs isolation, cell culture and proliferation analysis
PBMCs from 11 elderly ESRD patients and 11 elderly CMV serostatus-matched HI 
were isolated from peripheral blood, as described previously (20). These PBMCs 
(responder cells) were labeled with carboxyfluorescein diacetate succinimidyl 
ester (CFSE), according to manufacturer’s instructions (Thermo Fisher scientific, 
Waltham, MA, USA), and then co-cultured in triplicate at 5 × 104/well with allogeneic 
PBMCs, autologous PBMCs (both irradiated at 40 gray) at a 1:1 ratio or with 5 µg/
ml phytohaemagglutinin (PHA) (Sigma-Aldrich, St. Louis, MO, USA) as a positive 
control for 6 days. Culture medium consisted of RPMI 1640 with GlutaMAX, 10% 
heat-inactivated pooled human serum and 1% penicillin and streptomycin. After 6 
days, PBMCs were harvested, pooled, washed and stained with AmCyan-labeled 
CD3 (BD Pharmingen, Erembodegem, Belgium), Pacific Blue-labeled CD4 (BD), 
allophycocyanin-cyanin 7 (APC-Cy7)-labeled CD8 (BD); phycoerythin (PE)-
labeled CD28 (BD), APC-labeled CD45RO (BD), and PE-Cy7-labeled CCR7 (R&D 
systems, Uithoorn, the Netherlands) antibodies, and a live-dead marker ViaProbe 
(7-aminoactinomycin D, BD). Data were acquired on a FACSCanto II flow cytometer 
(BD). Percentages of proliferating cells were analyzed by Kaluza® software (Beckman 
Coulter, Brea, CA, USA). Kinetics of proliferation and precursor frequencies (PF), the 
latter defined as the proportion of cells present in the original sample being able 
to respond to the stimulus, were analyzed by Modfit LT® software (Verity Software 
House, Topsham, ME, USA). 
DNA isolation and TREC analysis 
DNA was isolated from PMBCs by QIAamp DNA Mini QIAcube Kit, according to 
manufacturer’s instructions (Qiagen, Hiden, Germany). TREC content was measured 
by TaqMan quantitative PCR as previously described (21). The ΔCt was calculated 
by subtracting the Ct value for the albumin PCR from that of the TREC PCR. One/
ΔCt was used to describe the TREC content of a sample. A Ct value greater than 
41 for the TREC PCR was interpreted as the sample having an undetectable TREC 
content.
Telomere length assay
Flow fluorescent in-situ hybridization was performed to determine the relative 
telomere length (RTL) of CD4+ and CD8+ T cells, as described previously (11, 19).  
Statistical analyses
Statistical analyses were performed using SPSS version 20 (IBM, Chicago, IL, USA) 
and GraphPad Prism version 6 (GraphPad Software, La Jolla, CA, USA). Categorical 
variables were compared using the χ2 test or Fisher’s exact test. Continuous variables 
were compared using t-test or Mann-Whitney U-test. All reported P-values are two-
sided and were considered statistically significant when P<0.05.
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RESULTS
Both CMV and ESRD accelerate the ageing phenotype of T cells 
The demographic and clinical characteristics of the study population are given in 
Table 1. Forty-nine ESRD patients (aged 65–79 years) and 44 age-matched HI 
(aged 65-89 years) were recruited in this study. The elderly ESRD patients consisted 
of a higher proportion (69.4%, P=0.02) of males compared to the HI (45.5%). 
Approximately half of the ESRD patients received RRT. CMV-immunoglobulin (Ig)
G seropositivity was present in 59.2% of elderly ESRD patients and in 63.6% of HI 
in this study. 
The effect of CMV on absolute T cell numbers and composition was confi ned mainly 
to the memory compartment. Elderly CMV seropositive ESRD patients, but not HI, 
had signifi cantly more total memory CD4+ T cells compared to their CMV seronegative 
counterparts (Fig. 1a). Within the CD4+ memory compartment, CMV seropositivity 
was associated with increased numbers of EM (Fig. 1e) and CD4+CD28- T cells in 
elderly ESRD patients (Fig. 1g). The association of CMV seropositivity with higher 
numbers of CD4+CD28- T cells was also observed in elderly HI (Fig. 1g). Elderly CMV 
seropositive ESRD patients had lower numbers of total (Fig. 1a) and naive (Fig. 1b) 
	
Fig. 1. Absolute numbers of circulating CD4+ T cell subsets in elderly healthy individuals (HI) 
and elderly end-stage renal disease (ESRD) patients. Numbers of (a) CD4+, (b) CD4+ naive, 
(c) CD4+ memory, (d) CD4+ central memory (CM), (e) CD4+ effector memory (EM) and (f) CD4+ 
highly differentiated effector memory (EMRA) and (g) CD28- CD4+ T cells in HI [n = 45; n = 16 
cytomegalovirus (CMV) seronegative and n = 29 CMV seropositive] and ESRD patients (n = 
49; n = 20 CMV seronegative and n = 29 CMV seropositive) was determined and dissected for 
CMV serostatus. Data are given as median with interquartile range. The open bars represent 
the CMV seronegative individuals and the closed bars represent CMV seropositive ones. 
P-value: * <0.05; ns: not signifi cant.
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CD4+ T cells than CMV seropositive HI. Moreover, central memory (CM) CD4+ T 
cells were lower in elderly ESRD patients compared to HI, irrespective of their CMV 
serostatus (Fig. 1d). Frequencies of T cell subsets also indicated CMV latency and 
ESRD to induce a more differentiated  T cell compartment. CMV seropositivity was 
associated with lower percentages of CD4+ T cells (Supporting information, Fig. S1a) 
and higher percentages of CD4+CD28- T cells (Supporting information, Fig. S1g). 
Percentages of naive CD4+ T cells were lower in CMV seropositive compared with 
CMV seronegative ESRD patients (Supporting information, Fig. S1b) and within the 
memory compartment, higher percentages of EM were observed in CMV seropositive 
ESRD patients compared with CMV seronegative patients (Supporting information, 
Fig. S1e). In agreement with the absolute number of T cells, the differences of T cell 
differentiation analyzed as percentage between elderly ESRD patients and HI were 
observed in the CMV seropositive group. Within CMV seropositive group, ESRD 
patients had lower percentages of naive CD4+ T cells (Supporting information, 
Fig. S1b) and higher percentages of EM CD4+ T cells compared to HI (Supporting 
information, Fig. S1e).   
Within the CD8+  T cell compartment, CMV latency induced a strong increase in 
total numbers of CD8+ T cells of both elderly ESRD patients as well as HI.  The 
median CD8+ T cell number in CMV seropositive ESRD patients amounted to 
	
Fig. 2. Absolute numbers of circulating of CD8+ T cell subsets in elderly healthy individuals 
(HI) and elderly end-stage renal disease (ESRD) patients. Numbers of (a) CD8+, (b) CD8+ 
naive, (c) CD8+ memory, (d) CD8+ central memory (CM), (e) CD8+ effector memory (EM) and 
(f) CD8+ highly differentiated effector memory (EMRA) and (g) CD28- CD8+ T cells in HI [ n 
= 45; n = 16 cytomegalovirus (CMV) seronegative and n = 29 CMV seropositive] and ESRD 
patients ( n = 49; n = 20 CMV seronegative and n = 29 CMV seropositive)  were determined 
and dissected for CMV serostatus.  Data are given as median with interquartile range. The 
open bars represent the CMV seronegative individuals and the closed bars represent of CMV 
seropositive ones.  P-value: * <0.05; **< 0.01; ns: not signifi cant.
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373 cells/µl, which was a >1.5-fold increase compared to the median of CD8+ in 
CMV seronegative patients (214 cells/µl, P<0.001 ) (Fig. 2a). A more than two-fold 
increase in numbers of CD8+  T cells was noted for CMV seropositive HI compared 
to CMV seronegative HI (476 cells/µl versus 217 cells/µl, P<0.001) (Fig. 2a). The 
increase in CD8+ T cells induced by CMV was due mainly to an increase in memory 
CD8+ T cells in both elderly ESRD patients and HI (Fig. 2c). Within the memory 
compartment, the number of EM was signifi cantly higher in CMV seropositive HI 
compared to CMV seronegative HI, and a similar trend was found in patients (Fig. 
2e). Increased numbers of highly differentiated T cell subsets including EMRA and 
CD8+CD28- were observed in both elderly ESRD patients and HI (Fig. 2f,g). Similar 
to the CD4+ T cell compartment, elderly CMV seropositive ESRD patients also had 
signifi cant lower numbers of naive CD8+ T cells when compared to CMV serostatus-
matched HI. In addition, also within the CD8+ T cell compartment, lower numbers of 
CM CD8+ T cells were observed, irrespective of CMV serostatus when comparing 
elderly ESRD patients to HI. Comparison of frequencies of CD8+ T cell subsets, 
revealed CMV seropositivity to be associated with higher frequencies of total CD8+, 
EMRA and CD28-CD8+ T cells (Supporting information, Fig.S2a,f,g, respectively) and 
lower frequencies of CM CD8+ T cells (Supporting information, Fig. S2d). In addition, 
percentages of naive CD8+ T cells were lower in CMV seropositive compared with 
CMV seronegative ESRD patients (Supporting information, Fig. S2b). Furthermore, 
higher frequencies of total memory (Supporting information, Fig. S2c), and within 
this lower frequencies of EM CD8+ T cells (Supporting information, Fig. S2e) were 
noted. Within the CMV seropositive group, ESRD patients had higher percentages 
of total, EMRA and CD28-CD8+ T cells than HI (Supporting information, Fig.2a, f, g, 
respectively) and lower frequencies of CM CD8+ T cells (Supporting information, Fig. 
	
Fig. 3. T cell receptor excision circle (TREC) content and CD31- expressing naive CD4+ 
and CD8+ T cells in elderly healthy individuals (HI) and end- stage renal disease (ESRD) 
patients. The (a) TREC content (HI: n = 39; ESRD patients: n = 43) and absolute number 
of CD31-expressing naive (b) CD4+ and (c) CD8+ T cells (HI: n = 44; ESRD patients: n = 
49) in elderly HI and ESRD patients was determined and dissected for cytomegalovirus 
(CMV) serostatus (open bars represent CMV seronegative and closed bars represent CMV 
seropositive individuals). Data are given as median with interquartile range. P-value: *<0.05; 
ns: not signifi cant.
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S2d). Both RRT (Supporting information, Table S1) and gender (data not shown) did 
not affect numbers of circulating T cell subsets in these elderly ESRD patients. 
Lower thymic output in CMV seropositive elderly ESRD patients 
TREC content was comparable for CMV seronegative and CMV seropositive ESRD 
patients or HI (Fig. 3a), confi rming the idea that CMV effects are more limited to the 
memory compartment. Interestingly, in 4.6% and 10.2% of the elderly ESRD patients 
and healthy individuals respectively, no DNA encoding for TREC was detected in 
the PCR assay, which could be related to the lower contribution of the thymus to 
the naive T cell pool at this age. Of note, in those cases in which DNA encoding for 
TRECs was detected, a signifi cant (P = 0.046) decrease was observed for TREC 
content in elderly CMV seropositive but not CMV seronegative ESRD patients 
compared to CMV serostatus-matched HI (Fig. 3a). In agreement with this, a lower 
number of recent thymic emigrants, defi ned as CD31-expressing naive CD4+ (Fig. 
3b: 88 cells/µl versus 146 cells/µl) and CD8+ T cells (Fig. 3c: 35 cells/µl versus 48 
cells/µl), was observed in elderly CMV seropositive ESRD patients compared to 
CMV serostatus-matched HI. Thymic output as measured by TREC content and 
CD31-expressing naive T cells was not infl uenced by RRT (Supporting information, 
Table S1) and gender (data not shown).
Enhanced telomere attrition in CMV-seropositive elderly ESRD patients
RTL was not signifi cantly different comparing CMV seropositive ESRD patients or 
HI to their CMV seronegative counterparts. CMV seropositive, but not seronegative, 
elderly ESRD patients had shorter telomeres within CD4+ (Fig. 4a, P<0.001) and 
CD8+ (Fig. 4b, P<0.001) T cells than CMV serostatus-matched HI. The median RTL 
of CMV seropositive ESRD patients amounted to 9.0% and 9.1% for CD4+ and CD8+ 
	
Fig. 4. Relative telomere length (RTL) of CD4+ and CD8+ T cells in elderly healthy individuals 
(HI) and elderly end-stage renal disease (ESRD) patients. The RTL of (a) CD4+ and (b) 
CD8+ T cells was determined in circulating T cells of HI [ n=36; n=14 cytomegalovirus (CMV) 
seronegative and n=22 CMV seropositive) and ESRD patients (n=28; n=12 CMV-seronegative 
and n=16 CMV-seropositive)  The open bars represent the CMV-seronegative individuals and 
the closed bars represent CMV-seropositive ones. Data are given as median with interquartile 
range.  P-value: ***<0.001; NS: not signifi cant.
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T cells and values observed in CMV serostatus-matched HI were 16.8% and 14.9% 
for CD4+ and CD8+ T cells, respectively. No signifi cant difference in RTL of CD4+ 
or CD8+ was observed between patients with RRT and without RRT (Supporting 
information, Table S1).  The RTL of CD4+ or CD8+ was not signifi cantly infl uenced by 
gender in our elderly population (data not shown).  
Proliferation characteristics of T cells from elderly ESRD patients and elderly 
HI are not different
The proliferative capacity as in percentages of proliferating CD4+ and CD8+ T cells in 
response to an allogeneic stimulus (Fig. 5a, b), as well as a polyclonal stimulus (PHA; 
Supporting information, Fig. S3a,b) was equal between elderly ESRD patients and 
elderly HI. In addition, a similar precursor frequency (PF) of CD4+ and CD8+ T cells 
able to respond to alloantigen (Fig. 5c,d) or a polyclonal stimulus (PHA, Supporting 
information 3c,d) was observed between elderly patients and HI. Moreover, no 
differences were observed with respect to proliferation kinetics of CD4+ (Fig. 5e) and 
CD8+ (Fig. 5f) T cells in response to alloantigen-stimulation. CMV did not infl uence 
signifi cantly the capacity of T cells to respond to allogeneic or polyclonal stimulation 
in both elderly ESRD patients and HI (Supporting information, Table S2).
	
Fig. 5. Proliferation of CD4+ and CD8+ T cells in response to allogeneic stimulation in elderly 
healthy individuals (HI) and elderly end-stage renal disease (ESRD) patients. Percentage of 
(a) dividing CD4+ and (b) CD8+ T cells in response to alloantigens. Precursor frequency (%) 
of (c) CD4+and (d) CD8+ T cells in response to alloantigens. Proliferation kinetics of (e) CD4+ 
and (f) CD8+ T cells in response to alloantigens. Peripheral blood mononuclear cells (PBMCs) 
isolated from 11 HI and 11 ESRD patients [fi ve cytomegalovirus (CMV) seronegativity and 
six CMV seropositivity] were used as response cells and the irradiated PBMCs from the third 
part were used as the allostimulation cells.  Data are given as individual values (a-d) and 
median with interquartile range (a-f); open symbols/bars represent HI and closed symbols/
bars represent the ESRD patients; ns: not signifi cant.
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DISCUSSION 
The main observation of this study is that CMV latency is a dominant factor for 
increased ageing of the peripheral T cells in elderly ESRD patients, outweighing 
the known premature T cell ageing effects of renal failure itself. In our previous 
study, premature ageing of peripheral T cells was demonstrated in ESRD patients 
but did not consider CMV latency and did not focus on elderly (≥ 65 years of age) 
patients (11). The influence of CMV latency versus uremia on T cell ageing was 
investigated in another cohort of young to middle-aged ESRD patients and showed a 
modest effect consisting of increased T cell differentiation status, in particular higher 
percentages of CD28-negative T cells, and reduced telomere length of CD8-positive 
T cells(18). The current study focused on the elderly ESRD patients and identified 
specific additive effects of ESRD and in particular CMV latency on the ageing of the 
T cell system in the elderly population. 
CMV latency is recognized increasingly as a significant factor for accelerated T-cell 
ageing (22), and as such may add to the increased risk for infections (23) as well 
as cardiovascular disease (24) in the healthy elderly. In elderly ESRD patients, the 
risk of cardiovascular disease events and death (16, 25-27) or infections (28) is 
even more increased. Studies in the very healthy elderly demonstrated an immune 
risk phenotype (IRP) for increased mortality defined by an inverted CD4/CD8 ratio 
and increased number of CD28-CD8+ T cells (29), which was associated with CMV 
seropositivity (13, 30). 
Our data indicate that CMV latency in combination with ESRD in the elderly is 
particular harmful to the T cell system, as numbers of naive T cells are also affected 
negatively, as well as the known ageing effects on memory T cells.  The decline in 
number of naive T cells is a key feature associated with loss of renal function, and 
in particular ESRD (11, 31). Naive T cells that have recently left the thymus contain 
TRECs and express mainly CD31 [Platelet and Endothelial Cell Adhesion Molecule 
1 (PECAM-1)] (32). TRECs were not detectable in several elderly healthy individuals 
or ESRD patients, suggestive of a low thymic output in the elderly population. This 
is in agreement with the observation generated in healthy individuals that a large 
part of the functional thymic tissue has been lost by the age of 50 years (33). Aside 
from the thymus contributing to the naive T cell pool, homeostatic proliferation of the 
remaining naive T cells is able to maintain the naive T cell pool (34). Homeostatic 
proliferation of naive T cells may occur in response to homeostatic cytokines like for 
example IL-7 (35) or in response to low- affinity self-antigens(36-38). The decline 
in naive T cells induced by ESRD in elderly might also be the result of defects in 
homeostatic proliferation since plasma levels of IL-7 were lower in ESRD patients 
compared to healthy individuals (31). Moreover, the decline in naive T cells could 
also result from differentiation towards memory T cells. The memory compartment in 
the ESRD patients is more differentiated, i.e. containing fewer CM T cells (31, 39). 
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Naive, but also CM, T cells are essential for generating a robust immune response 
(3, 4) and naive T cells contain a more diverse T cell receptor (TCR) Vβ  repertoire 
compared to memory T cells (40), allowing for a better response to newly encountered 
antigens such as vaccination antigens. Low in-vivo numbers of naive CD4+ recent 
thymic emigrants correlated well with reduced acute responsiveness and altered 
long-term persistence of human cellular immunity to yellow fever vaccination in the 
elderly population (41). The underlying mechanism for the reduction in naive and CM 
T cells in the peripheral blood is not yet clear, but may involve increased apoptosis 
(39, 42-44) or enhanced proliferation to more differentiated T cell subsets (11). 
During ageing, naive and CM T cells have been linked to increased sensitivity of 
tumor necrosis factor (TNF)-α-induced apoptosis (45, 46). Elevated concentrations 
of serum or plasma TNF-α is associated strongly with progressive loss of renal 
function (47, 48). TNF-α induced apoptosis may be an explanation of loss of naive 
and CM in elderly ESRD patients. CMV may reactivate in healthy individuals and 
more frequently in the elderly (49). This may be caused by an age-related decrease 
in T cell-mediated control of CMV reactivation as, e.g. INF-γ secretion in response to 
CMV peptide stimulation is decreased in very elderly individuals (50). Data in ESRD 
patients on CMV reactivation are largely absent, but the frequent presence of anti-
CMV IgM titers in dialysis patients suggests that CMV reactivation is not a rare event 
(51), and may even lead to CMV disease (52, 53). In addition, anti-CMV IgG titers 
are increased in elderly ESRD patients but not in healthy elderly individuals, which 
may also be interpreted as the result of frequent CMV reactivation (54). 
A plausible hypothesis could be that ESRD-related premature T cell ageing 
contributes to a decrease in anti-viral T cell immunity, which allows for more frequent 
CMV reactivation. Reactivation is controlled at the expense of expanded populations 
of CD28null T cells with reduced telomere length (18), fewer naive T cells and a 
narrowed TCR repertoire (55). The expansion of CD4CD28null T cells adds to the 
increased risk for atherosclerotic disease, while the overall antigen-specific T cell 
response is weakened further by the loss of T cell diversity. 
Unexpectedly, we were unable to attribute the phenotypical defects to specific or 
more general functional deficits using CFSE dilution as a read-out for proliferation 
of PBMC in response to an allo-antigen or polyclonal stimulus. This indicates that 
the overall proliferative potential of T cells is not severely affected in the elderly 
ESRD patient. However, the stimuli used in our proliferation assay do not allow 
for measuring the potential of T cells to initiate responses to newly encountered 
antigens that are more dependent on a diverse T cell repertoire. In addition, the 
use of CMV-seropositive donors as allogeneic stimuli might result in activation of 
CMV-specific T cells in CMV-seropositive responders in addition to the alloreactive 
T cells (56, 57). This might be an explanation for the trend in higher frequencies of 
proliferating T cells as well as precursor frequencies comparing CMV-seropositive 
responders to their negative counterparts (Supporting information, Table S2). By 
using high-throughput sequencing of the diversity of the TCR -repertoire (40, 58) this 
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might provide a more supportive functional read-out. 
In conclusion, CMV latency is a dominant factor for accelerated T cell ageing in 
elderly ESRD patients, and therefore should be taken into consideration to evaluate 
the risk of mortality, infection and response to vaccination in this patient population. 
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	Fig. S3. Proliferation of CD4
+ and CD8+ T cells in response to phytohaemagglutinin 
(PHA) stimulation in elderly healthy individuals (HI) and elderly end-stage renal disease 
(ESRD) patients. Percentage of (a) dividing CD4+ and (b) CD8+ T cells in response to 
PHA. Precursor frequency (%) of (c) CD4+ and (d) CD8+ T cells in response to PHA.  
Peripheral blood mononuclear cells (PBMCs) isolated from 11 HI and 11 ESRD patients [fi ve 
cytomegalovirus (CMV) seronegativity and six CMV seropositivity] were used as response 
cells. Data are given as individual values; open symbols/bars represent HI and closed 
symbols/bars represent the ESRD patients. NS: not signifi cant
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T-cell ageing parameters Patients with RRT Patients without RRT
T cell differentiation status (cells/µL)
CD3+ 950 (684-1649)a 1195 (888-1367)
CD4+ 560 (439-894) 695 (528- 876)
      naive CD4+ 166 (84-306) 158 (97-322)
      memory CD4+ 423 (292-671) 475 (341- 604)
      CM CD4+ 283 (160- 390) 295 (192- 469)
      EM CD4+ 169 (103- 227) 128 (95- 239)
      EMRA CD4+ 12 (6-26) 8 (4 -14)
      CD28- CD4+ 21 (2-58) 9 (2 -84)
CD8+ 297 (184- 433) 308 (233- 608)
      naive CD8+ 38 (19- 61) 33 (18- 66)
      memory CD8+ 243 (117- 380) 251 (173- 565)
      CM CD8+ 20 (10-24) 19 (11- 36)
      EM CD8+ 108 (58-180) 91 (36- 146)
      EMRA CD8+ 108 (45-214) 167 (60- 417)
      CD28- CD8+ 135 (51 -243) 129 (65- 373)
Proliferative history (RTL in %)
CD4+ 8.90 (7.75-13.63) 9.00 (7.00-11.80)
CD8+ 10.35 (7.85-17.10) 9.10 (7.85-14.93)
Thymic output
TREC (1 / delta CT value) 0.078 (0.072-0.089) 0.079 (0.071-0.088)
CD31+ naive CD4+ 100 (44-179) 88 (52-193)
CD31+ naive CD8+ 37 (18-59) 32 (14-59)
Table S1.: T cell ageing parameters of elderly end-stage renal disease (ESRD) patients with 
and without renal replacement therapy
a Numbers were given as median and interquartile range. 
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Table S2.:  Proliferation of CD4+ and CD8+ T cells in response to allogeneic and 
phytohaemagglutinin (PHA) stimulation in elderly healthy individuals (HI) and elderly end-
stage renal disease (ESRD) patients dissected for cytomegalovirus (CMV) serostatus
                        patient                           HI
 CMV-IgG (+) CMV-IgG (-) P-value CMV-IgG (+) CMV-IgG (-) P-value
allogeneic 
response 
CD4+
dividing cells (%) 25.1 
(18.0-48.3)a
8.8 
(7.8-49.2)
ns 42.8 
(16.6- 44.4)
17.2 
(8.5-29.2)
ns
precursor 
frequency (%)
7.3 
(5.0-14.5)
5.4 
(2.3-15.3)
ns 7.7 
(2.3-19.7)
5.6 
(2.1-22.3)
ns
CD8+
dividing cells (%) 37.9 
(13.2-57.7)
25.1
(14.7-63.2)
ns 38.3 
(16.4- 61.7)
25.7  
(17.6-56.2)
ns
precursor 
frequency (%)
10.0 
(2.2-20.0)
5.6 
(3.6-19.4)
ns 7.3 
(2.8-18.1)
4.1 
(2.7- 17.8)
ns
PHA response 
CD4+
dividing cells (%) 92.7 
(83.8-96.3)
93.3 
(87.1-97.8)
ns 82.5 
(30.8-96.2)
91.8 
(71.5-96.0)
ns
precursor 
frequency (%)
50.4 
(38.4-60.5)
69.8 
(46.6-70.8)
ns 14.0 
(4.8-55.0)
52.8 
(30.6-70.9)
ns
CD8+
dividing cells (%) 91.4 
(74.2-94.6)
90.7 
(77.3-98.1)
ns 80.8 
(15.3-97.3)
91.7 
(74.8-95.0)
ns
precursor 
frequency (%)
36.6  
(25.2-50.4)
47.0 
(28.1-75.5)
ns 14.4 
(2.1-46.4)
60.3 
(17.7-66.4)
ns
a Data were given as the median and interquartile range.  ns: not significant 
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ABSTRACT
Background: End-stage renal disease (ESRD) is associated with defective T-cell 
mediated immunity. A diverse T-cell receptor (TCR) Vβ -repertoire is central to 
effective T-cell mediated immune responses to foreign antigens. In this study, the 
effect of ESRD on TCR Vβ-repertoire was assessed. 
Results: A higher proportion of ESRD patients (68.9%) had a skewed TCR Vβ-
repertoire compared to age and cytomegalovirus (CMV) – IgG serostatus matched 
healthy individuals (31.4%, P<0.001). Age, CMV serostatus and ESRD were 
independently associated with an increase in shifting of the TCR Vβ-repertoire. More 
differentiated CD8+ T cells were observed in young ESRD patients with a shifted 
TCR Vβ-repertoire. CD31-expressing naive T cells and relative telomere length of T 
cells were not significantly related to TCR Vβ skewing. 
Conclusions: ESRD significantly skewed the TCR Vβ-repertoire particularly in the 
elderly population, which may contribute to the uremia-associated defect in T-cell 
mediated immunity. 
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BACKGROUND
Patients suffering from end-stage renal disease (ESRD) have an impaired T-cell 
mediated immune system, characterized by an increased susceptibility for 
infections(1), a decreased response to vaccination(2-4) and a heightened risk for 
virus-associated cancers(5). Loss of renal function is associated with a severe 
depletion of naive T cells and a shift to more differentiated memory T cells(6). An 
advanced decline in thymic output and attrition of telomeres was noted in both CD4+ 
as well as CD8+ T cells of ESRD patients(7, 8). These uremia-induced effects on T 
cells closely resemble premature T-cell aging and revealed a discrepancy of 15-20 
years between the patient’s immunological age of their T cells and their chronological 
age(7). 
A diverse (polyclonal) T cell receptor (TCR) -repertoire capable of recognizing a broad 
range of foreign antigens is key to an effective T-cell-mediated immune response(9). 
Naive T cells migrating from the thymus into the circulation, carrying CD31 antigen 
on their cell surface(10), possess the broadest TCR -repertoire (i.e. polyclonal 
TCR -repertoire)(11). The memory T cells that develop upon encountering of an 
antigen have a repertoire that is being skewed towards particular specificities (12) 
but this does not automatically imply a loss of TCR diversity. Similarly, although the 
composition of the circulating T cells may be profoundly altered in ESRD patients, it 
is not known whether this invariably leads to an oligoclonal TCR -repertoire reflecting 
a limited capacity to respond to novel encountered antigens.  
Most TCRs consist of an α and a β chain and each chain is composed of a variable 
(V) region and a constant (C) region. In the thymus, the V region of the TCR α and 
β chain is generated by random gene rearrangement of variable (V) and joining 
(J) genes or V, diversity (D) and J genes, respectively. Contraction of TCR Vβ-
repertoire has been reported to occur during aging, starting from roughly 600 × 103 
clonal types detected per 106 T cells in childhood and declining by 5×103 clones per 
year(13). The TCR Vβ-repertoire diversity might also be affected by chronic antigenic 
stimulation(14-16). For example, cytomegalovirus (CMV) latency may also induce 
contraction of the TCR Vβ-repertoire as it results in a vast expansion of CMV specific 
T cell-exceeding 4% of CD8+ T cells in immunocompetent donors (17) and these anti-
CMV T cells clones were stably maintained for 5 years(18). CMV-IgG seropositive 
ESRD patients have shorter telomeres within CD8+ T cells and an increased T cell 
differentiation status with higher percentages of CD57+ and CD28- CD4+ and CD8+ 
memory T cells(19). Both CMV latency and ESRD, alone or in combination, may 
profoundly alter the composition of the peripheral T cell compartment(19, 20).
We hypothesized that ESRD may decrease the TCR Vβ-repertoire diversity and that 
CMV latency could further add to this loss of diversity. In this study, we therefore 
assessed the TCR Vβ-repertoire diversity of ESRD patients relative to age- and 
CMV-IgG serostatus- matched healthy individuals (HI). The TCR Vβ-repertoire 
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diversity was evaluated by a qualitative multiplex DNA-based PCR of TCR Vβ-Jβ 
gene rearrangements, originally designed to diagnose lymphoproliferations(21). The 
generated Genescan profile was used to distinguish between a Gaussian distributed 
(diverse or polyclonal) and a more or less skewed (narrowed or even monoclonally 
expanded) TCR Vβ-repertoire.
Subjects and Methods 
Study population
Forty-five stable adult ESRD patients, defined as a glomerular filtration rate of ≤15 ml/
min with or without hemodialysis, on the waiting list for the first kidney transplantation 
and 51 healthy kidney donors were included (Table 1) from 1st November 2010  to 
1st October 2013 in nephrology department of Erasmus medical center. Patients with 
any clinical or laboratory evidence of acute bacterial or viral infection, malignancy, 
previous kidney transplantations, immunosuppressive drugs treatment within 28 
days prior to transplantation (except glucocorticoids) were excluded. Age, CMV-IgG 
serostatus and total T-cell number in the peripheral blood were matched between 
these two groups. Lithium-heparinized blood was drawn prior to transplantation of 
ESRD patients and healthy kidney donors. All individuals included gave informed 
consent and the local medical ethical committee approved the study (METC number: 
2012–022). It was conducted according to the principles of Declaration of Helsinki 
and in compliance with International Conference on Harmonization/Good Clinical 
Practice regulations.
Circulating T cell numbers and their differentiation status
Freshly drawn peripheral blood samples from 45 ESRD patients and 51 healthy 
individuals (HI) were  stained and acquired on a FACSCanto II flow cytometer (BD 
Biosciences, Erembodegem, Belgium) as described previously (7, 35)  to determine 
both frequencies and absolute numbers of the different T cell subsets as well as their 
differentiation status. Data were analyzed using FACS Diva software version 6.1.2 
(BD Biosciences). Detailed methods can be found in the Supplementary Methods 
section.
PBMCs isolation, DNA isolation and TCR Vβ-repertoire analysis
PBMCs from 45 ESRD patients and 51 healthy individuals (HI) were isolated from 
peripheral blood as described previously (3). One million PBMCs were snap-frozen 
for DNA isolation and the remaining were frozen at 10 million per vial until further 
use. DNA was isolated according to manufacturer’s instructions (QIAamp DNA Mini 
QIAcube Kit).  The TCR Vβ gene repertoire was measured by the multiplex TCR 
Vβ-Jβ gene PCR as developed and approved by the European consortium of 45 
laboratories (BIOMED-2 Concerted Action BMH4-CT98-3936) (21). The term skewed 
TCR Vβ-repertoire was used when the TCR Vβ showed an oligoclonal pattern with 
one or more clonal peak(s) on the Genescan profile and the term non-skewed Vβ 
-repertoire was used when the spectratype of TCR Vβ-repertoire on the Genescan 
profile showed a Gaussian distribution (21). 
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Sorting of T cell subsets 
Cryopreserved PBMCs were thawed, washed and resuspended in PBS. The PBMCs 
from 10 elderly patients (of which 50% were CMV-seropositive) and 10 elderly healthy 
individuals (of which 50% were CMV-seropositive) were  stained  and subsequently 
sorted into T cells subsets i.e. CD4+ naive/memory and CD8+ naive/ memory using 
flow cytometry based cell-sorting  (BD FACSAria™ II SORP, BD). A typical example 
of the gating strategy to dissect the different T cell subsets prior to sorting as well as 
the analysis of the purity of the sorted samples was given in Fig.S. 3.  The purity of 
all T cell subsets was over 95%. The details for flow cytometry-based cell-sorting of 
T cell subsets are given in the Supplementary Methods  section.
Telomere length assay
Flow fluorescent in situ hybridization was performed to determine the relative 
Table 1  Clinical and biological characteristics of the study population
 Healthy 
individuals
ESRD 
Patients
P value
Number of individuals 51 45  
Age (young/eldely) (years; mean ± SD) 33.1 ± 7.6 / 
68.0 ± 3.0
32.9 ± 9.2 / 
68.3 ± 3.5
NS/NS a
Sex (% male) 41.2 68.9 P < 0.05
CMV IgG serostatus (% pos) 52.9 51.1 NS
T cells number in peripheral blood (106/µl; mean 
± SD)
1274 ± 304 1164 ± 260 NS
Renal replacement therapy (number; %) 44.4
Duration of renal replacement therapy (months; median/range) 13 / 3-68
    Hemodialysis (%) 80.0
    Peritoneal dialysis (%) 15.0
    Peritoneal dialysis followed 
    hemodialysis (%)
5.0
Underlying kidney disease  
Nephrosclerosis/atherosclerosis/hypertensive 
nephropathy (%)
17.8
    Primary glomerulopathy (%) 6.7
    Diabetic nephropathy (%) 20.0
    Reflux nephropathy (%) 17.8
    Polycystic kidney disease (%) 20.0
    Other (%) 15.6
    Unknown (%) 2.2  
Abbreviations:  ESRD, end-stage renal disease; CMV, cytomegalovirus; NS, not significant 
aAge categories of young (≤45 years) and elderly ( ≥65 years) were used
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telomere length (RTL) of T cells as described previously (7, 35).  Detailed information 
is given in the Supplementary Methods section. 
Statistical analyses
Statistical analyses were performed using SPSS 20 (IBM, Chicago, IL, USA) and 
GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA, USA). Categorical 
variables were compared using the chi-square test or Fisher’s exact test. Continuous 
variables were compared using Mann-Whitney U-test. Binary logistic regression was 
used to estimate the probability that skewing of TCR repertoire was present given 
the values of explanatory variables. All reported P-values are two-sided and were 
considered statistically significant when P<0.05.
RESULTS
Study population characteristics 
The demographic and clinical characteristics of the study population are given in 
Table 1. Approximately 45% of ESRD patients received renal replacement therapy 
with the median dialysis time of 13 months. Twenty-one patients were within the 
young group (age 19 – 45 years) and 24 patients belonged to the elderly group (age 
65 – 77 years). 
ESRD is associated with a skewed TCR Vβ-repertoire
A TCR Vβ-repertoire was defined as non-skewed one when the spectratype of TCR 
Vβ-repertoire on the Genescan profile showed a Gaussian distribution (Fig.1a, left 
profile) or a skewed one showing an oligoclonal pattern with one (Fig. 1a middle 
profile) or more clonal (Fig. 1a, right profile) peak(s) on the Genescan profile. A skewed 
(or oligoclonal) TCR Vβ-repertoire was present in a larger (P<0.001) proportion 
(68.9%) of the ESRD patients compared to HI (31.4%) (Fig. 1b). Further dividing the 
results into single or multiple (oligo)clonal peaks did not lead to significantly different 
percentages in skewed TCR Vβ-repertoire between the ESRD patients and HI (Fig. 
1c). Percentages of individuals with multiple (oligo)clonal peaks in the skewed TCR 
Vβ-repertoire amounted to 51.6 % and 43.7% in ESRD patients and HI, respectively 
(P>0.05). In conclusion, ESRD is associated with skewing of the TCR Vβ-repertoire. 
Both Aging and CMV serostatus affect the TCR Vβ-repertoire diversity in ESRD 
patients
Dissecting the ESRD and healthy study population into a young and elderly group, 
revealed significantly more (P<0.001) skewing within the elderly ESRD patients 
compared to the age-matched HI, proportions were 87.5% versus 32.0%, respectively 
(Fig. 2a). In addition, an age-related skewing in TCR Vβ-repertoire was observed for 
ESRD patients (P < 0.01), but not for healthy individuals (Fig. 2a). Moreover, like for 
the overall study population, no differences were observed between the composition 
of multiple and single oligoclonal peaks in young and elderly ESRD patients with a 
skewed TCR Vβ-repertoire. (Fig. 2b).
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We then looked at the effect of CMV IgG seropositivity on TCR Vβ-repertoire 
skewing. A skewed TCR Vβ  -repertoire was observed in 41.7% and 16.7% of CMV-
IgG seropositive and CMV-IgG seronegative HI, respectively. Approximately, 91.3% 
of CMV-IgG seropositive ESRD patients had a skewed TCR Vβ  -repertoire whereas 
skewing of the TCR Vβ-repertoire occurred in 45.5% of CMV-IgG seronegative 
ESRD patients. CMV latency skewed (P < 0.01) the TCR Vβ-repertoire in both HI as 
well as ESRD patients (Fig. 2c). Data was further analyzed taking the effect of aging 
into account. In young CMV-IgG seropositive and negative patients, percentage of 
patients with a skewed TCR Vβ  repertoire amounted to 80.0% and 18.2%, whereas 
in the elderly percentages were 100% and 72.7%, respectively (Fig. 2d). A similar 
trend occurred in the healthy population, only reaching significance (P < 0.01) in the 
Fig. 1. Skewed and non-skewed TCR Vβ-repertoire distribution in healthy individuals (HI) and 
end- stage renal disease (ESRD) patients. The different genescan profiles obtained following 
spectratyping of the DNA-based multiplexed TCR Vβ PCR samples are depicted in a. This 
reaction consists of 23 Vβ primers and 9 Jβ primers. The green profile  represents the  6 Jβ 
primers (Jβ1.1,  Jβ1.2, Jβ1.3,  Jβ1.4, Jβ1.5, Jβ1.6), whereas the blue line represents the 3 
Jβ primers (Jβ2.2, Jβ2.6, and Jβ2.7) in this multiplex PCR. The red profile represents the 
internal size standard. The left profile shows a non-skewed (polyclonal) pattern, the middle 
one a skewed pattern with a single (oligo)clonal peak [size of the oligoclonal product is 253 
nucleotides (nt)] whereas the right panel depicts a skewed pattern with multiple (oligo) clonal 
peaks (sizes of the oligoclonal products are 252, 261 and 264 nt, respectively). The arrows 
indicate oligoclonal peaks within the genescan profile. b Frequency of ESRD patients (n = 
45) and age-matched HI ( n = 51) with a skewed (closed squares) and non-skewed (open 
squares) TCR Vβ-repertoire. c Frequency of single (open squares) and multiple (oligo)clonal 
peaks (closed squares) within a skewed TCR Vβ-repertoire of ESRD patients ( n = 31) and HI 
(n = 16). P value: * <0.05; **< 0.01; ***< 0.001; NS: not significant.
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value: * <0.05; **< 0.01; ***< 0.001; NS: not significant.
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elderly group (Fig. 2d). Although CMV latency significantly added to the skewing 
of the TCR Vβ-repertoire in ESRD patients, the effect of ESRD on the TCR Vβ-
repertoire was present in both CMV-seropositive as well as CMV-seronegative elderly 
individuals. The percentage of elderly patients with a skewed TCR Vβ-repertoire was 
significantly higher when compared to the CMV-status matched elderly HI (P < 0.05) 
(Fig. 2d).
Table 2 The variables related to a skewed TCR Vβ-repertoire
Non-skewed 
TCR Vβ
Skewed 
TCR Vβ
Odds ratio P value
Age (years, median) 41 65 3.1a <0.05
% of CMV seropositivity 30.7 74.5 13.8b <0.05
% of ESRD patients 28.6 70.0 10.2c <0.05
% of patients on renal replacement 
therapy
35.8 48.4 NS
Underlying kidney disease
   Nephrosclerosis/atherosclerosis/
hypertensive nephropathy
1 7 NS
   Primary glomerulopathy 0 3 NS
   Diabetic nephropathy 2 7 NS
   Reflux nephropathy 4 4 NS
   Polycystic kidney disease 2 7 NS
   Other 5 2
   Unknown 0 1
Abbreviations:  TCR, T cell receptor; NS, not significant.
a means the odds of a skewed TCR Vβ in elderly population is 3.1 times higher than in the 
young population. 
b means the odds of a skewed TCR Vβ in CMV- IgG seropositive population is 13.8 times 
higher than in the CMV- IgG seronegative population.
C means the odds of a skewed TCR Vβ in patients is 10.2 times higher than in the healthy 
individuals. 
Table 3 Frequency of elderly individuals with skewed and non-skewed TCR Vβ-repertoire in 
the sorted T cells subsets 
T cell subsets HI  ESRD patients  
Skewed Non-skewed P value Skewed Non-skewed P value
CD4 naive 0a 10 NS 0 10 NS
CD4 Memory 2 8 3 7
CD8 Naive 3 7 NS 3 7 <0.05
CD8 Memory 7 3 9 1
Abbreviations: TCR, T cell receptor -repertoire; ESRD, end-stage renal disease; HI, healthy 
individuals; NS, not significant. 
aData are shown as the numbers of individuals
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ESRD, aging, and CMV latency influenced the TCR Vβ-repertoire diversity 
independently
To test the influence of several factors such as ESRD, aging, CMV latency, and 
gender (as the percentage of males was significantly higher in the patients compared 
to HI) on skewing of the TCR Vβ-repertoire, a binary logistic regression model was 
used. Except for gender (P > 0.05), ESRD [P < 0.05, odds ratio (OR) = 4.8], age (P 
< 0.05, OR = 2.3) and CMV-IgG seropositivity (P < 0.05, OR = 6.7) were significantly 
Fig. 2. Skewed and non-skewed TCR Vβ-repertoire distribution in healthy individuals (HI) and 
end-stage renal disease (ESRD) patients dissecting the population into subgroups according 
to age and CMV-IgG serostatus. a Frequency of a skewed TCR Vβ-repertoire in young (n 
= 21) and elderly (n = 24) ESRD patients compared to age- matched HI (young, n =  26 
and elderly, n = 25). b Frequency of multiple (oligo) clonal peaks within a skewed TCR Vβ-
repertoire of young (n = 10) ESRD patients compared to elderly ESRD patients (n = 21). c 
Frequency of a skewed TCR Vβ-repertoire in CMV-IgG seropositive (n = 23) and seronegative 
(n = 22) ESRD patients, compared to CMV-IgG seropositive (n = 27) and seronegative (n = 
24) healthy individuals. d Frequency of a skewed TCR Vβ-repertoire in young ESRD patients 
with CMV- IgG seropositive status (n = 10) or CMV-IgG seronegative status (n = 11) and 
elderly ESRD patients with CMV-IgG seropositive status (n = 13) or CMV-IgG seronegative 
status (n = 11), compared to age-matched CMV-IgG seropositive (young n = 14, elderly n 
= 13) and CMV IgG seronegative (young n = 12, elderly n = 12) HI. The closed squares 
represent skewed or multiple oligo(clonal) peaks within skewed TCR Vβ-repertoires whereas 
the open squares represent non-skewed or single (oligo)clonal peaks within skewed TCR Vβ-
repertoires, respectively. P value: * <0.05; **< 0.01; ***< 0.001; NS: not significant.
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Fig. 3. Absolute number of circulating CD4+ and CD8+ T cell subsets in young (n = 10) and 
elderly end-stage renal disease (ESRD) patients (n = 21) with a skewed TCR Vβ-repertoire 
compared to age-matched ESRD patients without a skewed TCR Vβ-repertoire (young n=11; 
elderly n=3). A typical example of the gating strategy for dissection of the different T cell 
subsets by flow cytometry following a whole blood staining protocol is given in a. Briefly, 
lymphocytes were identified based on the forward/sideward characteristics followed by the 
selection of CD3+ T cells. These CD3+ T cells were then  dissected into CD4+ and CD8+  T 
cells. CCR7 and CD45RO were used to identify the CD4+ T cells subsets. Furthermore, 
CD28- T cells were examined within the total CD4+ population. A similar gating strategy was 
employed for determination of absolute numbers of CD8+ T cell subsets and the differentiation 
status. The number of b CD4+, c CD4+ naive, d CD4+ total memory, e CD4+ central memory 
(CM), f CD4+ effector memory (EM), g CD4+ highly differentiated effector T cells (EMRA), 
h CD4+CD28- T cells, as well as i CD8+, j CD8+ naive, k CD8+ total memory, l CD8+ central 
memory (CM), m CD8+ effector memory (EM), n CD8+ highly differentiated effector T cells 
(EMRA) and  CD8+CD28- T cells are shown. Data are given as median with interquartile 
range. The open bars represent ESRD patients with a non-skewed TCR Vβ-repertoire and 
closed bars correspond to ESRD patients with a skewed TCR Vβ-repertoire. P value: *<0.05; 
**<0.01; ***<0.001; NS: not significant.
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characteristics followed by the selection of CD3+ T cells. These CD3+ T cells were then  dissected into CD4+ and CD8+ T cells. 
CCR7 and CD45RO were used to identify the CD4+ T cells subsets. Furthermore, CD28- T cells were examined within the total 
CD4+ population. A similar gating strategy was employed for determination of absolute numbers of CD8+ T cell subsets and the 
differentiation status. The number of b CD4+, c CD4+ naive, d CD4+ total memory, e CD4+ central memory (CM), f CD4+ effector 
memory (EM), g CD4+ highly differentiated effector T cells (EMRA), h CD4+CD28- T cells, as well as i CD8+, j CD8+ naive, k CD8+
total memory, l CD8+ central memory (CM), m CD8+ effector memory (EM), n CD8+ highly differentiated effector T cells (EMRA) and  
CD8+CD28- T cells are shown. Data are given as median with interquartile range. The open bars represent ESRD patients with a 
non-skewed TCR Vβ-repertoire and closed bars correspond to ESRD patients with a skewed TCR Vβ-repertoire. P value: *<0.05; 
**<0.01; ***<0.001; NS: not significant.
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Fig. 4 Absolute number 
of CD31-expressing naive 
CD4+ and CD8+ T cells and 
relative telomere length 
(RTL) of  CD4+ and CD8+ 
T cells in end-stage renal 
disease (ESRD) patients 
with skewing in TCR Vβ-
repertoire compared with 
age-matched ESRD patients 
without skewing in TCR Vβ-
repertoire. A typical flow 
cytometric example of the 
analysis of CD31-expression 
within naive CD4+ (left 
histogram) and CD8+ (right 
histogram) T cells (identified 
as depicted within Fig.3A) 
is given in a. The number of 
CD31+ b CD4+ and c CD8+ 
naive T cells for young and 
old ESRD patients with a 
non- (open bars; young n = 
11, elderly n = 3) and skewed 
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Fig. 4 Absolute number of CD31-expressing naive CD4+ and CD8+ T cells and  relative telomere length (RTL) of  CD4+ and CD8+ T
cells in end-stage renal disease (ESRD) patients with skewing in TCR Vβ-repertoire compared with age-matched ESRD patients 
without skewing in TCR Vβ-repertoire. A typical flow cytometric example of the analysis of CD31-expression within naive CD4+ (left 
histogram) and CD8+ (right histogram) T cells (identified as depicted within Fig.3A) is given in a. The number of CD31+ b CD4+ and c
CD8+ naive T cells for young and old ESRD patients with a non- (open bars; young n = 11, elderly n = 3) and skewed (closed bars;
young n = 10, elderly n = 21) TCR Vβ-repertoire are given. In d, a typical flow cytometric example is depicted of the analysis to allow 
for the determination of relative telomere length (RTL). Histograms showing the median fluorescence intensity (MFI) of the FITC-
channel of samples incubated without (unfilled peak) and with the FITC-labelled PNA-probe (filled peak) are shown for the CCRF-
CEM 1301 subcell-line (left panel) and CD4+ (right panel), respectively. The RTL of e CD4+ and f CD8+ T cells are shown. Triangles 
represent the RTL of ESRD patients with a non-skewed TCR Vβ-repertoire (young n = 8, elderly n = 3) and squares correspond to 
ESRD patients with a skewed TCR Vβ-repertoire (young n = 6, elderly n = 19). Data are given as median with interquartile range. 
*<0.05; **<0.01; ***<0.001; NS: not significant.
(closed bars; young n = 10, elderly n = 21) TCR Vβ-repertoire are given. In d, a typical flow 
cytometric example is depicted of the analysis to allow for the determination of relative 
telomere length (RTL). Histograms showing the median fluorescence intensity (MFI) of the 
FITC-channel of samples incubated without (unfilled peak) and with the FITC-labelled PNA-
probe (filled peak) are shown for the CCRF-CEM 1301 subcell-line (left panel) and CD4+ (right 
panel), respectively. The RTL of e CD4+ and f CD8+ T cells are shown. Triangles represent 
the RTL of ESRD patients with a non-skewed TCR Vβ-repertoire (young n = 8, elderly n = 3) 
and squares correspond to ESRD patients with a skewed TCR Vβ-repertoire (young n = 6, 
elderly n = 19). Data are given as median with interquartile range. *<0.05; **<0.01; ***<0.001; 
NS: not significant.
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associated with  skewing of TCR Vβ-repertoire. A multiple binary logistic regression 
model was used to further analyze whether the effects on TCR Vβ-repertoire skewing 
were independent. ESRD (P < 0.05, OR =10.2), age (P < 0.05, OR =3.1) and 
CMV-IgG seropositivity (P < 0.05, OR =13.8) remained significant, indicating these 
factors to independently contribute to skewing of the TCR Vβ-repertoire. CMV-IgG 
seropositivity contributed mostly to the skewing of the TCR Vβ-repertoire followed by 
ESRD and age (Table 2). In the ESRD patients, neither renal replacement therapy 
(RRT) (P>0.05) nor underlying kidney disease (P > 0.05) were associated with 
skewing of the TCR Vβ-repertoire (Table 2).
Skewed TCR Vβ-repertoires are presented predominantly within the CD8+ 
memory T cell subset and is associated with more differentiated T cells
In order to determine whether skewing of TCR Vβ  was associated with specific T cell 
subsets, CD4+/CD8+ naive and CD4+/CD8+ memory T cells from 10 elderly healthy 
individuals (of which 50% were CMV seropositive) as well as 10 elderly ESRD patients 
(also containing 50% CMV-seropositive individuals) were FACS-sorted. Skewing of 
the TCR Vβ-repertoire significantly occurred in CD8+, but not CD4+, memory T cells 
in elderly ESRD patients only (Table 3). Within the CD8 memory T cells, a skewed 
TCR Vβ-repertoire was observed in 5 CMV-seropositive and 4 CMV-seronegative 
elderly ESRD patients.
The ratio of CD4+/CD8+ T cells was significantly lower in young and elderly ESRD 
patients with a skewed TCR Vβ-repertoire compared to age-matched ESRD patients 
without skewed TCR Vβ-repertoire, respectively (young: 1.73 versus 2.38 P < 0.05; 
elderly: 2.30 versus 4.71, P < 0.05). Next, we determined the association between 
having a skewed TCR Vβ-repertoire and T cell subsets as well as the differentiation 
status of T cells. In Fig. 3a, a typical flow cytometric example of the gating strategy 
for dissecting the different CD4+ T-cell subsets including naive, central memory 
(CM), effector memory (EM), highly differentiated effector memory (EMRA) as well 
as for determining the differentiation status of the T-cell compartment by analysis 
of  CD28- T cells is given. A similar approach was also employed for CD8+ T cells. 
Young ESRD patients with a skewed TCR Vβ-repertoire had increased numbers of 
more differentiated memory T cells, i.e. EMRA (Fig. 3n) as well as CD28-CD8+ T cells 
(Fig. 3o). The number of individuals without skewing in the elderly ESRD patients 
was limited (only 3 out of 24), which might explain why the comparison between 
non-skewed and skewed ESRD patients did not reach significance for CD8+ EMRA 
or CD8+ CD28- T cells but similar trends were observed (Fig.3n & 3o). Approximately 
80% of the young and 62% of the elderly ESRD patients, that had a skewed TCR 
Vβ-repertoire, were CMV-seropositive, confirming the previously described effects of 
CMV-latency on the T cell compartment. Moreover, the skewed TCR Vβ-repertoire 
was correlated with more differentiated CD8+ T cells in the healthy population as 
well. In the elderly healthy individuals, those with a skewed TCR Vβ-repertoire had 
more CD8+ T cells, more CD8+ memory, CD8+ EMRA and CD8+CD28- than the 
individuals without skewed TCR Vβ-repertoire (Fig. S1 H, J, M, and N). Within young 
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healthy individuals, the numbers of CD8+ memory (MEM), CD8+ effector memory 
(EM) and CD8+CD28- T cells were significantly higher in the individuals with skewed 
TCR repertoire than the individuals with a polyclonal TCR Vβ-repertoire (Fig. S1 J, L, 
N).  The proportions of CMV-IgG seropositive individuals within the HI with a skewed 
TCR repertoire amounted to 75% and 100% in young and elderly HI, respectively.  
Number of CD31+ naive T cells and relative telomere length (RTL) are not 
correlated to a skewed TCR Vβ-repertoire
Thymic output, assessed by number of CD31-expressing naive CD4+ and CD8+ T 
cells (Fig. 4a), was not different for ESRD patients or healthy individuals with and 
without a skewed TCR Vβ-repertoire. Remarkably, only elderly patients and HI with 
a skewed TCR Vβ-repertoire showed an age-related decline in CD31+ naive CD4+ T 
cells (Fig. 4b and Fig. S2A). An age- related decline in CD31+ naive CD8+ T cells was 
observed in both patients and HI (Fig. 4c and Fig. S2B). Another hallmark of T cell 
ageing is attrition of telomeres and a typical example of the flow cytometric analysis 
of telomere length is shown in Fig. 4d. Assessing the association of this parameter 
to skewing of the TCR Vβ-repertoire only revealed a trend to shorter telomeres in 
CD8+ (Fig. 4f) T cells of elderly ESRD patients with a skewed TCR Vβ  -repertoire 
compared to those without. The RTL of CD4+ /CD8+ T cells were not significantly 
different between the healthy individuals with and without a skewed TCR -repertoire 
either (Fig. S2C&D).
Discussion 
The main observation of this study is that ESRD independently skews the TCR Vβ-
repertoire. In combination with an older age and CMV seropositivity, this leads to a 
skewed TCR -repertoire in almost all elderly ESRD patients. This finding extends 
the knowledge that loss of renal function is associated with significant changes in 
several T-cell (aging) parameters such as thymic output, T-cell differentiation status 
and proliferative history as analyzed by relative telomere length analysis(6, 7). In 
contrast with these studies that demonstrate effects of ESRD on various T-cell 
parameters over a broad age range, skewing of the TCR Vβ-repertoire by ESRD 
is limited to the elderly, which indicates that young ESRD patients are still able to 
maintain a relatively diverse TCR Vβ-repertoire.
In our study, we tested all TCR Vβ gene families, in a multiplex DNA-based approach 
and considered different variables possibly influencing TCR Vβ-repertoire diversity, 
like age(13, 22), CMV-serostatus (17), gender (23), ESRD, RRT and underlying 
kidney disease (24, 25). Although CMV was the strongest factor amongst the 
examined variables, affecting both the young and elderly ESRD patients as well 
as elderly HI, ESRD seems to introduce skewing in both the CMV-seronegative as 
well as CMV-seropositive elderly group. We only observed an age-related effect on 
TCR Vβ skewing in our ESRD patient population, but aging alone does not seem 
to significantly compromise TCR Vβ skewing. It is also reported that the TCR-Vβ 
-repertoire of CD8+ T cells was already skewed in young CMV-seropositive HI and 
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did not modulate further with age(26). Also, Sunder-Plassmann et al. (27) showed 
ESRD patients receiving hemodialysis treatment to have a skewed TCR Vβ-
repertoire, with an impressive increase of TCR Vβ6.7 and a massive deletion of 
the TCR Vβ8 in peripheral blood lymphocytes compared to healthy controls. In our 
study, we were unable to find a significant association between RRT and skewing 
of the TCR Vβ-repertoire. This is in accordance with our previous findings, which 
did show a significant effect of ESRD on ageing of the peripheral T cells but hardly 
any differences between patients with or without RRT (8). Gender also did not affect 
TCR Vβ skewing and in agreement with the research by Sunder-Plassmann et al. 
(27), we did not find a significant contribution of underlying kidney disease with 
respect to skewing of the TCR Vβ-repertoire. This might indicate that the chronic 
inflammatory milieu (28) in which the T cells circulate and the significant changes in 
the peripheral T cell compartment (6) as a consequence of the loss of renal function 
causes oligoclonality of the TCR -repertoire.
A skewed TCR Vβ-repertoire is associated with significant changes in composition 
of peripheral T cells and related to a highly differentiated pattern. A skewed TCR 
Vβ-repertoire in HI was correlated to an increased number of highly differentiated 
memory CD8+ T cells. This might be due to the fact that most of the healthy individuals 
with a skewed TCR Vβ-repertoire were CMV-seropositive. CMV latency introduces 
significant changes in the peripheral T cell compartment, in particular  affecting CD8+ 
T cells (29) and is known to introduce skewing of the TCR Vβ-repertoire as a result 
of expansion of CMV-specific T cell clones in the HI (17). In refractory cytopenia 
patients, TCR Vβ skewing correlates with an expansion of effector CD8+ T cells(30). 
A similar correlation between a skewed TCR Vβ-repertoire and an increased number 
of highly differentiated memory CD8+ T cells was also found in young ESRD patients 
and tended to be significant in the elderly patients. Also within ESRD patients, a large 
proportion was CMV-IgG seropositive, highlighting the possibility that skewing of 
TCR Vβ-repertoire may be likewise related to clonal expansions of antigen-specific 
T cells directed to CMV or expansion of other TCR-specificities, e.g. TCR Vβ 6.7 as 
reported before (27). 
CD31-expressing naive T cells have undergone a lower number of cell divisions(10) 
and have a broader TCR Vβ-repertoire than those lacking CD31(11). Some clones 
could be lost during naive T cell homeostatic proliferation (31), as a massive deletion 
of the TCR Vβ8 was observed in peripheral blood lymphocytes of hemodialysis 
patients(27). However, the numbers of CD31- expressing naive T cells were not 
significantly different between the patients with skewed and non-skewed TCR Vβ-
repertoire. In addition, the skewed TCR Vβ-repertoire was predominantly observed 
in the sorted CD8+ memory compartment and not in naive T cells. This implies that 
some memory T-cell clones proliferate more efficiently in response to the ESRD 
associated pro-inflammatory environment or antigenic stimulation such as CMV. 
Clonal expanded CD8+ T cells are also observed in the peripheral blood of multiple 
sclerosis patients. Based on the current findings, we plan to conduct a more in 
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depth analysis of the TCR Vβ-repertoire including both the diversity (the number of 
specific clones) and the relative abundance of particular clones (the number of reads 
per clone). The clinical implications of having a skewed or less diverse TCR Vβ-
repertoire prior to kidney transplantation are not yet explored. However, analysis of 
TCR Vβ-repertoire diversity following transplantation has been the subject of several 
studies (32, 33). Miqueu et al. (34) reported a skewed -repertoire to be related to 
an increased risk of humoral chronic rejection after kidney transplantation. It might 
be of interest to investigate the consequences of a skewed TCR Vβ-repertoire 
before kidney transplantation with respect to clinical outcomes following kidney 
transplantation like rejection episodes or to examine whether this TCR Vβ-repertoire 
would change after kidney transplantation.
CONCLUSIONS
ESRD significantly and independently skews the TCR Vβ-repertoire in the elderly 
individuals and this skewed TCR Vβ pattern is associated with more differentiated T 
cells subsets. Assessing the TCR Vβ-repertoire diversity in more detail will increase 
our knowledge with respect to the defective T-cell mediated immunity observed 
in ESRD patients and will allow to evaluate its clinical relevance with respect to 
transplantation.
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SUPPORTING INFORMATION
Circulating T cell numbers and their differentiation status
Absolute numbers of T cells were obtained using BD TruCount TM tubes. Briefly, 
20 µl of the 6-color TBNK reagent (BD Multitest™, BD Bioscience) was used in 
combination with a Trucount™ tube  (BD Biosciences) and 50 µl of EDTA blood. 
This tube contains a fixed number of beads (i.e. bead count; lot-specific) which 
enables calculation of absolute numbers of cells per µl of blood. The 6-color TBNK 
reagent contains fluorescein isothiocyanate (FITC)-labeled anti-CD3, phycoerythrin 
(PE) labeled anti-CD16/CD56, peridinin chlorophyll protein (PerCP) - cyanine dye 
(CY) ™5.5-labeled anti-CD45, PE-Cy™7- labeled anti-CD4, allophycocyanin (APC) 
- labeled anti-CD19, APC-Cy7 labeled anti-CD8. 
Analysis of the T cell differentiation status was performed using flow-cytometry 
following the whole blood staining protocol. Briefly, whole blood was stained with 
AmCyan-labeled anti-CD3 (BD) in combination with pacific blue (PB)-labeled anti-
CD4 (BD) and APC-Cy7-labeled anti-CD8 (BD). T cells were defined as CD4+ or 
CD8+ and further defined into four different subsets based on the expression of 
CCR7 and CD45RO using FITC- labeled anti-CCR7 (R&D systems, Uithoorn, The 
Netherlands) and APC-labeled anti-CD45RO (BD). Naive T cells were identified as 
CCR7+ and CD45RO-, central memory (CM) cells as CCR7+ and CD45RO+, effector 
memory (EM) cells as CCR7- and CD45RO+ and the highly differentiated effector 
memory (EMRA) cells as CCR7- and CD45RO-. T-cell differentiation is associated 
with loss of CD28 expression on the cell surface. Numbers of CD28- (or CD28null) T 
cells within the T-cell subsets were determined by staining with PerCP-Cy5.5-labeled 
anti-CD28 (BD). Thymic output was analyzed by determining numbers of CD31-
expressing cells within the naive T-cell pool upon staining with PE-labeled anti-CD31 
(Biolegend, Europe BV, Uithoorn, the Netherlands). Samples were measured on the 
FACSCanto II (BD) acquiring at least 5x104 T lymphocytes. 
Sorting pure T cell subsets 
PBMCs were stained with AmCyan-labeled CD3 (BD Pharmingen, Erembodegem, 
Belgium), Pacific Blue-labeled CD4 (BD), APC-Cy7- labeled CD8 (BD); APC-labeled 
CD45RO (BD), PE- CY7-labeled CCR7 (R&D systems, Uithoorn, The Netherlands) 
and a live-dead marker ViaProbe (7-Aminoactinomycin D, BD) was included. After 
staining, the cells were washed and resuspended at 20-25x106/mL and sorted  into 
CD4+ and CD8+ Naive/memory T cells (BD FACSAria™ II SORP, BD). Naive T cells 
were identified as CCR7+ and CD45RO- and the remaining CD4+ or CD8+ T cells 
were collected as memory T cells.
Telomere length assay
Briefly, PBMCs were thawed and stained with either anti-CD4-biotin (Beckman-
Coulter, BV, Woerden, the Netherlands) or anti-CD8-biotin (Biolegend) followed by 
staining with streptavidin-Cy5 (Biolegend). After fixation and permeabilization, the 
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telomere length of T cells was determined using the telomere PNA-kit/FITC (Dako 
BV, Heverlee, Belgium) according to manufacturer’s instructions. The subcell line 
1301 of CCRF-CEM, known for its long telomeres was treated in a similar way and 
used as an internal control. The relative telomere length was calculated using the 
following formula, comparing the median fluorescence intensity (MFI) of the FITC 
signal of the samples to that of the sub-cell line.
RTL *100%
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Fig. S1. Absolute number of circulating CD4+ and CD8+ T cells in young ( n= 8) and elderly 
healthy individuals (HI, n = 8) with skewing in TCR Vβ-repertoire compared to age-matched 
HI without a skewing in TCR Vβ-repertoire (young n = 18; elderly n = 17). The number of (A) 
CD4+, (B) CD4+
 
naive, (C) CD4+ total memory, (D) CD4+ central memory (CM), (E) CD4+effector 
memory (EM), (F) CD4+ highly differentiated effector T cells (EMRA), (G) CD4+CD28- T cells, 
as well as (H) CD8+, (I) CD8+
 
naive, (J) CD8+ total memory, (K) CD8+ central memory (CM), 
(L) CD8+ effector memory (EM), (M) CD8+ highly differentiated effector T cells (EMRA) and (N) 
CD8+ CD28- T cells are shown. Data are given in median with interquartile range. Open bars 
represent HI with a non-skewed TCR Vβ-repertoire and closed bars correspond to HI with a 
skewed TCR Vβ-repertoire. *<0.05, **<0.01, ***<0.001; NS: not signifi cant.
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Fig S2. Absolute number of CD31-expressing naive and relative telomere length (RTL) of 
CD4+ and CD8+ T cells of healthy individuals (HI) with skewing in TCR Vβ-repertoire compared 
to age-match HI without skewing in TCR Vβ-repertoire. Number of (A) CD31+CD4+ naive and 
(B) CD31+CD8+ naive T cells, in addition with RTL of (C) CD4+ and (D) CD8+ T cells are shown. 
Data are given in median with interquartile range. Open bars represent absolute number of 
CD31- expressing naive T cells of HI with a non-skewed TCR Vβ-repertoire (young n = 18; 
elderly n = 17) and closed bars correspond patients with a skewed TCR Vβ-repertoire (young 
n = 8, elderly n = 8). Triangles represent the RTL of patients with a non-skewed TCR Vβ-
repertoire  (young n = 17, n = 17) and squares correspond patients with a skewed TCR Vβ-
repertoire (young n = 7, elderly n = 8).  *<0.05; **<0.01; ***<0.001; NS: not signifi cant
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Fig. S3 (A) A typical example of the gating strategy to sisect the different T cell subsets prior 
to sorting and (B) the analysis of the purity of CD4+ naive/memory sorted samples.
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ABSTRACT 
A broad T cell receptor (TCR-)-repertoire is required for an effective immune response. 
TCR-repertoire diversity declines with age. End-stage renal disease (ESRD) patients 
have a prematurely aged T-cell system which is associated with defective T-cell 
mediated immunity. Recently, we showed that ESRD may significantly skew the TCR 
Vβ-repertoire. Here we assessed the impact of ESRD on the TCR Vβ-repertoire 
within different T-cell subsets using a multi-parameter flow-cytometry-based assay, 
controlling for effects of ageing and CMV latency. 
Percentages of 24 different TCR Vβ-families were tested in circulating naive and 
memory T cell subsets of 10 ESRD patients and 10 age- and CMV-serostatus-
matched healthy individuals (HI). The Gini-index, a parameter used in economics 
to describe the distribution of income, was calculated to determine the extent of 
skewing at the subset level taking into account frequencies of all 24 TCR Vβ-families. 
In addition, using HI as our reference population, the differential impact of ESRD was 
assessed on clonal expansion at the level of a TCR Vβ-family.
CD8+, but not CD4+, T-cell differentiation was associated with higher Gini-TCR 
indices. Gini-TCR indices were already significantly higher for different CD8+ 
memory T-cell subsets of young ESRD patients compared to their age-matched HI. 
ESRD induced expansions of not one TCR Vβ-family in particular and expansions 
were predominantly observed within the CD8+ T cell compartment. All ESRD patients 
had expanded TCR Vβ-families within total CD8+ T cells and the median (IQ range) 
number of expanded TCR Vβ-families/patient amounted to 2 (1-4). Interestingly, 
ESRD also induced clonal expansions of TCR Vβ-families within naive CD8+ T cells 
as 8 out of 10 patients had expanded TCR Vβ-families. The median (IQ range) 
number of expanded families/patient amounted to 1 (1-1) within naive CD8+ T cells.
In conclusion, loss of renal function skews the TCR Vβ-repertoire already in young 
patients by inducing expansions of different TCR Vβ-families within the various T 
cell subsets, primarily affecting the CD8+ T cell compartment. This skewed TCR Vβ-
repertoire may be associated with a less broad and diverse T-cell-mediated immunity. 
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INTRODUCTION 
End-stage renal disease (ESRD) patients have a decreased vaccination efficacy (1-
4), an increased susceptibility for infection (5-7) and a higher risk for the development 
of tumors (8-11). Loss of renal function is associated with a prematurely aged 
T-cell system (12), most likely caused by the uremia-induced pro-inflammatory 
environment(13). These uremia-induced effects on T cells are expressed as a 
decline in thymic output, a severe depletion of naive T-cell compartment, a shift to 
more highly differentiated memory T-cell subsets, attrition of T-cell telomeres (14) 
and a defective TCR-induced ERK phosphorylation (15).
 
A broad T cell receptor (TCR) -repertoire capable of recognizing a wide range of 
foreign antigens is crucial for adequate T-cell mediated immune responses (16). 
Most TCRs consist of an α and β chain and each chain is composed of a variable 
(V) and a constant (C) region (17). The TCR Vβ-repertoire can be assessed using 
several approaches such as gene scan spectratyping via a DNA-based PCR (18), 
Vβ-family phenotyping by flow-cytometry (19-21), and assessment of clonal diversity 
via next generation sequencing (NGS) (22, 23). Gene scan spectratyping of the TCR 
Vβ-repertoire is at best a semi-quantitative measurement. Both flow-cytometry and 
NGS result in a more accurate quantitative assessment of the TCR Vβ-repertoire. 
As NGS is more labor-intensive and sorting of highly pure T cells or their subsets is 
required, many researchers prefer to use flow-cytometry. Flow-cytometry allows for 
measuring percentages of TCR Vβ-families at the T cell-subset level obviating the 
need for cell sorting.
We recently examined the TCR Vβ-repertoire in ESRD patients using multiplex DNA-
based spectratyping. We showed ESRD to significantly and independently skew the 
TCR Vβ-repertoire in older individuals and this skewing was predominantly present 
within the CD8+ memory T-cell compartment (24). However, details of this skewed 
TCR Vβ-repertoire in ESRD patients are still lacking and quantitative data related to 
the impact of ESRD on TCR Vβ-repertoire in the various T-cell populations is rare. 
During ageing the TCR Vβ-repertoire has been reported to contract (25). Ageing 
is associated with a decline in the naive T-cell compartment which possess the 
broadest TCR-repertoire (26), and a shift towards memory T cells, developing 
upon encountering of an antigen and having a skewed repertoire towards particular 
specificities (27, 28). The prevalence of CMV-seropositivity is high amongst 
ESRD patients, varying from 30-100%, depending on socio-economic and ethnic 
background (29). CMV latency profoundly affects circulating T cells resembling 
features of ageing, including increased frequencies of more differentiated memory 
T cells (30, 31) and loss of telomere length (32). CMV latency may also induce 
contraction of the TCR Vβ-repertoire as it induces expansion of CMV-specific T cells 
immunocompetent donors (33) and these CMV-specific clones are stably maintained 
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Fig. 1. Gini-TCR indices for different T cell subsets. The different Gini-TCR indices are 
depicted for HI (a, c, e and g) and ESRD patients (b, d, f and h). First, the Gini-TCR indices 
for RTE (CD31+ naive) and CD31- naive CD4+ (a and b) and CD8+ T (c and d) cells are given, 
respectively. Next, the differentiation-associated effects on Gini-TCR indices are depicted for 
CD4+ (e and f) and CD8+ (g and h) T cell subsets, including naive, central memory (CM), 
effector memory (EM) and terminally differentiated effector memory (EMRA) T cells. *; ** 
and *** refl ect P-values <0.05; 0.01 and 0.001, respectively. Data from 10 HI and 10 ESRD 
patients are given as median with interquartile range.
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for 5 years (34). Thus TCR Vβ-repertoire diversity may be affected by various factors. 
In this study, we assessed the TCR Vβ-repertoire diversity within different T-cell 
subsets in ESRD patients using a flow-cytometry-based taking into account the 
effects of  ageing and CMV latency.
MATERIALS AND METHODS
Study population
A cohort of ten stable ESRD patients, either younger individuals (n=5, age<45 years) 
or older individuals (n=5, age≥65 years) with an oligoclonal TCR Vβ-repertoire, as 
determined by DNA-based spectratyping earlier (24) were studied in more detail at 
the T-cell subset level using a flow-cytometry based assay for TCR Vβ-repertoire 
analysis. Patients having a glomerular filtration rate below 15 mL/min and either 
or not receiving receiving renal replacement therapy were included. Patients were 
excluded from the study when having a bacterial or viral infection, malignancy, a 
previous transplantation or taking immunosuppressive medication (except for 
glucocorticoids). The patient data are compared to those generated from ten age- 
and CMV-matched healthy individuals (HI) with a polyclonal TCR Vβ-repertoire, 
as determined by DNA-based spectratyping (24). Lithium-heparinized blood was 
drawn from ESRD patients and HI. Written informed consent was obtained from all 
individuals included. The study was approved by the local medical ethical committee 
(METC number: 2012–022) and conducted according to the principles of Declaration 
of Helsinki and in compliance with International Conference on Harmonization/Good 
Clinical Practice regulations.
Sample preparation
Peripheral blood mononuclear cells (PBMCs) were isolated from 35 mL of lithium-
heparinized blood by density centrifugation as described previously (38) and then 
frozen at 10x106 PBMC per vial at -190◦C until further use. 
Cryopreserved PBMCs (1 vial of 10x106 PBMCs) were thawed, counted, washed 
and resuspended in Isoflow™ Sheath Fluid (Beckman Coulter B.V., Woerden, 
Netherlands). The PBMCs were stained with Brilliant Violet (BV) 510 labeled 
anti-CD3 (BioLegend, Uithoorn, Netherlands), Alexa Fluor (AF)700 labeled anti-
CD4 (Beckman Coulter B.V.) and Allophycocyanin (APC)-Cy7 labeled anti-CD8 
(BioLegend) to identify CD4+ and CD8+  within CD3+T cells. ECD labeled anti-
CD45RO (Beckman Coulter B.V.), PE-Cy7 labeled anti-CCR7 (BD, Erembodegem, 
Belgium), V450 labeled anti-CD31 (BD; clone WM59), Peridinin chlorophyll-A protein 
(PerCP)-Cy5.5 labeled anti-CD28 (BD) and APC labeled anti-CD57 (BioLegend) as 
well as fluorescence minus one controls (FMOs) were used to appropriately identify 
the different T-cell subsets (illustrated in Fig. S1b-d in Supplementary Material). 
As shown in Fig. 1b, CCR7 and CD45RO are used to distinguish the different 
naive and memory T-cell subsets, i.e. naive (CD45RO-CCR7+), central memory 
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(CM, CD45RO+CCR7+), effector memory (EM, CD45RO+CCR7-) and terminally 
differentiated effector memory CD45RA+ subsets (EMRA, CD45RO-CCR7-). CD31-
expression within naive T cells (Fig.S1c) identifies T cells that recently have 
left the thymus, also referred to as recent thymic emigrants (RTE) (39). Loss of 
CD28 (CD28- T cells) and gain of CD57 (CD57+ T cells) expression is observed in 
relation to increased replicative history (40, 41) and allows for identification of more 
differentiated T cells (Fig.S1d). 
Subsequently, the cell suspension was divided into 8 tubes (100 µL/tube) labeled 
A-H, corresponding to the different antibody cocktails to stain for the 24 TCR Vβ-
families (IOTest® Beta Mark TCR V beta repertoire kit, Beckman Coulter B.V).  Each 
cocktail contains antibodies directed to 3 different Vβ-families, i.e one is fluorescein 
isothiocyanate (FITC-), one is PE-labeled and one is labeled with both FITC and 
PE. Table 1 shows the description of the antibodies directed to the different TCR 
Vβ-families in tube A to H. A typical example of the proportions of several TCR Vβ-
Tube Vβ family Fluorochrome Clone 
A Vβ 5.3 PE 3D11
Vβ 3 FITC CH92
Vβ 7.1 PE+FITC ZOE
B Vβ 9 PE FIN9
Vβ 16 FITC TAMAYA1.2
Vβ 17 PE+FITC E17.5F3
C Vβ 18 PE BA62.6
Vβ 20 FITC ELL1.4
Vβ 5.1 PE+FITC IMMU157
D Vβ 13.1 PE IMMU222
Vβ 8 FITC 56C5.2
Vβ 13.6 PE+FITC JU74.3
E Vβ 5.2 PE 36213
Vβ 12 FITC VER2.32
Vβ 2 PE+FITC MPB2D5
F Vβ 23 PE AF23
Vβ 21.3 FITC IG125
Vβ 1 PE+FITC BL37.2
G Vβ 11 PE C21
Vβ 14 FITC CAS1.1.3
Vβ 22 PE+FITC IMMU546
H Vβ 13.2 PE H132
Vβ 7.2 FITC ZIZOU4
Vβ 4 PE+FITC WJF24
Table 1 TCR Vβ-families in tube A-H
Detailed information with respect to the different TCR Vβ-family antibodies in tube A-H, 
labels and clones (IOTest® Beta Mark TCR V β-repertoire kit, Beckman Coulter) .
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families within CD3+ T cells from tube A, tube B and tube C is depicted in Fig.S1a, 
the last 3 plots. 
The samples were measured on a Navios flow cytometer (10-color configuration; 
Beckman Coulter B.V.) and at least 0.5 million CD3+ T cells were acquired for 
each tube. Data were analyzed by Kaluza™ software (Beckman Coulter B.V.). The 
number of events acquired for a specific T-cell subset needed to be more than 100 
to allow for reliable analysis of frequencies of TCR Vβ-families within this population. 
The only subset that did not meet this criterion was the EMRA population within the 
CD4+ T cells. 
Gini-TCR index and calculation of expanded TCR Vβ-families
The Gini index is used to describe the distribution of income in economic statistics. 
As the distribution of TCR Vβ-families shows similarities to that of income, the Gini 
index can also be applied in TCR Vβ-repertoire analysis by flow-cytometry. It has 
already been used in TCR-sequencing studies (42, 43), and was recently also 
introduced as an accurate and reliable way for analyzing TCR Vβ-repertoire data 
obtained by flow-cytometry (44). The TCR (Vβ)-Gini index with scores ranging from 
low to high indicates TCR Vβ-families from equal distribution (broad repertoire; i.e. 
low score) to unequal distribution (skewed repertoire; i.e. high score). A Microsoft 
excel file allowing for automatic calculation of the Gini-TCR index using percentages 
Table 2 Demographic and clinical characteristics of the study population
 Healthy individuals ESRD patients P-value
Number of individuals 10 10
Age  (years;range) 
young group (<45 years) 36 (26-42) 28 (20-29) 0.06
elderly group (>65 years) 68 (65-73) 70 (65-73) 0.92
Sex (% male) 60 40 0.66
CMV IgG serostatus (% pos) 60 60 1.00
RRT ( %) n.a. 70 n.a.
Duration of RRT (months; median/rang) 20 (7 - 68)
Hemodialysis (%) 85.7
Peritoneal dialysis (%) 14.3
Underlying kidney disease
    Primary glomerulopathy (%) 20
    Diabetic nephropathy (%) 30
    Reflux nephropathy (%) 10
    Polycystic kidney disease (%) 20
    Lupus nephritis (%) 10
    Unknown (%) 10  
ESRD: end-stage renal disease; CMV: cytomegalovirus; RRT: renal replacement therapy; 
n.a.: not applicable 
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of 24 TCR-Vβ families is provided in the supporting fi le (44).  
An expansion in a TCR Vβ-family induced by ESRD is defi ned as a frequency above 
the mean percentage + 2 times the standard deviation (SD) of a certain TCR Vβ-
family obtained using the HI as reference population. By using this approach, fi nding 
an expansion by chance is lower than 2.5%.  
Statistical analyses 
Gini-TCR indices or median number of expanded TCR Vβ-families/individual 
between two different T-cell subsets within individuals were compared with Wilcoxon 
signed rank test and Friedman test followed by Dunn’s Multiple Comparison T test 
was used for comparing more than two different T-cell subsets. Trend analyses were 
performed using two-way ANOVA, comparing different subsets between individuals 
or CD4+ and CD8+ T cells. In addition, the effect of ESRD with respect to numbers 
of expanded TCR Vβ-families within different T cell subsets is done using Fisher’s 
exact test. Two-sided p values <0.05 were considered statistically signifi cant. All 
statistical analyses were performed with GraphPad Prism 5. 
Fig. 2. Effect of ESRD on Gini-TCR indices of CD8+ T-cell subsets. In a) the median and IQ 
range of the Gini-TCR indices for HI (N=10) and ESRD patients (N=10) for different CD8+ 
T-cell subsets is depicted whereas in b) and c) those for the young and older group (N=5) are 
given, respectively.  P value: * < 0.05.
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RESULTS
Study population
Detailed information of the study population is given in Table 2. Ten ESRD patients 
(5 younger individuals: age 20-29 years & 5 older individuals: age 65-73 years) and 
10 age-matched HI (5 younger individuals age 26-42 years & 5 older individuals: 
age 65-73 years) were recruited into this study. Sixty percent of the ESRD and HI 
study population is CMV-seropositive. Seven out of 10 ESRD patients received renal 
replacement therapy (RRT). 
Gini-TCR indices increase with T-cell differentiation 
Naive T cells expressing CD31 are considered to be recent thymic emigrants and the 
least-differentiated T-cell subset. In ESRD patients, CD31-expressing naive T cells 
tended to or have a lower Gini-TCR index when compared to their CD31- counterparts 
within CD4+ (Fig. 1b) and CD8+ T cells (Fig. 1d), respectively. For HI, a significant 
lower Gini-TCR index was only observed for CD31-expressing naive CD8+ (Fig. 1c) 
but not CD4+ (Fig. 1a) T cells when compared to CD31- naive T cells. Furthermore, 
a T-cell differentiation-associated increase in Gini-TCR indices was noted for CD8+ 
(Fig. 1g and 1h), but not CD4+ (Fig. 1e & 1f), T cells.  The median value (IQ range) 
increased significantly (P<0.001) from 36.5 (33.7-37) and 35.5 (33.8-37.9) in naive T 
cells to 49 (43-64.6) and 52.4 (44.9-72.8) in the highly differentiated effector memory 
(EMRA) CD8+ T cells for HI and ESRD patients, respectively. 
ESRD patients have increased Gini-TCR indices within memory CD8+ T cell 
subsets 
We next analyzed the influence of ESRD, ageing and CMV latency on skewing of 
the TCR Vβ-repertoire by comparing Gini-TCR indices for different T-cell subsets 
including total CD3+ T cells, as well as naive, CD31+ naive, total memory (MEM), 
CM, EM, EMRA, CD28- and CD57+ populations within both the CD4+ and CD8+ T 
cell subsets.  ESRD effects with respect to Gini-TCR indices were limited to the 
CD8+ T cell compartment as it tended to induce higher Gini-TCR indices (P=0.06) in 
CD8+ memory T cells when compared to HI (Fig. 2a). The median (IQ range) value 
for Gini-TCR index in CD8+ memory T cells amounted to 48.4 (45.8-63.3) and 43.8 
(41.1-51.2) for ESRD patients and HI, respectively.  Younger (Fig. 2b), but not older 
(Fig. 2c), ESRD patients had significantly higher Gini-TCR indices within the CD8+ 
CM (P<0.05), EM  (P<0.05)  and CD57+ T cell compartment when compared to age-
matched HI. The median (IQ range) for Gini-TCR in CD8+ CM, EM and CD57+ T cells 
amounted to 47.4 (40.8-54.2) versus 35.3 (34.0-39.2), 54.4 (49.6-68.5) versus 43.7 
(42.4-50.8) and 77.6 (65.8-78.4) versus 59.2 (57.2-67.1) for younger ESRD patients 
versus younger HI. 
The following results, describing Supplementary Table 1 and 2 need to be 
interpreted with caution as the P-values were not adjusted for the number of 
parameters compared. 
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Table 3 Effect of ESRD on expansions of TCR Vβ-families
# of ESRD patients 
with/without  
expansions
Median # of 
expanded TCR Vβ-
families
 (IQ range)
Total # of expanded 
TCR Vβ-families
CD3+ 7/3 1 (0-2) 15
CD4+ 5/5 1 (0-2) 10
 CD31+ naive 6/4 1 (0-1) 9
naive 3/7 0 (0-1) 5
MEM 9/1 1 (1-3) 16
CM 6/4 1 (0-2) 11
EM 6/4 1 (0-2) 13
EMRA 7/3 2 (0-2) 15
CD28- 9/1 1 (1-1) 12
CD57+ 9/1 1 (0-2) 11
CD8+ 10/0 2 (1-4) 26
CD31+ naive 7/3 1 (0-2) 15
naive 8/2 1 (1-1) 12
MEM 10/0 2 (2-4) 28
CM 7/3 2 (0-3) 20
EM 9/1 4 (2-4) 32
EMRA 10/0 2 (1-3) 26
CD28- 10/0 3 (1-3) 28
CD57+ 9/1 3 (1-4) 25
Fig. 3. Expansions of TCR Vβ-families within CD8+ memory T cells from ESRD patients. 
Boxes and error bars represent the mean and 95% confi dence interval (mean ± 2SD) of 24 
TCR-Vβ families from 10 healthy individuals (HI). Red dots correspond to expanded TCR Vβ-
families from ESRD patients (frequencies> mean+2SD from HI).
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Ageing effects were not visible when comparing Gini-TCR indices for the different 
T-cell subsets between younger and older ESRD patients (Supplementary Table 
1). In HI, ageing effects were confined to the CD8+ T cell compartment and an 
ageing-related increasing trend in Gini-TCR index was observed for CD8+ CM T 
cells (P=0.06), as the median (IQ range) for Gini-TCR amounted to 40.1 (39.1-44.1) 
in older HI versus 35.3 (34.0-39.2) in younger HI. An increased Gini-TCR index 
(P=0.03) was observed for older HI, within CD8+CD28- T cells (Supplementary 
Table 1). The median (IQ range) value for Gini-TCR in CD8+CD28- T cells amounted 
to 42.0 (40.6-47.4) versus 57.8 (43.7-63.7) for younger and older HI, respectively. 
CMV latency did not significantly affect Gini-TCR indices apart from a CMV-related 
increasing trend within CD4+CD57+ T cells (P=0.07) of HI, but not ESRD patients, 
i.e. the median (IQ range) Gini-TCR index amounted to 67.0 (57.4-72.2) for CMV-
seropositive HI versus 45.6 (35.5-58.0) for CMV-seronegative ones (Supplementary 
Table 2). No differences were observed when comparing CMV-seronegative and 
CMV-seropositive ESRD patients to their CMV-serostatus matched HI with respect 
to Gini-TCR indices for the different T-cell subsets (data not shown). 
Clonal expansions of TCR Vβ-families in different T-cell subsets
Apart from characterizing the impact of ESRD on Gini-TCR indices for the different 
T-cell subsets, we also evaluated the impact of ESRD on clonal expansions of TCR 
Vβ-families by comparing frequencies to the average+2SD obtained using HI as 
reference population. Fig. 3 shows a typical example of expanded TCR Vβ-families 
within CD8+ memory T cells of ESRD patients. 
Clonal expansions of TCR Vβ-families were observed within the CD3+ T cells in 7 
out of 10 ESRD patients (Table 3). Half versus all of the ESRD patients showed 
expanded TCR Vβ-families within CD4+ and CD8+ T cells (P<0.05), respectively. The 
median (IQ range) number of expanded TCR Vβ-families per patient amounted to 1 
(0-2) and 2 (1-4) families for CD4+ and CD8+ T cells (P<0.05), respectively (Fig. 4a). 
Interestingly, expansions were also detected within the naive T cell compartment, 
as 3 out of 10 and 8 out of 10 patients had expansions of TCR Vβ-families within 
the naive CD4+ and CD8+ T cell compartment, respectively (Table 3). Most clonal 
expansions were observed within the (more differentiated) memory CD8+ T cell 
subsets (Fig. 4a).  The median (IQ range) number of expanded TCR Vβ-families 
amounted to 1 (1-1) versus 2 (2-4) for naive and memory CD8+ T cells, respectively 
(P<0.05). Moreover, ESRD affected different TCR Vβ-families as illustrated in Fig. 3 
for CD8+ memory T cells. ESRD induced expansions within both younger (Fig. 4b) 
as well as older (Fig. 4c) ESRD patients when compared to their age-matched HI.
Discussion 
The main finding of this study is that the multiparameter flow-cytometry-based 
approach for evaluating the skewed TCR Vβ-repertoire diversity in ESRD patients 
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showed that TCR skewing can be observed primarily in CD8+ T-cell subsets, including 
naive T cells . However, higher Gini-TCR indices, indicative for an enhanced TCR 
Vβ-repertoire skewing, were specifi cally associated with more differentiated CD8+, 
but not CD4+, T-cell subsets in both ESRD patients and HI. 
Fig. 4. ESRD effect on TCR Vβ-families within T-cell subsets. Using HI (N=10) as a reference 
population, we evaluated the number of TCR Vβ-families that were expanded per patient for a 
T-cell subset (frequency of a TCR Vβ-family exceeding the mean+2SD value obtained for HI) 
(a). In b and c, the median (IQ range) of expansions per young and older patient for a T-cell 
subset is depicted using the young (N=5) and older HI (N=5) as a reference, respectively. The 
open bars represent the median and IQ range for the different CD4+ T-cell subsets, whereas 
the closed bars represent that for the different CD8+ T-cell subsets.
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Our previous data showed that ESRD may lead to a skewed TCR Vβ-repertoire 
as assessed by DNA spectratyping, providing at best semi-quantitative information 
about TCR Vβ-clonality (24). The current study provided more quantitative details 
with respect to this skewed TCR Vβ-repertoire at the T cell subset level using the 
Gini-TCR index as a tool for calculating skewness (44) and evaluating number/type 
of expanded TCR Vβ-families. Higher Gini-TCR indices are indicative of a more 
skewed TCR Vβ-repertoire. The current study confirmed several of our previous 
findings. Increased skewing of the TCR Vβ-repertoire was observed for more 
differentiated CD8+, but not CD4+, T cells, corresponding to our spectratyping data 
as well as findings described by others (27, 45). In addition to the Gini-TCR index, we 
calculated the number of TCR Vβ-families per patient that were expanded beyond 
the mean+2SD values of HI. This approach yielded similar results as the Gini-
index but gives detailed information at the individual patient level for the different 
T-cell subsets. For instance some patients have a large number of expanded TCR 
Vβ-families while others show only a few. Moreover, ESRD did not seem to affect 
one TCR Vβ-family in particular, indicative of expansions of different clonal origin. 
Altogether, using both Gini-TCR indices as well as the number of TCR Vβ-family 
expansions, revealed skewing to mainly occur within the CD8+ and in particular 
within the CD8+ memory T-cell subset similar to what was observed before using 
DNA-based spectratyping on sorted T-cell subsets (24). 
The commercially available flow-cytometry-based assay, used to characterize 
the TCR Vβ-repertoire, is composed of 24 different TCR Vβ-antibodies covering 
about 70% of the normal human TCR Vβ-repertoire (brochure Beckman Coulter). 
Evaluating other TCR Vβ-families as well as TCR Vα and TCR Vγ/Vδ families may 
contribute to a better understanding of the whole TCR-repertoire. In this respect, γδ+ 
T cells account for approximately 8% of CD3+ peripheral blood T cells and around 
6% of γδ+ T cells were observed within CD3+CD8+, but not CD4+ T cells in HI (19). 
As frequencies of γδ+ T cells may also vary amongst individuals, it might be more 
accurate to evaluate the TCR Vβ-repertoire not within total CD3+, like performed in 
the current study, but within αβ+ CD3+ T cells.
Interestingly, using this multi-parameter flow-cytometry based approach, we were 
also able to detect expanded TCR Vβ-families within the naive T-cell compartment. 
This characteristic has, to our knowledge never been described for ESRD patients. 
Uremia induces a pro-inflammatory environment significantly affecting T-cell 
mediated immunity characterized by increased risk for infections (5) and decreased 
vaccination efficacy (1, 46). We have observed that progressive loss of renal 
function is accompanied by a severe depletion of the naive T-cell compartment 
and a relative shift towards more differentiated  memory T cells (47). Naive T cells 
employ a mechanism referred to as homeostatic proliferation in order to maintain 
the naive T-cell pool that is not replenished by newly developed naive T cells from 
the thymus due to thymic involution. Homeostatic proliferation occurs in response to 
homeostatic cytokines, e.g. IL-7, or low affinity self antigens presented by antigen-
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presenting cells (48). This mechanism has been described to be associated with a 
decline in TCR Vβ-repertoire diversity within naive T cells with increasing age (27, 
49). ESRD enhanced homeostatic proliferation of naive T cells to a similar extent as 
observed in older HI (12) and as a consequence of this compensatory mechanism, 
loss of TCR Vβ-repertoire diversity may also be induced by ESRD within naive CD8+ 
and/or CD4+ T cells. 
Naive T cells are required to mount adequate immune responses to newly 
encountered antigens (50, 51). ESRD patients, with a severely depleted naive T-cell 
compartment (47), are hampered in inducing adequate protection to for example 
HBV vaccination as a result of defective generation of antigen-specific memory T 
cells (46). The ESRD-associated defects in T-cell composition as well as function, 
reminiscent of ageing-associated T-cell defects, led to the concept of premature 
T-cell ageing introduced in 2011 (12). ESRD patients have a T-cell compartment that 
is aged by 15-20 years compared to their chronologic age, using age-matched HI 
as a reference. Consistent with premature T-cell ageing (12), we observed ESRD-
associated increases in Gini-TCR indices and TCR Vβ-expansions to occur already 
at young age.
Ageing is known to affect TCR Vβ-repertoire diversity towards a more skewed pattern, 
starting from roughly 600×103 clonotypes detected per 106 T cells in childhood, 
declining by 5×103 clonotypes per year (25).  Age-related effects were limited within 
our cohort of HI and this may be a consequence of the selection procedure applied. 
We did select HI with a polyclonal (i.e. non-skewed) TCR Vβ-repertoire using DNA-
based spectratyping(24), to ensure a relatively standard healthy population to be 
used as reference for comparison to ESRD patients. The ESRD patient population 
however only consisted of individuals with an oligoclonal (skewed) TCR Vβ-
repertoire. This might have resulted in an underestimation of the effect of ageing on 
TCR Vβ-families. Likewise, our selection procedure may also explain the minimal 
effects of CMV in both cohorts. 
CMV latency is known to introduce skewing of the TCR Vβ-repertoire induced by 
expanded CMV-specific T cell clones in both HI (33-35) and ESRD patients (24). 
CMV latency may result in a vast and long-lasting expansion of CMV-specific T cells 
(33, 34). Moreover, CMV latency has additional effects mainly on circulating CD8+ T 
cells of ESRD patients (52). 
ESRD, ageing, and CMV all influenced the TCR Vβ-repertoire diversity to a different 
extent (24), however, because of different factors present in the environment, they 
all have their specific effect on clonotype selection. Even though these findings need 
to be verified in a larger cohort without preselection using DNA-based spectratyping 
of TCR Vβ-repertoire, our study already shed some light on this altered TCR Vβ-
repertoire at the T-cell subset level in particular with respect to ESRD.
End-stage renal disease causes skewing in the TCR Vβ-repertoire primarily within CD8+ 
T-Cell Subsets 
87
4
Relating TCR-repertoire data to functional capacities of T cells is warranted to 
increase knowledge on uremia-induced T-cell defects in ESRD patients. Moreover, 
tracking TCR clones in whole blood or tissue infiltrates may provide additional 
information on antigen specificity important for diagnosis of infection and allograft 
rejection after transplantation (53-55). 
In conclusion, ESRD is associated with a skewed TCR Vβ-repertoire as a result of 
variable TCR Vβ-family expansions, but not one in particular. ESRD, ageing and 
CMV latency exert their effects by influencing different TCR Vβ-families. This altered 
repertoire may be associated with a less broad and less diverse T-cell mediated 
immunity.
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SUPPORTING INFORMATION
Fig. S1 (right) Gating Strategy multi-parameter flow-cytometric analysis TCR Vβ-repertoire. 
Briefly, lymphocytes were identified based on the forward/sideward characteristics (a, first plot) 
followed by the selection of CD3+ T cells (a, second plot). These T cells were then dissected 
into CD4+ and CD8+ T cell (a, third plot). Furthermore, a typical flow-cytometric result for 
CD3+ T cells with respect to tube A-C, each containing 3 different Vβ-families (identified by 
PE+,PE+FITC+ and FITC+), is depicted in the last three plots of (a). A similar approach is also 
followed for tubes D-H and all subsets.  Fluorescence minus one controls (FMOs) from the 
base for all subsequent gating performed to identify the different populations within CD4+ and 
CD8+ T cells. CCR7 and CD45RO were used to identify naïve and different memory T-cell 
subsets (b, first and latter 3 plots for CD4+ and CD8+ T cells, respectively).  Loss of CD28 and 
gain of CD57 expression were used for identification of highly differentiated T cells (d, first and 
latter 3 plots for CD4+ and CD8+ T cells, respectively). 
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Supplementary file 
Template for calculating the Gini-TCR index using % of TCR Vb-families within CD3+ T cells 
of patient 1
*copy/paste arranged % of 24 TCR Vbeta families
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ABSTRACT
Background
Patients with end-stage renal disease (ESRD) have an impaired immune response 
with a prematurely aged T-cell system. Mitogen-activated protein kinases (MAPKs) 
including extracellular signal-regulated kinase (ERK) and p38, regulate diverse 
cellular programs by transferring extracellular signals into an intracellular response. 
T cell receptor (TCR)-induced phosphorylation of ERK (pERK) may show an age-
associated decline, which can be reversed by inhibiting dual specific phosphatase 
(DUSP) 6, a cytoplasmic phosphatase with substrate specificity to dephosphorylate 
pERK. The aim of this study was to assess whether ESRD affects TCR-mediated 
signaling and explore possibilities for intervening in ESRD-associated defective 
T-cell mediated immunity. 
Results  
An age-associated decline in TCR-induced pERK-levels was observed in the 
different CD4+ (P<0.05), but not CD8+, T-cell subsets from healthy individuals (HI). 
Interestingly, pERK-levels of CD4+ T-cell subsets from young ESRD patients were in 
between young and elderly HI. A differentiation-associated decline in TCR-induced 
ERK and p38 phosphorylation was observed in T cells, although TCR-induced p38 
phosphorylation was not significantly affected by age and/or ESRD. Frequencies of 
TCR-induced CD69-expressing CD4+ T cells declined with age and were positively 
associated with pERK. In addition, an age-associated tendency of increased 
expression of DUSP6 was observed in CD4+ T cells of HI and DUSP6 expression 
in young ESRD patients was similar to old HI. Inhibition of DUSP6 significantly 
increased TCR-induced pERK-levels of CD4+ T cells in young and elderly ESRD 
patients, and elderly HI.
Conclusions 
TCR-mediated phosphorylation of ERK is affected in young ESRD patients consistent 
with the concept of premature immunological T cell ageing. Inhibition of DUSP6 
specific for pERK might be a potential intervention enhancing T-cell mediated 
immunity in ESRD patients.
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BACKGROUND
ESRD patients have a defective T-cell mediated immune system that is clinically 
characterized by an increased risk of a variety of infections (1, 2) and impaired 
response of vaccination (3-7). Infections are the second leading cause of mortality 
following cardiovascular disease and a major cause of morbidity in ESRD patients(8). 
Uremia-associated T-cell defects closely resemble premature immunological 
T-cell ageing (9). ESRD patients have a discrepancy of 15-20 years between the 
immunological T-cell age and their chronological age (10). Declined thymic output, 
more differentiated memory T cells, T cells lacking co-stimulatory molecules like 
CD28, skewed T cell receptor (TCR) Vβ repertoire diversity and shorter telomere 
length are observed in ESRD patients compared to age-matched healthy individuals 
(HI) (11). 
TCR-induced signaling mediates clonal (positive or negative) selection of thymocytes 
in the thymus and initiates T cell immune responses in the periphery, consisting 
of T cell proliferation and differentiation (12). The mitogen-activated protein kinase 
(MAPK) pathway is one of the major pathways induced upon TCR stimulation (13). 
Activation of MAPK is mediated by phosphorylation of MAPK and downregulated by 
MAPK phosphatase resulting in inactive MAPK (14). In particular, the extracellular 
signal-regulated kinase (ERK) pathway is one of the important MAPK pathways. 
Phosphorylation of  ERK can reduce sensitivity of cells to apoptosis and promote 
cell proliferation (15). ERK activity controls the positive feedback loop in the TCR-
induced activation cascade and reduced ERK activity affects signal strength and 
activation of T cells (16, 17). Reduced phosphorylation of ERK is associated with 
decreased interleukin-2 (IL-2) production (18) and vice versa (19).  Dual specific 
phosphatases (DUSPs) represents a family of phosphatases that dephosphorylate 
phosphor-threonine and phosphor-tyrosine residues on MAPK and that are pivotal 
regulators of MAPK activities. DUSP6 is a cytoplasmic phosphatase with substrate 
specificity to dephosphorylate pERK (20). Ageing is also associated with defective 
signaling pathways (21, 22). Recently it was shown that decreased phosphorylation 
of ERK in naive CD4+ T cells from elderly HI was associated with more time to 
build up the required signaling strength following stimulation compared to those from 
young HI. This decreased phosphorylation of ERK can be overcome by inhibiting 
DUSP6 (16).
P38 is another pivotal protein in the MAPK pathway (23) and of interest with respect 
to age-related changes is T cell activation. Most stimuli, including engagement of 
TCR, costimulatory receptors, inflammation, stress, growth factors, as well as DNA 
damage induce phosphorylation of p38 by various pathways (24, 25). Although 
phosphorylation of ERK and p38 from T cells share some upstream molecules after 
triggering of TCR, such as phosphorylation of CD3 zeta-chain associated protein 
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kinase of 70 kDa (ZAP70) (26), they each have their unique upstream MAPK kinases 
(MKKs) (14). Highly differentiated CD4+ T cells lacking expression of CD28 are 
accumulated in elderly healthy individuals (27), patients with ESRD (28), following 
chronic viral infection (29), and also in patients suffering from autoimmune disease 
(30). Senescent CD27-CD28-CD4+ T cells employ an MKK-independent mechanism 
for phosphorylating p38 and depend on 5’ adenosine monophosphate-activated 
protein kinase (AMPK) and transforming growth factor-β-activated protein kinase 
1(TAK1)-binding protein 1(TAB1) ex vivo (31). 
Little is known as to how MAPK signaling pathways in ESRD patients. Understanding 
MAPK signaling in ESRD patients may increase knowledge about mechanisms of 
uremia-associated impaired T-cell mediated immunity and offer possibilities for 
intervention. Here, we demonstrate that TCR-induced phosphorylation of ERK, and 
not p38, in CD4+ T cells decreases with age and T cell differentiation. This pathway 
is specifically affected in young ESRD patients and at the level of elderly healthy 
individuals, compatible with the concept of premature immunological T cell ageing 
in patients with renal failure. In addition, inhibition of DUSP6 may offer a potential 
intervention for improving T-cell mediated immunity in ESRD patients.  
METHODS
Study population
In line with our previous studies, young and elderly patients groups were defined 
based on their chronological age (32, 33). Twenty-four stable ESRD patients, 
defined as having a glomerular filtration rate of ≤15 ml/min with or without renal 
replacement therapy (RRT; i.e. dialysis) and 24 HI were included (Study population 
characteristics are described in Table 1) at the outpatient clinic. Patients with any 
clinical or laboratory evidence of acute bacterial or viral infection, malignancy, 
immunosuppressive drug treatment within 28 days prior to transplantation (except 
for glucocorticoids) were excluded. Lithium-heparinized blood was drawn of ESRD 
patients and healthy kidney donors. All individuals included gave informed consent 
and the local medical ethical committee approved the study (METC number: 2012–
022). It was conducted according to the principles of Declaration of Helsinki and in 
compliance with International Conference on Harmonization/Good Clinical Practice 
regulations.
PBMCs preparation
Peripheral blood mononuclear cells (PBMCs) were isolated from peripheral blood 
from HI and ESRD patients as described previously (34) and then cryopreserved for 
further analysis. 
Phosphorylation-specific flow cytometry
PBMCs were stained with eFluor-450-labeled anti-CD7 (eBioscience, Vienna, 
Austria), allophycocyanin-Cy7 (APC-Cy7)-labeled anti-CD8 (BD, Erembodegem, 
pERK-dependent defective TCR-mediated activation of CD4+ T cells in end-stage renal 
disease patients 
103
5
Belgium), Brilliant Violet (BV)-510-labeled anti-CD16 (BD) and fluorescein 
isothiocyanate (FITC)-labeled anti-CCR7 (R&D system, Uithoorn, the Netherlands) 
for 30 min at room temperature. Then 1 million PBMCs/50µl were prepared for 
stimulation by labeling cells with 20 µg/ml mouse anti-human CD3 (BD) and mouse 
anti-human CD28 (BD) each on ice for 20 min, followed by an incubation with goat-
anti mouse IgG (BD) for cross-linking on ice for 20 min. Stimulation was initiated by 
transferring cells to a 37 °C water bath for 10 minutes. Cells were fixed using Cytofix 
(BD) at 37 °C for 10 minutes and then permeabilized in 70% methanol at -20oC 
for 30 min. Subsequently, cells were stained with peridinin chlorophyll (PerCP)-
labeled anti-CD4 (BD), phycoerythrin (PE)-Cy7-labeled anti-CD45RO (BioLegend, 
Uithoorn, Netherlands), PE-labeled anti-phospho-p38MAPK (pT180/pY182) (BD), 
and Alexa Fluor (AF) 647-labeled anti-phospho-ERK1/2 (pThr202/pTyr204) (BD). 
Phosphorylation was measured on a BD FACSCanto II flow cytometer (BD) and data 
were analyzed by Kaluza™ software (Beckman Coulter, Woerden, Netherlands). 
Median fluorescence intensity (MFI) of phosphorylated ERK or p38, generated by 
Kaluza™, were multiplied by 256 to make them comparable to the data analyzed by 
FACS Diva software (linear value instead of log-transformed value) (BD). The MFI 
obtained for anti-CD3/anti-CD28-stimulation were corrected by subtracting the MFI 
of the unstimulated condition. 
Table 1 Clinical characteristics of the study population
 HI ESRD patients P value
Number of individuals 24 24
Age groups (years; mean ± SD) ns
young 29,4±5,6 34,6±8,0 
elderly 70,5±5,8 70,8±4,2
Sex (% male) 50 79,2 ns
CMV IgG serostatus (% pos) 62,5 62,5 ns
RRT (number;%) 11; (45,8%)
Duration of RRT in months  (median with range) 22  (1—37)
Hemodialysis (number) 7
Peritoneal dialysis (number) 4
Underlying kidney disease (number ; %) 
atherosclerosis/hypertensive nephropathy 8; (33%)
primary glomerulopathy 4; (17%)
Diabetic nephropathy 6; (25%)
congenital disorder 3; (13%)
others 2; (8%)
unknown  1; (4%)  
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CD69 and IL-2 measurement 
PBMCs were either not or stimulated with anti-CD3/anti-CD28 T-cell expander 
beads (Invitrogen Dynal, Oslo, Norway) at different ratios, i.e. 1 cell / 0.1 bead, 1 
cell / 0.5 bead, 1 cell / 1 bead for 6 hours in human culture medium (HCM; RPMI-
1640 with GlutaMAX, 10% heat-inactivated pooled human serum and 1% penicillin 
and streptomycin) (Lonza, Breda, Netherlands) with Golgistop (BD). Then cells were 
stained with AmCyan-labeled anti-CD3 (BD), Pacifi c Blue-labeled anti-CD4 (BD), 
APC-Cyanin 7 (APC-Cy7)-labeled anti-CD8 (BD), APC-labeled anti-CD45RO (BD) 
and PE-Cy7-labeled anti-CCR7 (R&D Systems) antibodies and a live–dead marker 
ViaProbe (7-aminoactinomycin D; 7AAD; BD). Upon fi xation with FACS lysing 
Fig. 1 Typical example of the gating strategy for analysis of phosphorylation of ERK (pERK) 
in naive CD4+ T cell subsets. Briefl y, (a) lymphocytes were identifi ed based on the forward/
sideward characteristics followed by (b) the selection of CD7+ CD16- T cells. c These T 
cells were then dissected into CD4+ and CD8+ T cells. d CCR7 and CD45RO were used 
to identify naive and different memory subsets within CD4+ T cells. Furthermore, (e) pERK 
was measured in naive CD4+ T cells without and with CD3/CD28 stimulation, and median 
fl uorescence intensities (MFI) were shown (values multiplied by 256 in brackets). A similar 
gating strategy was employed for phosphorylation of ERK and p38 in all T cells subsets
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solution (BD) and permeabilization using FACS permeabilizing solution 2 (BD), cells 
were stained intracellular using PE-labeled anti-CD69 (BD) and FITC-labeled anti-
IL-2 (BD). Percentages CD69-expressing and IL-2 producing CD4+ T cell subsets 
were evaluated upon measuring the samples on a BD FACSCanto II flow cytometer 
(BD). Data were analyzed by Kaluza™ software (Beckman Coulter).
DUSP6/1 inhibition 
PBMCs were pre-incubated in HCM including 50 µM (E)-2-benzylidene-3-
(cyclohexylamino)-2, 3-dihydro-1 H-inden-1-one (BCI) (Merck – Millipore, 
Amsterdam, Netherlands) at 37°C for 1h. BCI has been shown to be an inhibitor of 
DUSP6 and DUSP1 activity. PBMCs were subsequently washed 3 times and then 
stimulated by CD3/CD28 antibodies (as described previously) for 10 mins and then 
MFI of pERK of BCI-pretreated T cells was measured by phosphorylation-specific 
flow cytometry as described previously.
DUSP6/1 measurement
PBMCs were stained with AmCyan-labeled anti-CD3 (BD), Pacific Blue-labeled anti-
CD4 (BD), APC-Cy7-labeled anti-CD8 (Biolegend); APC-labeled anti-CD45RO (BD) 
and PE-Cy7-labeled anti-CCR7 (R&D Systems) antibodies and 7-AAD for 30 min at 
4 °C. Upon fixation and permeabilization using Fix/Perm buffer (eBioscience), 1% 
bovine serum albumin (Zwijndrecht, Netherlands) was used to block Fc receptors. 
Then cells were further stained with AF647-labeled anti-DUSP6 (Santa Cruz 
Biotechnology, Heidelberg, Germany) and PE-labeled anti-DUSP1 (Santa Cruz 
Biotechnology) for 30 min at 4 °C.  MFI of DUSP6 and DUSP1 was measured on 
a BD FACSCanto II flow cytometer (BD) and data were analyzed using FACS Diva 
software version 6.1.2 (BD).
Statistical analyses
Data were analyzed by Graphpad Prism 6 (GraphPad Software, CA, USA). 
Comparison between two groups (non-parametric data) were using Mann Whitney 
test. Comparison in multiple groups were using Friedman test followed by Dunn’s 
Multiple Comparison T test or repeated ANOVA test followed by Bonferroni’s multiple 
comparison test. Comparison between DUSP6-treated and non-treated conditions 
was done by Paired T- test.  All reported P-values are two-sided and were considered 
statistically significant when P<0.05.
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RESULTS
Study population 
The demographic and clinical characteristics of the study population are given in 
Table 1. Twelve patients were within the young group (age 22-44 years) and 12 
patients belonged to the elderly group (age 66-78 years). Age- and cytomegalovirus 
(CMV)-matched HI, i.e. 13 young (age 21- 40 years) and 11 elderly (age 65- 74 
years) HI were included for comparison. Approximately half of the ESRD patients 
received RRT (dialysis) with a median dialysis time of 22 months. 
Decreased ERK phosphorylation in young ESRD patients
A typical flow cytometric example for analysis of ERK phosphorylation is given in 
Fig. 1. First, we compared phosphorylation of ERK and p38 between young and 
elderly HI or young and elderly ESRD patients. A significant age-related lower TCR-
mediated phosphorylation of ERK was observed within all CD4+ T cell subsets from 
HI (Fig. 2a-d). For example, the median of MFI value of  CD4+ phosphorylated ERK 
(pERK) was 658 in young HI, which was significantly higher than 535 in elderly HI 
(p=0.015) (Fig. 2a). This trend consistently existed between young and elderly HI 
when we compared MFI value of pERK in CD4+ naive (median 722 vs. 612, p=0.022) 
(Fig. 2b), CM (median 666 vs. 489, p=0.021) (Fig. 2c) and EM subsets (517 vs. 364, 
p=0.018) (Fig. 2d). Due to the almost absent EMRA subset within the CD4+ T cells, 
phosphorylation of ERK and p38 within this subset was not evaluated.
However, no significant differences in expression levels of pERK in total CD4+  T 
cells or the subsets were found comparing young and elderly ESRD patients (Fig. 
2a-c & d).  For example, the median (interquartile range) MFI value of CD4+ pERK in 
young patients was 613 (490- 664) and 541 (413- 801) in elderly patients (p=0.51). 
The median MFI value for CD4+ pERK in young patients was in between the MFI 
values of young HI [658 (485- 1212)] and elderly HI [535 (305- 620)] but did not 
significantly differ from either group (respectively p=0.13 and p=0.06). This age-
associated decline in pERK was not found for CD8+ T cell subsets (Fig. 2e-h & i). 
In addition, an age-related decline in TCR-mediated phosphorylation of p38, was 
absent in CD4+ T cells (Fig. 3a-c & d) as well as CD8+ T cells (Fig. 3e-h & i) of both 
HI and ESRD patients. In conclusion, ESRD patients have a defective ERK, but not 
p38, phosphorylation in CD4+ T cells, that is independent of age and at a level similar 
to aged HI. 
Phosphorylation of ERK is associated with T-cell differentiation status
Next, we compared phosphorylation of ERK and p38 within different T cell subsets 
to assess whether differentiation-associated effects exist in the study groups. In all 
groups, a gradual decrease in TCR-induced phosphorylation capacity was seen with 
increasing CD4+ T cell differentiation. Phosphorylation of ERK was highest in naive 
CD4+ T cells of young HI, followed by that in the CM and EM subsets of the memory 
compartment (Fig. 4a). Median MFI dropped from 722 to 666 and 517 in the naive, 
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Fig. 7 Auto-phosphorylation (baseline) of ERK according to T cell differentiation status in 
healthy individuals (HI) and end stage renal disease (ESRD) patients. Phosphorylation of 
ERK in CD4+ T cells from (a) young HI (n = 13), (b) elderly HI (n = 11), (c) young patients (n = 
12), and (d) elderly patients (n = 12), as well as CD8+ T cells from (e) young HI, (f) elderly HI, 
(g) young patients, and  (h) elderly patients. Blank bars and bars with light grey to dark grey 
represent naive, central memory (CM), effector memory (EM) and highly differentiated effector 
T cells (EMRA) T cells, respectively. P value: *<0.05; ** < 0.01; *** < 0.001; Data are given as 
median with interquartile range.
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CM and EM T cell subset, respectively. Interestingly, in elderly HI as well as both 
groups of ESRD patients (Fig. 4b, c & d), pERK levels were still highest within naive 
CD4+ T cells compared to the more differentiated EM T cell subset, but the difference 
with that observed within CM T cells disappeared. ERK phosphorylation within CM 
is higher than that within the EM compartment in young and elderly HI (Fig. 4a & b), 
as well as in young patients (Fig. 4c), but not in elderly patients (Fig. 4d). Differences 
for the various CD8+ T-cell subsets with respect to TCR-mediated phosphorylation 
of ERK between naive and CM compartment, or between EM and EMRA were less 
outspoken and not significantly different in HI (Fig. 4e & f) and patients (Fig. 4g & 
h). Similar to ERK, phosphorylation of p38 showed a similar trend to decrease with 
increasing differentiation status but no significant decline in phosphorylation of p38 
from naive to CM in CD4+ in HI and patients (Fig. 5a-c & d). In CD8+ T cells, p38 
phosphorylation was decreased in highly differentiated EMRA compared to CM in HI 
and patients (Fig. 5e-g & h). In conclusion, a differentiation-associated decrease in 
anti-CD3/CD28-induced phosphorylation of ERK and p38 in T cells was present in 
HI and patients. 
Auto-phosphorylation (baseline) of ERK was associated with ageing in HI and 
increased according to differentiation status in CD4+ T cells
Baseline phosphorylation of ERK (i.e. auto-phosphorylation) was significantly lower 
for total and naive CD4+T cells in young HI compared with elderly HI, however, this 
trend was not observed in patients (Fig. 6a & b). Baseline levels of pERK were 
significantly lower in the CD8+ memory compartment (CM, EM and EMRA) when 
comparing young to elderly HI, but no age-related differences were observed for 
patients (Fig. 6g, h & i). Baseline phosphorylation of ERK was lower in the naive 
CD4+ T cells when compared to CM and/or EM in HI (Fig. 7 a & b) and patients 
(Fig. 7c & d). Naive CD8+ T cells also had lower baseline pERK when compared 
to EMRA in elderly HI (Fig. 7f), CM and EM in young patients (Fig. 7g), and EM in 
elderly patients (Fig. 7h). Naive CD4+ T cells had lower baseline phosphorylated 
p38 compared to CM or EM in elderly HI (Additional file 1: Fig. S1b), and lower p38 
phosphorylation compared to EM in young patients (Additional file 1: Fig. S1c). In 
CD8+ T cells, p38 auto-phosphorylation in naive compartment was significantly lower 
than that of EMRA in young and elderly HI (Additional file 1: Fig. S1e & f), but this 
trend was not observed in the patient population (Additional file 1: Fig. S1g & h). To 
summarize, an age- as well as differentiation-related increase in baseline levels of 
pERK was observed for CD4+ T cells.  
Neither CMV-serostatus nor RRT significantly influenced ERK or p38 
phosphorylation
CMV-seropositivity may promote immunological T-cell ageing and was therefore 
analyzed for its association with MAPK pathway activation. However, ERK or p38 
phosphorylation within T cells showed no significant difference comparing CMV-
seropositive individuals to their CMV- seronegative counterparts in healthy individuals 
and ESRD patients respectively (Additional file 1: Fig. S2 & S3). Moreover, in ESRD 
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Fig. 8 Percentages of CD69-expressing and IL-2 producing CD4+ T cell subsets in healthy 
individuals (HI) and end-stage renal disease (ESRD) patients. Percentages of CD69+ CD4+T 
cells were shown from healthy individuals (HI) (young n = 4, elderly n = 5) and end-stage 
renal disease (ESRD) patients (young n = 4, elderly n = 5) for (a) total, (b) naive, (c) memory 
CD4+ T cells, and frequencies of IL-2 expression were given for (d) total, (e) naive, (f) 
memory CD4+ T cells. Red dots and orange squares represent young and elderly HI, and 
blue upward- and purple downward-facing triangles correspond to young and elderly patients, 
respectively. The association between (g) percentages of CD69+ or (h) IL-2+ CD4+ T cells 
and ERK phosphorylation (depicted as fold increase by dividing the MFI of stimulated cells 
by that of unstimulated cells) is depicted. (i) The differentiation-associated relation between 
percentages of CD69+ and different CD4+ T cell subsets (naive, CM, EM) is shown. Black and 
blue downward-facing triangles represent 1 cell/0.1 bead and 1 cell/1 bead stimulation, and 
red squares correspond to 1cell/0.5 bead stimulation.  ◊ represents a signifi cant difference 
in the percentage of CD69+ T cells calculated for each specifi c CD4+ T cell subset when 
comparing young with elderly HI, or when comparing young with elderly patients. * represents 
a signifi cant difference in the percentage of CD69+ T cells comparing CD4+ subsets or CD8+ 
subsets within each study group. P value: ◊ <0.05;* < 0.05; **< 0.01; ***<0.001. Data are given 
as medians.
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patients, ERK or p38 phosphorylation was not significantly different between the 
patients receiving RRT (i.e. dialysis) and those without RRT (Additional file 1: Fig. 
S4 & S5). In conclusion, neither CMV-serostatus nor RRT significantly influenced 
TCR-stimulation induced phosphorylation of ERK or p38. 
Age-related decline in anti-CD3/CD28-induced CD69-expressing CD4+ T cells 
positively associated with phosphorylation of ERK 
A typical flow cytometric example for analysis of frequencies of CD69-expressing 
and IL-2 producing CD4+ T cells after CD3/CD28 stimulation was given in Additional 
file 1: Fig. S6. Higher frequencies of CD69-expressing CD4+ T cells were observed in 
young HI compared to that in elderly HI when stimulated with different ratios of anti-
CD3/CD28 beads to cells (Fig. 8a). This age-related decline in CD69-expressing 
cells was observed for naive CD4+ T cells in the healthy population at a ratio of 1:0.1 
(Fig. 8b) and at 1:0.1 and 1:1 ratios for memory CD4+ T cells (Fig. 8c). Percentages 
of IL-2 producing CD4+ T cells did not reveal an age-associated decline in our study 
population (Fig. 8d, e & f). Percentages of CD69-expressing CD4+ T cells following 
stimulation with anti-CD3/CD28 beads  (at ratios 1:0.5 and 1:1) were associated 
with ERK phosphorylation, presented as the fold increase in MFI dividing the MFI 
from stimulated samples by that of unstimulated samples (Fig. 8g). Percentages of 
IL-2 producing CD4+ T cells were not associated with pERK (Fig. 8h). In addition, 
frequencies of CD69-expressing CD4+ T cells were significantly higher in the naive 
subset compared to CM or EM (Fig. 8i). In short, an age-related decline in anti-
CD3/CD28-induced percentages of CD69-expressing CD4+ T cells was observed 
and percentages of CD69-expressing CD4+ T cells were positively associated with 
phosphorylation of ERK.  
BCI promoted TCR-mediated phosphorylation of ERK  
BCI is known to inhibit DUSP6 but also decrease levels of DUSP1 (product document, 
Merck – Millipore).  BCI did not significantly enhance phosphorylation of ERK in young 
HI; in contrast, in elderly HI and both young and elderly ESRD patients, the pERK 
level was significantly upregulated in all CD4+ T cell subsets pretreated with BCI 
compared to that without (Fig. 9a-c & d). The average fold increase in pERK levels 
in naive CD4+ T cell subsets were 3.8, 2.5, and 2.1 in elderly HI, young and elderly 
ESRD patients, respectively. This was not observed for CD8+ T cells (Additional file 
1: Fig. S7). In short, BCI promoted TCR-mediated phosphorylation of ERK in CD4+ T 
cells of both elderly HI as well as young and old ESRD patients. 
DUSP6 and DUSP1 expression in CD4+ T cells 
In an attempt to unravel whether effects of BCI on pERK levels were mediated by 
interfering with DUSP6 and/or DUSP1, we measured DUSP6 and DUSP1 levels 
within CD4+ T cells in a small fraction of our study cohort. Due to limited availability 
of materials only 10 HI (4 young and 6 elderly) and 9 ESRD patients (4 young 
and 5 elderly) could be included. A typical flow cytometric example for analysis of 
DUSP6 and DUSP1 is given in Additional file 1: Fig. S8. An age-associated trend 
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of increased levels of DUSP6 was noted for total and naive CD4+ T cells in HI (Fig. 
10a & b). The opposite was present comparing young to old ESRD patients (Fig. 
10a, b & c). Levels of DUSP6 in young ESRD patients were similar to old HI. Like 
observed for pERK, a signifi cant differentiation-associated increase in DUSP6 levels 
was observed (Fig. 10d). Interestingly, DUSP1 expression in CD4+ T cells was quite 
comparable between both young and elderly HI and patients (Fig. 10e, f, & g).  To 
conclude, an age-related tendency of increased levels of DUSP6, but not DUSP1, 
was observed for HI. Moreover, DUSP6 expression was signifi cantly associated with 
T-cell differentiation status in CD4+ T cells.  
Fig. 9 Phosphorylation of ERK in CD4+ T cell subsets without and with BCI treatment from 
healthy individuals (HI) and end-stage renal disease (ESRD) patients. Phosphorylation of 
ERK for BCI-pretreated or not BCI-pretreated cells is given for different CD4+ T cell subsets: 
(a) total, (b) naive, (c) central memory (CM) and (d) effector memory (EM) of HI (young n = 
5; elderly n = 5) and ESRD patients (young n = 5; elderly n = 5). Dots and squares represent 
young and elderly HI, upward- and downward-facing triangles correspond to young and elderly 
patients, respectively. P value: *<0.05; Data are given as individual values.
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Fig. 10 DUSP6 and DUSP1 expression in CD4+ T cell subsets from healthy individuals (HI) 
and end-stage renal disease (ESRD) patients. DUSP6 expression in (a) total, (b) naive and 
(c) memory CD4+ T cells; (d) Differentiation-associated DUSP6 expression in CD4+ T cells 
; DUSP1 expression in (e) total, (f) naive  and (g) memory CD4+ T cells; Dots and squares 
represent young (n = 4) and elderly HI (n = 6), and upward- and downward-facing triangles 
correspond to young (n = 4) and elderly (n = 5) patients, respectively. P value: * < 0.05; **< 
0.01; ***<0.001; Data are given as (individual values and) medians with interquartile ranges. 
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DISCUSSION 
The main observation of this study was that TCR-mediated phosphorylation of ERK 
in CD4+  T cells of young patients was in between young and old HI. Phosphorylation 
of ERK decreased in highly differentiated T-cell subsets compared to naive T cells. 
This defective TCR-mediated phosphorylation was specific as it could be restored 
by addition of a DUSP6 inhibitor. TCR-induced p38 phosphorylation was comparable 
between ESRD patients and HI. 
Beyond midlife, the immune system shows age-related features and its defensive 
capabilities becomes impaired (35). The uremia-associated inflammatory 
environment present in ESRD patients accelerates this age-related immune 
senescence process. In addition to declined thymic output, accumulation of highly 
differentiated T cells, short telomere length (10, 33, 36) and narrowed TCR Vβ 
-repertoire diversity (32), this study indicates that young ESRD patients also have a 
defective CD4+ TCR activation judging from the reduced capacity to phosphorylate 
ERK upon TCR-triggering. ERK activity is critical for TCR threshold calibration, as 
it controls positive feedback loops in TCR-induced activation (17). Reduced ERK 
activity impairs TCR signal strength and activation, and favors T cells with higher 
affinity to antigen to be activated, leading to a contracted immune response to a 
given antigen  (16). The ERK phosphorylation upregulation of early activation marker 
CD69 on T cells ensures a proper inducing activation of T cells in the lymph node 
(37), and also play an important role in T cell  proliferation (38) and IL-2 production 
(39, 40). In addition, ERK activation impacts cellular apoptosis as it inhibits Fas-
mediated apoptosis in T cells (41).  Evaluating ERK phosphorylation is a valuable 
tool to study more upstream molecules in the defective T-cell mediated immune 
system from ESRD patients. T cells from rheumatoid arthritis (RA) patients exhibit 
several defects which can also be viewed as premature immunological ageing (42). 
However, ERK phosphorylation in CD4+ T cells of RA patients selectively increased 
(43). This increased ERK activation lowers the TCR threshold in T cells of RA patients 
to respond to self-antigens, which may partly explain the adaptive immune system of 
RA patients to exhibit abnormalities that go beyond the local inflammatory response 
in the synovium (44). 
DUSP6 is a cytoplasmic phosphatase with substrate specificity for phosphorylated 
ERK. In elderly individuals, silencing of DUSP6 increased the expression of T cell 
activation markers, such as CD69 and CD25, IL-2 production as well as proliferative 
response (16). Inhibition of DUSP6 could be a potential intervention to increase 
CD4+ TCR-sensitivity by enhancing ERK phosphorylation in ESRD patients. BCI (an 
inhibitor of DUSP6 and 1) enhanced TCR-induced pERK in CD4+ T cells from elderly 
HI, young and elderly ESRD patients, but not young HI, implying a role for DUSP6 
and/or DUSP1 in regulation of ERK phosphorylation. Based on the age- as well as 
differentiation-related expression of DUSP6, but not DUSP1, in our HI, a potential 
role for DUSP6 may be present in defective TCR-induced ERK phosphorylation, 
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especially in elderly HI and young patients. This needs to be confirmed in a larger 
cohort. Furthermore, use of siRNA specific for DUSP6 is required to draw a more 
definite conclusion with respect to the role of DUSP6 in defective TCR-induced 
phosphorylation of ERK in ESRD patients. The lack of age-related effects on pERK 
in CD8+ T cells of ESRD patients and HI, the latter confirming observations done by 
another study (16), as well as absence of effects of BCI on pERK levels in CD8+ T cells, 
indicates a different role for DUSP6 in CD8+ T cells compared to CD4+ T cells. We did 
not observe an association between DUSP6 expression and ERK phosphorylation 
in CD4+ T cells in ESRD patients. This could be due to the small cohort size or imply 
other DUSPs (e.g. 2, 4 or 5) (45-49) or upstream signaling molecules to contribute to 
this defective TCR-induced ERK phosphorylation in ESRD patients. 
ERK over-phosphorylation might be as bad as defective ERK phosphorylation. ERK 
over-activation from kidney cells occurs in the physiologic setting in some chronic 
kidney diseases, such as compensatory kidney hypertrophy and in pathologic 
conditions for example glomerular disease(50). Increased ERK phosphorylation in 
T cells predisposes for autoimmunity for example rheumatoid arthritis (43). Over-
expression of DUSP6 is also reported to impair T-cell function in chronic viral 
infections such as hepatitis C virus infection (51). Therefore, more research is 
warranted evaluating inhibition of DUSP in the setting of defective T-cell mediated 
immunity in ESRD patients.
We analyzed the effect of latency for CMV as it represents chronic antigenic 
stimulation of T cells, but ERK- or p38-activation of CD4+ or CD8+ T cells was not 
different between the CMV-IgG seropositive population and CMV-IgG seronegative 
population following CD3/CD28 stimulation. Highly differentiated memory CD4+ and 
CD8+ T cells may accumulate in CMV seropositive individuals and are functional 
CMV-specific T cells (29, 52, 53). The results of our study show that non-specific 
TCR stimulation does not identify a defect p38 and ERK signaling associated with 
CMV seropositivity. In accordance with the results of a previous study, uremia is the 
major determinant affecting MAPK pathway parameters in ESRD patients and not 
RRT (9, 11, 33). 
In the present study, we induced phosphorylation of p38 in T cells via triggering 
CD3 (54) and  CD28 (26). Lack of CD28 may only partly explain the decreased p38 
activation in more differentiated CD4+ T cells. In addition to that, senescent human 
CD27-CD28- CD4+ T cells lack several essential upstream components including 
ZAP70 and the loss of TCR signaling machinery in those cells was associated with 
a defective calcium influx (31), which may indicate the decreased response of TCR-
mediated activation in the more differentiated T cells. Interestingly, in contrast to 
the p38 activation following CD3/CD28 stimulation, baseline levels (spontaneous 
phosphorylation) of p38 increased during T cells differentiation (55). This might be 
caused by DNA damage in these more differentiated T cells and mediated by TAB1 
(MKK-independent molecule), a key molecule involved in this auto-phosphorylation 
(31).  
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Conclusion
We have described for the first time a uremia-mediated defect in TCR-induced 
phosphorylation of ERK which may contribute to the impaired T-cell mediated 
immune response in ESRD patients. Inhibition of DUSP6 specific for pERK can 
restore defective p-ERK-mediated activation of CD4+ T cells in ESRD patients. 
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Fig. S6. Typical example of the 
gating strategy for analysis of 
percentages of CD69+ CD4+ 
T cell subsets. Briefly, (a) 
lymphocytes were identified 
based on the forward/sideward 
characteristics followed by (b) 
the selection of CD3+ living T 
cells. (c) These T cells were 
then dissected into CD4+ and 
CD8+ T cells. (d) CCR7 and 
CD45RO were used to identify 
	
	
	
naive and different memory subsets within CD4+ T cells. Furthermore, (e) percentages of 
CD69+ were measured for CD4+ T cells stimulated or not with different ratios of anti-anti-CD3/
CD28 beads (blank control, 1 cell /0.1 bead, 1 cell /0.5 bead, 1 cell/1 bead).  A similar gating 
strategy was employed for analysis of CD69+ and IL2+ the different CD4+ T cells subsets.
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Fig. S7. Phosphorylation of ERK in CD8+ T cell subsets without and with BCI treatment from 
healthy individuals (HI) and end-stage renal disease (ESRD) patients. Phosphorylation of 
ERK for BCI-pretreated or not BCI-pretreated cells is given for different CD4+ T cell subsets: 
(a) total, (b) naive, (c) central memory (CM) and (d) effector memory (EM) of HI (young n=5; 
elderly n=5) and ESRD patients (young n=5; elderly n=5). Dots and squares represent young 
and elderly HI, upward- and downward-facing triangles correspond to young and elderly 
patients, respectively. P value: *<0.05; Data are given as individual values.
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Fig. S8. Typical example of the gating strategy for analysis of DUSP6 and DUSP1 expression 
in CD4+ T cell subsets. Briefly, (a) lymphocytes were identified based on the forward/sideward 
characteristics followed by (b) the selection of CD3+ living T cells. (c)These T cells were then 
dissected into CD4+ and CD8+ T cells. (d) CCR7 and CD45RO were used to identify naive 
and different memory subsets within CD4+ T cells. Furthermore, (e) DUSP6 or (f) DUSP1 
expression was measured in CD4+ T cells and median fluorescence intensities (MFI) were 
evaluated (values multiplied by 256 in brackets). Grey peaks represent staining without the 
specific antibodies (fluorescence minus one, FMO), and pink peaks correspond to staining 
with antibodies directed to DUSP6 or DUSP1. A similar gating strategy was employed for 
analysis of DUSP6 and DUSP1 expression in all CD4+ T cells subsets. 
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ABSTRACT
The absence of anti-CMV IgG is used to classify pre-transplant patients as naive for 
CMV infection (CMVneg patients). This study assessed whether pre-transplant CMV-
specific T-cell immunity exists in CMVneg patients and whether it protects against 
CMV-infection after kidney transplantation. The results show that CMV-specific 
CD137+IFNγ+CD4+ and CD137+IFNγ+CD8+ memory T cells were present in 46% and 
39% of CMVneg patients (n=28) although at much lower frequencies compared to 
CMVpos patients (median 0.01% versus 0.58% for CD4+ and 0.05% versus 0.64% 
for CD8+ T cells) with a less differentiated CD28-expressing phenotype. In line with 
these data, CMV-specific proliferative CD4+ and CD8+ T cells were observed  in 
CMVneg patients, which significantly correlated with the frequency of CMV-specific 
T cells. CMV-specific IgG-antibody secreting cells (ASC) could be detected at low 
frequency in 36% of CMVneg patients (1 versus 45 ASC/105 cells in CMVpos patients). 
CMVneg patients with pretransplant CMV-specific CD137+IFNγ+CD4+ T cells had a 
lower risk to develop CMV-viremia after transplantation with a CMVpos donor kidney 
(relative risk: 0.43, p=0.03). In conclusion, a solitary CMV-specific T-cell response 
without detectable anti-CMV antibodies is frequent and clinically relevant as it is 
associated with protection to CMV-infection following transplantation with a kidney 
from a CMVpos donor.
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INTRODUCTION
Kidney transplant (KT-) recipients are at increased risk for infections following 
transplantation, one of the major threats being cytomegalovirus (CMV).  A primary 
infection or reactivation with CMV may cause a viremia and can lead to severe CMV 
disease with organ involvement (1).  Patients at increased risk for an infection with 
CMV either receive prophylactic or pre-emptive anti-viral therapy (valganciclovir) 
following kidney transplantation (2). Classification of the risk for a CMV-infection 
prior to KT is based on the presence of anti-CMV immunoglobulin (Ig)G  in the patient 
in combination with the CMV-serostatus of the kidney donor. Immunity to viruses, 
for example CMV, is dependent on adequate help from CMV-specific CD4+ T cells 
enabling production of neutralizing antibodies by CMV-specific B-cells/plasma blasts 
and effective cytotoxic CD8+ T cell (CTL) responses (3-5). Absence of neutralizing 
antibodies does not necessarily imply that the antigen was not encountered before 
as cellular immunity might still be present. Furthermore, it is known that in end-stage 
renal disease (ESRD) patients protective humoral immunity is not maintained and 
often not achieved (6, 7). Therefore, several groups have proposed to include an 
evaluation of cellular immunity against CMV in the risk assessment strategy to more 
accurately assess sensitization prior to transplantation (8-10). Data are scarce as to 
whether the presence of limited cellular immunity protects from CMV-viremia after 
kidney transplantation and no detailed insights into which T-cell subsets are involved 
in just-sufficient protection are available, as cellular immunity is mainly assessed by 
ELISpot (11). 
T-cell differentiation can be assessed by using expression of CD45RO or CD45RA 
and the lymph node homing chemokine receptor CCR7 which is able to identify 
naive T cells and different memory T cell subsets, i.e. central memory (CM), effector 
memory (EM) and finally terminally differentiated EM CD45RA+ (EMRA)(12). This is 
accompanied by loss of the co-stimulatory marker CD28. Particularly, an effective 
CMV-specific T cell response yields many highly differentiated CD28null T cells (13, 
14). As we have previously shown, this T-cell response adds to immunological T-cell 
ageing observed in the circulation of ESRD patients, resulting in a shift towards more 
differentiated memory T cells and enhanced telomere attrition (14, 15). Whether 
presence of limited cellular immunity to CMV impacts T-cell ageing characteristics in 
ESRD patients is not known. 
The aim of this study is to assess CMV-specific T-cell immunity including the 
differentiation stage of CMV-specific T cells, and to determine its clinical relevance 
with respect to protection from CMV-viremia following transplantation in a cohort of 
CMV-seronegative patients. Furthermore, the impact on T-cell ageing parameters 
was evaluated. 
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MATERIAL AND METHODS
Study population
In a cohort of stable CMV-seronegative and, as a control, age- and gender-
matched CMV-seropositive recipients of a kidney from a CMV-seropositive donor 
(D+/R- and D+/R+, respectively), CMV-specific immunity was assessed prior to 
transplantation and linked to CMV-viremia following KT.  Most of the patients (86%) 
received induction therapy with basiliximab (Simulect®, Novartis). The standard 
triple immunosuppression given following transplantation  consisted of tacrolimus 
(Prograf®, Astellas Pharma), mycophenolate mofetil (Cellcept®, Roche) and 
prednisolone (the first 3 months post-KT), the first given to 93% and the latter two to 
all of the patients. The first six months following transplantation, anti-viral prophylaxis 
with valganciclovir 450 mg q.d. was given and if necessary adjusted for impairment 
of renal function. Patient characteristics are listed in Table 1. All patients gave written 
informed consent to participate in this study. The study was approved by the Medical 
Ethical Committee of the Erasmus MC (METC number 2010-080) and conducted in 
accordance with the Declaration of Helsinki and the Declaration of Istanbul.
Detection of CMV-viremia and CMV-specific antibodies
Serum immunoglobulin G (IgG) antibodies to CMV (expressed as arbitrary units/
mL (AU/mL)) were measured with an enzyme immune assay (Biomerieux, VIDAS, 
Lyon, FRANCE). An outcome of ≥6 AU/mL was considered positive. Patients were 
monitored at a 3 months interval  during the first year following transplantation with 
respect to presence of CMV DNA. Diagnosis of a CMV-viremic episode was based 
on the presence of copies (expressed in international units/mL) of CMV DNA in 
blood and established by a quantitative polymerase chain reaction (qPCR) at the 
department of Virology at the Erasmus MC. An outcome of >50 international units/
mL was indicative for a CMV-viremia.
Isolation of peripheral mononuclear cells (PBMCs)
Prior to KT, PBMCs were isolated as described in detail before (16) from heparinized 
blood samples drawn from CMV-seronegative and CMV-seropositive patients and 
stored at 10 million PBMCs per vial at -150oC until further use. 
Detection of CMV-specific CD137-expressing cytokine producing T cells 
PBMCs of 28 CMV-seronegative and 14 CMV-seropositive patients were thawed, 
allowed to rest for 8 hours at 37oC and stimulated (5x106 PBMCs/mL) in  RPMI-
1640 containing glutamax (GibcoBRL, Paisley, Scotland) supplemented with 100 
IU/mL penicillin, 100 ug/mL streptomycin and 10% heat-inactivated pooled human 
serum, further referred to as standard culture medium. Stimulation was performed 
in polystyrene tubes (BD Pharmingen, Erembodegem, Belgium) in the presence 
of co-stimulation CD49d (1 µg/mL; BD) without (background) or with a mixture of 
overlapping peptide pools covering the whole pp65 and IE-1 protein of CMV (1 μg/
ml; PepTivator-CMV pp65 and IE-1; Miltenyi Biotec GmbH, Bergisch Gladbach, 
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Germany) and Brefeldin A (Golgiplug; BD Pharmingen) for 12 hours. This intracellular 
cytokine staining assay facilitates detailed characterization of CMV-specific CD4+ as 
well as CD8+ T cells as these can be identified by de novo expression of CD137 in 
combination with effector molecules (17). As a positive control, PBMC of 10 CMV-
seronegative and 5 CMV-seropositive patients were stimulated with the combination 
of phorbol myristate acetate (PMA; 50 ng/mL; Sigma Aldrich, St. Louis, MO, USA) 
and ionomycin (1 µg/mL; Sigma Aldrich) and treated as described above.
Subsequently, a surface staining was performed to identify naive (CD45RO-CCR7+) 
and memory T cell subsets (12). Central memory (CM) T cells are CD45RO+CCR7+, 
effector memory (EM) CD45RO+CCR7- and terminally differentiated effector memory 
(EMRA) CD45RO-CCR7-. In addition, less and more differentiated T cell subsets were 
also identified by CD28 (i.e. less differentiated being CD28+ and more differentiated, 
lacking CD28, referred to as CD28null). The following monoclonal antibodies were 
used: Brilliant Violet (BV)-510 labeled anti-CD4 (Biolegend Europe BV, Uithoorn, The 
Netherlands), Pacific Blue (PB) labeled anti-CD45RO (Biolegend), allophycocyanin-
Cy7 (APC-Cy7) labeled anti-CD8 (BD, Erembodegem, Belgium), peridinin 
chlorophyll-Cy5.5 (PerCP-Cy5.5) labeled anti-CD28 (BD) and phycoerythrin-Cy7 
(PE)-Cy7 labeled anti-CCR7 (BD). Following fixation and permeabilization, cells 
were stained intracellular using APC-labeled anti-CD137 (BD) and PE-labeled anti-
IFNγ (BD Pharmingen). IL-2 producing cells were only evaluated in a fraction of the 
patients tested, i.e. 12 CMV-seronegative and 6 CMV-seropositive patients by co-
staining intracellular using fluorescein isothiocyanate (FITC)-labeled anti-IL-2 (BD). 
Samples were measured on the FACSCanto II (BD Pharmingen), aiming for 0.5-
1x106 of T cells to be acquired, and analyzed using FACSDiva software version 6·1.2 
(BD). The gating strategy for identifying CMV-specific CD137+CD4+T cells within the 
different subsets and in combination with cytokine production are shown in Fig. S1, 
a similar approach was followed for CD8+ T cells. The median (IQ range) background 
of CD137-expressing CD4+ T cells of all samples amounted to 0.05% (0.03%-0.07%) 
whereas that of CD137-expressing CD8+ T cells was higher, amounting to 0.44% 
(0.23%-1.02%). The median background value for CD137+IFNγ+ CD4+ and CD8+ 
and CD137+IL-2+ CD4+ T cells of all samples were 0.01% (0.01%-0.02%), 0.04% 
(0%-0.09%) and 0.01% (0.01%-0.01%), respectively. Most of the background signal 
within CD4+ T cells was observed in cells co-expressing CD28 and of a CM/EM 
phenotype whereas that observed for CD8+ T cells were predominantly lacking 
CD28 and of the EM/EMRA-phenotype. Since frequencies obtained for the various 
parameters differed considerably amongst patients, we  subtracted the unstimulated 
value per patient from that after CMV-peptide stimulation to calculate the net signal 
as shown in the results. A positive detectable CMV-specific response was identified if 
the net response was over 0. Only detectable CD4+ and CD8+ CD137+ CMV-specific 
T cell responses were analyzed in more detail with respect to cytokine production 
and phenotypic aspects. 
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Detection of CMV-specific proliferating T cells 
PBMC of 12 CMV-seronegative and 6 CMV-seropositive patients, were thawed 
and labeled with carboxyfluorescein diacetate succinimidyl ester according to 
manufacturer’s instruction (CFSE; Molecular Probes®, the Netherlands) and 
subsequently stimulated in triplicate in standard culture medium at 5x104/well (96 
wells-round bottom-shaped plate) without or with CMV-lysate (30 µg/mL; Microbix 
Biosystems Inc, Ontario, Canada) or with a mixture of overlapping peptide pools 
covering the whole pp65 and IE-1 protein of CMV (both at a final concentration of 1 
μg/ml; PepTivator-CMV pp65 and IE-1; Miltenyi Biotec). Stimulation with CMV-lysate 
might allow for characterization of the total pool of CMV-specific CD4+ T cells as the 
overlapping peptide pools cover only 2 (albeit dominant) peptides of the CMV protein. 
Proliferation of CMV-specific CD8+ T cells was only analyzed following stimulation 
with overlapping peptide pools of pp65 and IE-1 and not whole CMV-lysate due to their 
restriction with respect to length (number of amino acids) of the peptides presented 
in the context of HLA class I. Following 6 days, cells were harvested, stained  using 
monoclonal antibodies directed against CD3, CD4, CD8, CD28 (again to identify 
less-differentiated versus more-differentiated subsets amongst proliferating T cells) 
and dead cells were excluded using 7-aminoactinomycin D (7-AAD). Samples were 
measured on the FACSCanto II (BD) and analyzed using FACS Diva software 
version 6.1.2 (BD), percentages of CMV-specific proliferating T cells were calculated 
by subtracting percentages of T cells proliferating in absence of these stimuli. The 
median (IQ range) of proliferating CD4+ and CD8+ T cells in absence of a stimulus 
amounted to 0.83% (0.50%-2.48%) and 1.42% (0.69%-3.36%), respectively. A 
positive detectable response was identified if the net response was over 0. 
Total and CMV-specific IgG antibody secreting cells
PBMCs of 11 CMV-seronegative and, as a positive control, 4 CMV-seropositive 
patients were thawed and subsequently stimulated at a density of 2x106/mL for 
5 days with R848 and recombinant IL-2, according to manufacturer’s instruction 
(U-Cytech BV, Utrecht, The Netherlands). On day 4, the wells of a 96-well plate were 
coated overnight at 4oC according to manufacturer’s instruction. Coating consisted 
of either an anti-human IgG antibody, for enumeration of total IgG antibody secreting 
cells (ASC) or CMV-lysate (30 µg/mL Microbix Biosystems Inc, Ontario, Canada), for 
enumeration of CMV-specific IgG ASC. Following stimulation, cells were harvested, 
counted and added to the coated ELISpot plate at different concentrations, each 
in triplicate. After a 7 hour incubation (37oC, 5% CO2), cells were lysed and debris 
washed away using PBS/0.05% Tween-20. Subsequently, the wells of the ELISpot 
plate were incubated for one hour at 37oC with a biotinylated anti-human IgG 
(detection) antibody and upon washing followed by an incubation with phi-labeled 
anti-biotin antibody (GABA) for one hour at 37oC. Finally ASC were visualized, upon 
a washing procedure, using an activation solution (U-Cytech BV) resulting in a silver 
precipitate upon incubation in the dark at room temperature. Color development 
was stopped using di-ionized water and spots were counted using an ELISpot 
reader (Bioreader®-600V, BIO-SYS GmbH, Karben, Germany). CMV-IgG ASC are 
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expressed as number/105 cells as well as a frequency of total IgG ASC. 
In addition to analyzing ASC, a sample prior to and following stimulation was analyzed 
for B cell blast formation by flow cytometry . The following panel of monoclonal 
antibodies was used: BV510-labeled anti-CD19 (Biolegend), BV421-labeled anti-
CD38 (BD) and PE-Cy7-labeled anti-CD27 (eBioscience). Plasma blasts were 
CD19+CD38highCD27+. 
Absolute numbers of CD4+ and CD8+ T cells and T-cell differentiation status by 
flow cytometry
Absolute numbers of T-cell subsets (18) and T-cell differentiation status (19) were 
determined using a whole blood staining as described in detail before. 
Telomere length assay
Relative telomere length of CD4+ and CD8+ T cells were determined by Flow 
fluorescent in situ hybridization (flow-FISH) as described previously (15, 20). 
Statistical analyses
Statistical analyses were performed using GraphPad Prism version 5.01. Non-
parametric Mann-Whitney U-test or Kruskall-Wallis test followed by a post-hoc 
analysis (Dunns multiple comparison test). Categorical variables were compared 
using the Fisher’s exact test. The non-parametric Spearman rank correlation 
coefficient (Spearmans Rho, Rs) was used to evaluate associations between various 
parameters. P-values<0.05 for two sides were considered statistically significant. 
RESULTS
Study population characteristics
The demographic and clinical characteristics of the study population are given in 
Table 1. Twenty-eight CMV-seronegative and 14 age- and gender-matched CMV-
seropositive patients were included in this study. Both groups were well-matched 
with no significant differences in clinical characteristics. Approximately half of the 
CMV-seronegative versus none of the CMV-seropositive patients experienced a 
CMV viremia within 12 months after transplantation (P<0.01). 
CMV-seronegative patients frequently have CMV-specific T cells 
CMV-specific CD4+ and CD8+ T cells, identified by expression of CD137 upon 
stimulation with a peptide pool of the 2 immunodominant proteins pp65 and IE-1 
(CD137+CD4+ and CD137+CD8+) were present in 16 out of 28 CMV-seronegative 
patients.  Median (IQ range) values of the positive responses amounted to 0.03% 
(0.01%-0.11%) and 0.10% (0.03%-0.18%) for CD4+ and CD8+ T cells, respectively 
(Fig. 1A,C, black dots). A positive correlation was observed between the CD4+ and 
CD8+ level of CMV-specific T-cell response in CMV-seronegative patients (Rs=0.50, 
P<0.05). The percentages of CMV-specific CD137-positive CD4+ and CD8+ T cells 
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Table 1 Demographic and clinical characteristics of study population
   D+/R+ (n=14) D+/R- (n=28) P-value
Age in years A,B 50 (19-63) 47.5 (21-76) NS
Male 50% (7) 68% (19) NS
CMV IgG titer (AU/ml) 47.5 (9-354)
CMV viremia 46% (13)
Time point of CMV viremia post-KT 
(months)
   5 (2-12)
Renal replacement therapy B NS
-Pre-emptive transplantation 43% (6) 43% (12)
-Patients on dialysis 57% (8) 57% (16)
Underlying kidney disease  B NS
- Nephrosclerosis/atherosclerosis/
hypertension
14% (2) 25% (7)
- Primary glomerulopathies 36% (5) 29% (8)
- Diabetes 21% (3) 11% (3)
- Urinary tract infections/stones  3% (1)
- Reflux nephropathy  3% (1)
- Polycystic Kidney Disease  7% (2)
- Other/unknown      29% (4) 22% (6)
Previous KT B 1 1 NS
Mismatches HLA class I A 2 (1-4) 2 (0-4) NS
Mismatches HLA class IIA 1 (0-2) 1 (0-2) NS
Immunosuppressive medication
-Basiliximab induction therapy C
- Prednisolone D
- MMF 
- Tacrolimus
- switch Tacrolimus->EverolimusF
79% (11)
100% (14)
100% (14)
93% (13)
7%   (1)
89% (25)
100% (28)
100% (28)
93% (26) 
7% (2)
NS
NS
NS
NS
NS
Donor age in years A,B 42 (27-66) 57 (29-72) <0.01
A = median (min-max), B= at pre-KT,  
C = Given at day 0 and day 4 post-KT, D = Given the first 3 months post-KT, 
F= 6 months post-KT 
NS=not significant
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(present in 14 and 11 out of 14 CMV-seropositive patients, respectively) were 
significantly (P<0.001) higher in CMV-seropositive patients and amounted to 0.61% 
(0.11%-1.04%) and 1.45% (0.44%-8.69%) (Fig. 1A,C, open dots), respectively.  
CMV-specific CD137+CD4+ and CD137+CD8+ T cells were predominantly of the 
memory phenotype in both CMV-seropositive as well as CMV-seronegative patients. 
However, significantly higher percentages (P<0.05) of CD137+CD4+ and CD137+CD8+ 
T cells in CMV-seronegative patients had a naive phenotype when compared to 
CMV-seropositive patients (Fig. 1,D, respectively). No differences were observed 
when comparing the maximal capacity of T cells to express CD137 between CMV-
seronegative and CMV-seropositive patients upon PMA/ionomycin-stimulation (Fig. 
S2 A and B). 
CMV-specific T cells in CMV-seronegative patients produce IFNγ and IL-2 
Next, the presence and distribution of IFNγ and IL-2 producing CMV-specific 
T cells was studied. In 13 out of 28 CMV-seronegative patients, CMV-specific 
IFNγ+CD137+CD4+T cells were present and median (IQ range) frequencies amounted 
to 0.01% (0.01%-0.04%) versus 0.58% (0.16%-0.87%) for CMV-seropositive patients, 
that all had CMV-specific IFNγ+CD137+CD4+T cells (Fig. 1E, P<0.001). In CMV-
seronegative patients, approximately 37% of the CMV-specific CD137-expressing 
CD4+T cells produced IFNγ compared to 69% in CMV-seropositive patients (P<0.05). 
IFNγ producing CMV-specific CD137+CD4+ T cells all co-expressed CD28 and 
similar frequencies were present within the CM and EM subset of CMV-seronegative 
patients. In CMV-seropositive patients a slightly more differentiated phenotype was 
observed as 16% (P<0.01) of these cells lacked CD28 and 75% were classified as 
EM T cells (Fig. 1F).  
In 12 CMV-seronegative and 6 CMV-seropositive patients frequencies of IL-2 
producing CD4+ T cells specific for CMV were evaluated as we have previously shown 
these to be associated with anti-CMV IgG titers (6). CMV-specific CD137+CD4+ IL-
2+ T cells were detected in 9 out of 12 (75%) of CMV-seronegative versus all of 
the CMV-seropositive patients and median (IQ range) frequencies amounted to 
0.01% (0.01%-0.01%) and 0.26% (0.01%-0.87%) for CMV-seronegative and CMV-
seropositive patients (P<0.05; Fig. 1G). Forty percent of CMV-specific CD137-
expressing CD4+ T cells of CMV-seronegative patients produced IL-2 compared 
to 37% in CMV-seropositive patients. In CMV-seronegative patients almost all IL-2 
producing cells co-expressed CD28, in contrast to the presence of CD28null CMV-
specific IL-2 producing cells (10%) in the CMV-seropositive group (P<0.01; Fig. 1H).
IFN-γ producing CD137+CD8+ T cells were detected in 11 out of 28 (39%) CMV-
seronegative and 11 out of 14 (79%) CMV-seropositive patients. Median (IQ range) 
frequencies amounted to 0.05% (0.01%-0.12%) and 0.64% (0.22%-1.90%) within the 
total CD8+ T cell population for CMV-seronegative and CMV-seropositive patients, 
respectively  (Fig. 1I, P<0.01). Only 9% of CD137-expressing CD8+ T cells produced 
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IFNγ in CMV-seronegative versus 36% of CMV-seropositive patients (P<0.01). 
The differentiation status of these cells was similar for both groups and most IFNγ+ 
CD137+CD8+ T cells were found within the EM and highly differentiated EMRA subsets 
(Fig. 1J). In CMV-seronegative patients, 65% of CMV-specific IFNγ producing cells 
co-expressed CD28, in contrast to the presence of 89% CD28null IFNγ producing 
cells in CMV-seropositive patients (P<0.05; Fig. 1J). The frequency of CMV-specific 
CD137+CD8+ T cells producing IL-2 was low, i.e.median and IQ range amounted 
to: 0.001% (0.001%-0.001%) and 0.024% (0.01%-0.05%) of the total CD8+ T cells 
for CMV-seronegative and CMV-seropositive patients, respectively. As less than 5% 
of CD137-expressing CD8+ T cells produced IL-2, no further dissection into T-cell 
subsets was done.
The CMV-specific CD137+ CD4+ and CD8+ T cells with a naive phenotype, present 
at higher frequencies in CMV-seronegative patients (Fig. 1B & 1D), did not produce 
IL-2 (Fig. 1H) or IFNγ (Fig. 1F & 1J). 
Collectively, these data show that in a substantial fraction of CMV-seronegative 
patients cytokine producing cells are present within CMV-specific CD137-expressing 
T cells, although at lower frequenciesSimilar to CMV-seropositive patients, these 
are mainly of the memory phenotype albeit less differentiated as they are more 
CD28+. No differences were observed when comparing the maximal capacity of T 
cells to express CD137 (Fig. S2A and B) and produce cytokines between CMV-
seronegative and CMV-seropositive patients (Fig. S2C, D and E). 
CMV-specific T cell proliferation in CMV-seronegative patients 
In addition to measuring the capacity to exert effector function by producing cytokines, 
we evaluated CMV-specific T cell proliferation by using both CMV-lysate and the 
peptide pool of the immunodominant proteins pp65 and IE-1 (Fig. 2A and 2B, typical 
flowcytometric example). CMV-lysate-induced proliferation was observed in 10 out of 
12 CMV-seronegative KT-recipients for CD4+ T cells, respectively. Median (IQ range) 
percentages of proliferating CD4+ T cells amounted to 2.2.55% (0.88%-7.09%) (Fig. 
Fig. 1 (left) Cytomegalovirus (CMV)-specific CD137-expressing and cytokine producing 
T cells. Peripheral mononuclear cells of patients were stimulated for 12-hours in presence 
of brefeldin A and αCD49d alone or with a mixture of ppp65 and IE-1 overlapping peptide 
pools. Subsequently, cells are cell surface and intracellular stained to determine frequencies 
and phenotypic characteristics of CMV-specific CD137-expressing T cells as well as those 
producing cytokines. CMV-specific CD137-expressing CD4+ (A) and CD8+ (C) T cells are 
depicted dissected for CD4+ (B) or CD8+ (D) T cells co-expressing or lacking CD28 and the 
different naive and memory T cell subsets. A similar approach is followed for CMV-specific 
CD137-expressing IFN-γ and IL-2 producing CD4+ [(E, G) and dissection in (F, H) and CD8+ 
(I) and dissection in panel (J)] T cells, respectively. Closed and open symbols/bars (medians 
of) represent CMV-seronegative and CMV-seropositive patients, respectively. * P<0.05; ** 
P<0.01, *** P<0.001
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2C). Proliferation in response to the mixture of pp65- and IE-1-overlapping peptide 
pools was observed in a smaller proportion of CMV-seronegative patients, i.e. 7 and 
3 out of 12 KT-recipients for CD4+ and CD8+ T cells (median and IQ range: 0.35% 
and 0.09%-0.64% (Fig. 2C) and 0.33% and 0.19%-1.00% (Fig. 2E), respectively). 
CD4+ T cells of CMV-seropositive patients proliferated vigorously to CMV-lysate. The 
median percentage of proliferating CD4+ T cells was 36% (Fig. 2C). Proliferation in 
response to the mixture of pp65- and IE-1-overlapping peptide pools amounted to 
6.34%  (3.47%-24.32%) and 9.64% (4.26%-43.63%) for CD4+ and CD8+ T cells, 
respectively (Fig. 2C and E). In CMV-seronegative patients, most (>97%) of the 
proliferating CD4+ T cells co-expressed CD28, indicative for a less-differentiated 
phenotype. In CMV-seropositive patients approximately 10% of all proliferating CD4+ 
T cells were CD28null (Fig. 2D). This difference in differentiation status was even more 
pronounced in proliferating CD8+ T cells as 78% of these cells in CMV-seronegative 
patients expressed CD28 compared to approximately 34% of CMV-seropositive 
patients (P<0.05)  (Fig. 2F). Frequencies of CMV-specific IFNγ-producing CD137+ 
CD4+ T cells and IL-2 producing CD137+ CD4+ T cells were positively correlated with 
percentages of proliferating CD4+ T cells (for IFNγ:Rs=0.63; P=0.02 (CMV-lysate) 
and Rs=0.71; P=0.02 (pp65/IE-1 peptides), for IL-2:Rs=0.62; P=0.02 (CMV-lysate) 
and Rs=0.74; P=0.01 (pp65/IE-1peptides)). 
Low frequency of CMV-specific IgG ASC in CMV-seronegative patients
Next we evaluated whether CMV-specific memory B cells could be detected in the 
circulation of CMV-seronegative patients. The frequency of plasma blasts within the 
circulation is very low but can be induced from B cells upon polyclonal stimulation. 
The total B cell number and responses may be negatively affected in ESRD patients 
and therefore we first documented that this protocol can indeed induce plasma blasts. 
As shown in Fig. 3A, plasma blasts were induced (CD27+CD38highCD19+, from 1.4% 
to 48.1%) following a 5-day polyclonal stimulation. Next, total IgG and CMV-IgG 
ASC were quantified by ELISpot. CMV-IgG ASC were detected above background 
in 4 out of 11 (36%) of CMV-seronegative patients and net median (IQ range) CMV-
specific IgG ASC amounted to only 1/105 (1-10/105), i.e. 0.08% (0.02%-0.14%) of 
total IgG ASC (Fig. 3B and C). All CMV-seropositive patients had detectable CMV-
IgG ASC (median 45 cells/105 (7-114/105),  0.38% (0.11%-1.70%) of total IgG ASC). 
Interestingly, CMV-specific IFNγ- as well as IL-2-producing CD137+CD4+ T cells of 
the total patient group (CMV-seropositive as well as CMV-seronegative patients) 
were positively correlated with numbers of CMV-specific IgG ASC (Rs=0.52; P<0.05 
and Rs=0.53; P<0.05, respectively). 
CMV-specific CD137+ IFNγ + CD4+ T cell responses protect against CMV-viremia
The CMV-specific T-cell response in CMV-seronegative patients was evaluated for 
clinical relevance by relating it to the occurrence of CMV viremia after transplantation. 
In 13 out of 28 (46%) CMV-seronegative patients a CMV-viremia developed during 
the first year following transplantation with a CMV-seropositive donor kidney. 
CMV-seronegative patients with  CMV-specific CD137+IFNγ+CD4+ T cells prior to 
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Table 2 Effects of CMV-immunity on T-cell parameters prior to transplantation
CMVpos ESRD 
patients
CMVneg ESRD 
patients
CMVneg ESRD patients P-value*
(N=14) without CMV-
specific 
CD137+IFNγ+CD4+ 
T cells  (N=15)
with CMV-specific 
CD137+IFNγ+CD4+ T 
cells (N=13)
T cells 1184 (887-
1519)
1039 (636-1360) 1057 (750-1340) ns
CD4+ T cells 629 (444-786) 714 (373-916) 639 (451-821) ns
CD4+ Tnaive cells 110 (73-173) 213 (119-531) 226 (163-354) ns
CD4+ TMEM cells 535 (292-641) 385 (185-512) 434 (255-641) ns
CD4+ TCM cells 263 (174-389) 227 (137-366) 283 (176-363) ns
CD4+ TEM cells 185 (106-301) 116 (100-148) 108 (80-273) ns
CD4+ TEMRA cells 7 (5-21) 11 (4-18) 8 (3-13) ns
CD4+CD28null T 
cells
29 (3-65) 3 (2-5) 3 (1-20) ns
CD4+CD31+ 
Tnaive cells
63 (43-123) 170 (61-264) 144 (91-222) ns
CD8+ T cells 465 (316-618) 257 (168-445) 240 (213-469) ns
CD8+ Tnaive cells 84 (39-120) 104 (59-198) 84 (44-179) ns
CD8+ TMEM cells 349 (271-528) 140 (87-277) 191 (167-246) ns
CD8+ TCM cells 15 (9-88) 16 (7-30) 25 (13-44) ns
CD8+ TEM cells 110 (59-144) 85 (46-188) 83 (53-122) ns
CD8+ TEMRA cells 151 (85-287) 37 (25-69) 41 (18-76) ns
CD8+CD28null T 
cells
228 (85-276) 37 (24-86) 58 (23-67) ns
CD8+CD31+ 
Tnaive cells
79 (39-118) 98 (57-175) 76 (41-175) ns
CD4+ RTL 10.20 (9.2-
15.2)
11.2 (9.1-17.8) 12.1 (9.4-14.1) ns
CD8+ RTL 10.85 (7.7-14) 13 (9.7-21.2) 11.4 (9.1-16) ns
Cell numbers are given in cells/µLblood; data represent median (interquartile range); 
* when comparing CMVneg ESRD patients without to those with CMV-specific 
CD137+IFNγ+CD4+ T cells.
 MEM, memory; CM, central memory; EM, effector memory; EMRA, terminally differentiated 
effector memory (CD45RA+); RTL, relative telomere length given as a %
transplantation had a lower risk to develop a CMV-viremia after transplantation with 
a CMV-seropositive donor kidney compared to those without (relative risk: 0.43, 
p=0.03). No differences in percentages of CMV-specific IFNγ producing CD137+CD4+ 
T cells were observed between CMV-seronegative patients without and those with a 
CMV-viremia (data not shown).
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Fig. 2 Cytomegalovirus (CMV)-specifi c T-cell proliferation. A typical example of the gating 
strategy for analysis of CMV-specifi c T cell proliferation is shown. Briefl y, based on forward/
sideward characteristics live cells are gated and depicted in a dot plot to further select living 
(7AAD-negative) CD3+ T cells (A). These were then further dissected into CD4+ and CD8+ T 
cells (A). CD4+ and CD8+ T cells are fi nally plotted to visualize proliferation (CFSE-dilution) 
and CD28 expression and a typical example for background proliferation within CD4+ and 
CD8+ T cells is shown in the last two plots in panel A.  In panel B, typical  (detectable) 
proliferative responses of CD4+ and CD8+ T cells to CMV-lysate (CD4+ T cells alone; upper 
graphs) or a mixture of overlapping peptides for pp65/IE-1 (both CD4+ and CD8+ T cells; 
middle and lower graphs, respectively) are depicted for a CMV-seronegative (left panel) and 
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Fig. 3 Cytomegalovirus (CMV)-specific B-cell responses. A B cell ELISpot assay was performed 
in order to enumerate CMV-specific and total IgG antibody secreting cells (ASC). In panel (A), 
a typical flow cytometric example is given of B cell blasts, identified as CD19+CD27+CD38high 
cells, prior to an following a 5-day stimulation with R848 and recombinant IL-2 on the left side. 
On the right side, the individual and median frequencies of B cell blasts are depicted prior to 
stimulation and following a 5-day stimulation for 15 KT-recipients (11 CMV-seronegative and 
4 CMV-seropositive patients). Following B-cell stimulation, cells were transferred at different 
numbers/well to wells of a 96-well B-ELISpot plate coated with CMV-lysate or an anti-human 
IgG antibody or not coated (containing PBS; background IgG producing cells). In panel (B), 
representative examples are shown for background, CMV-specific and total IgG ASC as 
determined within CMV-seropositive and CMV-seronegative patients. In panel (C), individual 
and median (detectable) CMV-specific and total IgG ASC, corrected for background (number 
of spots in absence of a coating antibody) for CMV-seropositive (open symbols) and CMV-
seronegative (closed symbols) patients are depicted. * P<0.05; *** P<0.001
CMV-seropositive patient (right panel).  Percentages of CMV-specific proliferating CD4+ and 
CD8+ T cells, corrected for frequencies of proliferating CD4+ or CD8+ T cells in absence of a 
stimulus, are depicted in panels (C,E), respectively. A dissection of uncorrected CMV lysate- 
or peptide-induced proliferating T cells (set to 100%) into those lacking or expressing CD28 
are shown in panels (D,F) for CD4+ and CD8+ T cells, respectively. CMV-seronegative (with a 
detectable response) and CMV-seropositive patients are shown in closed and open symbols, 
respectively, and bars represent medians and interquartile range of the patient groups. * 
P<0.05; ** P<0.01
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CMV-associated T-cell defects mimicking T-cell ageing are not present in CMV-
seronegative patients with CMV-specific T cells
CMV latency leaves a clear fingerprint on the T cell immune system. The CMV-
associated changes in the circulating T cell compartment of CMV-seropositive ESRD 
patients comprise of a reduced telomere length, significant expansion of the CD8+ 
T cell pool and increased differentiation status of the memory T cells, notably the 
induction of CD28null T cells in both CD4+ and CD8+ T cells (21, 22). However, such 
changes were not observed when comparing CMV-seronegative patients with and 
without detectable CMV-specific CD137-expressing IFNγ producing CD4+ T cells ( 
Table 2).
DISCUSSION
In the present study, we evaluated the presence of CMV-specific cellular and 
humoral immunity in a cohort of CMV-seronegative patients and assessed the clinical 
relevance with respect to the risk for a CMV-viremia after kidney transplantation. 
Data revealed the presence of a low frequency of CMV-specific T-cells in over half of 
these patients. Interestingly, in particular IFNγ producing CMV-specific CD4+ T cells 
were associated with  protection from CMV-viremia following transplantation with a 
kidney from a CMV-seropositive donor. Thus a protective anti-CMV cellular immunity 
may exist in the absence of serum anti-CMV IgG. 
Presence of cellular immunity in the absence of protective antibodies is not 
uncommon.  Possible explanations for this disassociation may be that either cellular 
immunity is inefficient to induce adequate humoral immunity (6, 7) or that protective 
antibodies are not adequately maintained. Both these mechanisms may hold true for 
patients with end-stage renal disease. It is known that T-cell dependent vaccines (e.g. 
HBsAg, tetanus toxoid, diphtheria) are poor inducers of protective antibody titers in 
these patients and antibody titers are poorly maintained (23-25). A detailed analysis 
of the dynamics and quality of the antigen-specific T cell response after vaccination 
with HBsAg in ESRD patients showed a poor generation of memory CD4+ T cells 
(6, 7). In particular, the presence of antigen-specific CD4+ EM T cells correlated 
significantly with the titers of anti-HBsAg and a similar relation could be shown for 
anti-CMV IgG. The results of this study also showed a statistically significant relation 
between the presence of IL-2 or IFNγ producing CMV-specific CD4+ T cells and anti-
CMV IgG ASC. Therefore, a weak induction of a CMV-specific T cell response may 
underlie the inadequate generation of an anti-CMV humoral response. In addition, 
it could still be possible that a low but detectable anti-CMV humoral response was 
generated initially but not adequately maintained.
Although there may be concerns associated with  reliably measuring low frequencies 
of CMV-specific T cells, the multi-parameter CD137 flow cytometric assay as 
described previously(17), allows for a detailed characterization of total pool of 
antigen-specific T cells which is related with other parameters analyzed within this 
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paper and is associated with clinical outcome, i.e CMV-viremia. The detailed analysis 
of the CMV-specific response within T cell subsets revealed that CMV-specific 
memory CD4+ and CD8+ T cells were less differentiated in the CMV-seronegative 
patients than in CMV-positive patients. This was evident by relatively more CD28+ 
memory T cells and less CMV-specific T cells producing effector cytokines like 
IFNγ and IL-2. Of interest was the detection of a CMV-specific CD137+ response 
in phenotypically naive T cells that did not produce cytokines. These cells may be 
part of so-called early branched off memory T cells that are phenotypically naive T 
cells but are in fact memory T cells in an early developmental stage of which some 
are able to exert effector function (26). Again this finding supports the concept of 
a less well-differentiated CMV-specific T-cell response. In this respect, a paper by 
Redeker et al. (27) nicely illustrated, in a mouse model, the large inter-individual 
variations in the height of the CMV-specific T cell responses to be dependent on 
the initial viral load which also influences the extent of memory T-cell inflation and 
phenotype of CMV-specific T cells. CMV-infection generally leads to long-lasting 
substantial changes in circulating T cells, even more so in ESRD patients(13, 28-31). 
In particular, highly differentiated EMRA T cells lacking CD28 T cells are expanded 
in the CD8+ T cell population and to a lesser extent in the CD4+ T cell population 
(13-15). This typical footprint of CMV-infection in the composition of circulating T 
cells was not found in the CMV-specific T cells of CMV-seronegative patients. This 
indicates that these patients have encountered CMV but only mounted a limited T 
cell response. The most likely explanation is low-level of exposure to viral antigens 
that may not result in the specific imprint induced by high viral antigen exposure 
which results in sustained CMV-specific IgG serum titers (32, 33). Furthermore, a 
proportion of CMV-seropositive patients, had no or low frequencies of CMV-specific 
CD8+ T cells but had CMV-specific CD4+ T cells as well as CMV-IgG producing cells 
prior to transplantation, that were sufficient to prevent from a CMV reactivation. This 
was in contrast with a paper by Tey et al. that described  hematopoietic stem cell 
transplant recipients, a different group of immunocompromised patients, deficient in 
reconstituting CMV-specific immunity to have higher viral loads (34).  Our data are 
remarkably consistent with a recent study by de Lucia et al. (11) that identified CMV-
specific T cell responses in 30% of CMV seronegative individuals. However, their 
data were generated by ELISpot and therefore lack a more in-depth analysis of the T 
cell subsets involved. They also claim the detection of CMV-specific memory B cells 
but frequencies were unfortunately not reported. 
In conclusion, assessment of anti-CMV-IgG does not seem to suffice for properly 
identifying CMV-naive individuals, as a significant proportion has a weak cellular 
CMV-specific response, which is associated with protection against CMV-viremia 
after transplantation with a CMV-seropositive donor kidney. We therefore propose 
to include assessment of cellular immunity in the risk assessment prior to kidney 
transplantation. Furthermore, monitoring of CMV-specific cellular immunity following 
transplantation, i.e. at the end of anti-CMV prophylaxis might be useful for further 
identifying patients at risk for a CMV viremia, requiring additional anti-viral therapy or 
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Fig. S1 Typical gating strategy for CMV-specific CD137-expressing and cytokine producing CD4+ T cells. A typical flow-cytometric example is depicted 
for analysis of CMV-specific CD137-expressing and cytokine producing CD4+ T cells for a CMV-seropositive (A-C) and CMV-seronegative (D-F) patient. 
Briefly, based on forward/sideward characteristics live cells are gated and depicted in a dot plot to further select CD4+ and CD8+ T cells. The CMV-
specific CD137-expressing CD4+ T cells are selected [(A,D), first plot] as well as the IFNγ and IL-2 cells within CD137-expressing CD4+ T cells [(A, D), 
second plot]. CD137-expressing CD4+ T cells are subsequently dissected into naive and different memory T cell subsets [(A, D), third plot] using CCR7 
and CD45RO expression (CCR7+CD45RO-: naive, CCR7+CD45RO+: CM, CCR7-CD45RO+: EM and CCR7-CD45RO-: EMRA) or CD28+ and CD28null T 
cells [(A, D), fourth plot]. IFNγ (B, E) as well as IL-2 (C, F) producing CD137-expressing CD4+ T cells were analyzed in a similar way. Furthermore, the 
same approach was also applied for analysis of CMV-specific CD137-expressing and cytokine producing CD8+ T cells (not shown). Percentages  of 
CD137-expressing CD4+ T cells are of total CD4+ T cells and percentages of cytokine+ within CD137+ CD4+ T cells are given as a proportion of CD137+ 
CD4+ T cells (set to 100%) and in brackets the frequency of CD137+ cytokine+ within total CD4+ T cells is depicted. The dissection with respect to a 
certain T-cell phenotype is done by setting the % of CD137+ or CD137+cytokine+ CD4+ T cells to 100% 
adjustment of immunosuppressive medication (35).
Acknowledgements
This research was fi nancially supported by the Dutch Kidney Foundation 
(KSPB.10.12) and the China Scholarship Council funding the PhD fellowship of 
Ling Huang (fi le no: 201307720043).
Disclosures
The authors have no confl icts of interest to disclose.
Protective cytomegalovirus (CMV)-specifi c T-cell immunity is frequent in kidney transplant 
patients without serum anti-CMV antibodies 
151
6
SUPPORTING INFORMATION
Fig. S1 Typical gating strategy for CMV-specifi c CD137-expressing and cytokine producing 
CD4+ T cells. A typical fl ow-cytometric example is depicted for analysis of CMV-specifi c 
CD137-expressing and cytokine producing CD4+ T cells for a CMV-seropositive (A-C) and 
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specific CD137-expressing CD4+ T cells are selected [(A,D), first plot] as well as the IFNγ and IL-2 cells within CD137-expressing CD4+ T cells [(A, D), 
second plot]. CD137-expressing CD4+ T cells are subsequently dissected into naive and different memory T cell subsets [(A, D), third plot] using CCR7 
and CD45RO expression (CCR7+CD45RO-: naive, CCR7+CD45RO+: CM, CCR7-CD45RO+: EM and CCR7-CD45RO-: EMRA) or CD28+ and CD28null T 
cells [(A, D), fourth plot]. IFNγ (B, E) as well as IL-2 (C, F) producing CD137-expressing CD4+ T cells were analyzed in a similar way. Furthermore, the 
same approach was also applied for analysis of CMV-specific CD137-expressing and cytokine producing CD8+ T cells (not shown). Percentages  of 
CD137-expressing CD4+ T cells are of total CD4+ T cells and percentages of cytokine+ within CD137+ CD4+ T cells are given as a proportion of CD137+ 
CD4+ T cells (set to 100%) and in brackets the frequency of CD137+ cytokine+ within total CD4+ T cells is depicted. The dissection with respect to a 
certain T-cell phenotype is done by setting the % of CD137+ or CD137+cytokine+ CD4+ T cells to 100% 
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Fig. S2 CD137-expressing and cytokine producing T cells upon stimulation with PMA and 
ionomycin. Peripheral mononuclear cells of patients were stimulated for 12-hours in presence 
of brefeldin A and αCD49d alone or with a mixture of PMA and ionomycin. Subsequently, 
cells are cell-surface and intracellular stained to determine the maximal capacity of T cells to 
express CD137 and produce cytokines. PMA/ionomycin-induced CD137-expressing CD4+ (A) 
and CD8+ (B) T cells, corrected for background (αCD49d only), are depicted as a percentage 
of total CD4+ or CD8+ T cells. A similar approach is followed for PMA/ionomycin-induced 
CD 137-expressing IFN-g and IL-2 producing CD4+ (C,E) and CD137-expressing IFN-g CD8+ T 
cells (D). Closed and open symbols/bars represent CMV-seronegative and CMV-seropositive 
patients, respectively.
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SUMMARY
The number of patients suffering ESRD, especially the proportion of elderly patients 
keeps growing rapidly (1). ESRD is accompanied by an impaired T cell immune 
system (2).  This uremia-associated immune deficiency is reflected by a poor 
vaccination efficacy (3-6), an increased susceptibility for infections (7-9) and a high 
risk for developing tumors (10-13). Uremia-associated immune deficiency thereby 
contributes to the increased  morbidity and mortality observed in ESRD patients 
(14, 15).  Previous studies have shown that ESRD-associated changes in peripheral 
T cells are compatible with the concept of premature immunological ageing. This 
means that T cell characteristics of ESRD patients are on average similar to those of 
healthy individuals (HI) who are 15-20 years older over a wide range of age (20-80 
years). The impact of premature immunological ageing and factors influencing this 
phenomenon in the elderly ESRD patients (>65 years) is of particular interest given 
the increase in elderly ESRD patients in  recent years. One of the major factors 
that needs to be taken into account is a previous infection with cytomegalovirus 
(CMV). CMV is a highly prevalent herpes virus which after primary infection (usually 
at an early age) establishes latency in the host after leaving a clear foot print in the 
circulating T-cell population. 
Individuals with CMV latency can be easily detected by the presence of anti-CMV 
antibodies (CMV-seropositive) and the substantial impact on the composition and 
function of circulating T cells. This CMV-related impact includes changes in T-cell 
composition which are associated with T-cell ageing. The aim of this thesis is to 
improve our understanding of the ESRD-associated defective T-cell mediated 
immune system by evaluating functional in addition to phenotypic aspects, thereby 
taking into account the impact of CMV. A better understanding is needed, particularly 
in elderly ESRD patients to facilitate personalized immunosuppression thereby 
contributing to a better patient outcome after transplantation. 
ESRD, the immune status of ESRD patients, the concept of premature ageing, 
different T-cell ageing parameters and the role of CMV infection are introduced in 
chapter 1. We briefly highlight the traditional parameters for evaluating T-cell ageing 
and describe relatively new promising tools for evaluating the immune status of an 
ESRD patient in more detail taking into account phenotypic (TCR Vβ-repertoire 
diversity) as well as functional (signaling pathways) aspects upon TCR-mediated 
activation of T cells.
The effects of ESRD and CMV on circulating T cells of elderly ESRD patients were 
studied in chapter 2. CMV latency is associated with enhanced T-cell differentiation 
in both elderly patients and age-matched HI. The effects of ESRD on T cells mainly 
exist within the CMV seropositive population. CMV seropositive elderly patients 
had less thymic output, a reduction in numbers of naive and CM T cells, and their 
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T cells had shorter telomeres compared with CMV seropositive HI. Most of these 
ageing parameters were comparable between elderly CMV seronegative patients 
and elderly CMV seronegative HI except for a lower number of CM T cells observed 
in elderly CMV seronegative patients. These findings indicate that the premature 
immunological ageing effect of ESRD in the elderly ESRD patients is very limited in 
CMV-seronegative patients. However, CMV latency drives to a significant extent the 
ageing of the peripheral T cell compartment in elderly ESRD patients.  
A diverse (polyclonal) TCR Vβ-repertoire capable of recognizing a broad range of 
foreign antigens is key to an effective T-cell mediated immune response (16) and is 
known to decrease with ageing (17). The TCR Vβ-repertoire diversity was assessed 
in ESRD patients by qualitative multiplex DNA-based spectratyping in Chapter 3; We 
found ESRD to skew the TCR Vβ-repertoire and this skewed TCR Vβ-repertoire was 
mainly observed within isolated CD8+ memory T cells. Using a multiple binary logistic 
regression model, CMV seropositivity was found to contribute the most to skewing 
of the TCR Vβ-repertoire followed by ESRD and age. Based on these findings, 
this skewed TCR Vβ-repertoire was further examined in more detail. In Chapter 
4, we investigated TCR Vβ-repertoire within T-cell subsets in ESRD patients using 
a quantitative flow cytometry-based approach, which covers 24 different TCR Vβ-
families. The Gini-index, a parameter used in economics to describe the distribution 
of income, was calculated to determine the extent of skewing. In this study, using 
age- and CMV serostatus-matched HI as a reference population, we found young 
ESRD patients to already have significantly higher Gini-TCR indices for different 
CD8+ memory T cell subsets. ESRD induced expansions of not one TCR Vβ-family 
in particular and expansions were predominantly observed within the CD8+ T cell 
compartment. Interestingly, clonal expansions were already observed within naive 
CD8+ T cells. This skewed TCR Vβ-repertoire may be associated with a less broad 
and diverse T-cell mediated immunity in ESRD patients.
Important signal transduction pathways engaged upon T-cell activation include ERK 
and p38, both belonging to the MAPK family, which are known to be affected in the 
elderly HI. In Chapter 5, we studied effects of ESRD on more upstream signaling 
pathways of TCR-mediated T-cell activation. Young HI had a significantly higher 
TCR-induced pERK in total CD4+ T cells and subsets compared to elderly HI. 
Interestingly, this age-associated decline in phosphorylation of ERK was not found 
in ESRD patients and pERK-levels from young ESRD patients were in between 
young and elderly HI. The phosphorylation level of ERK was positively associated 
with frequency of CD69-expressing CD4+ T cells upon TCR-induced activation of T 
cells. Increased levels of DUSP6 might be one of the mechanism contributing to this 
defective phosphorylation of ERK as inhibition of DUSP6 significantly increased the 
pERK level in elderly HI and both young as well as old ESRD patients. In addition, we 
found a higher baseline level of p38  in the highly differentiated T cells compared with 
naive T cells, which may contribute to the uremia related defective T-cell immunity. 
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CMV IgG-seronegative (CMVneg) patients receiving kidneys from CMV IgG-
seropositive (CMVpos) donors are at high risk to develop a CMV infection, but still 
a considerable proportion (30%-40%) of this group does not experience a CMV 
infection(18). Therefore, we hypothesized that CMV-specific cellular immunity may 
exist in a fraction of CMVneg patients that may prevent from a CMV infection in CMVneg 
recipients receiving kidneys from CMVpos donor. In Chapter 6, we showed that low 
frequencies of CMV-specific T cells frequently exist in part of the CMVneg  patients 
and that these cells are of a less differentiated memory phenotype when compared 
to those from CMVpos patients. CMV-specific IgG-antibody secreting cells could also 
be detected at low frequencies in a fraction of CMVneg  patients. Interestingly, pre-
transplant CMV-specific CD137+IFNγ+CD4+ T cells in  CMVneg  recipients may protect 
against  CMV viremia  after transplantation with a  CMVpos donor kidney.  
DISCUSSION
The overall aim of this thesis was to improve our understanding of the T-cell mediated 
immune system in elderly ESRD patients before kidney transplantation by evaluating 
both phenotypic as well as functional aspects. A more in depth characterization of 
the T-cell mediated immunity might allow for a proper risk assessment with respect 
to rejection and facilitate individualized immunosuppressive regimes. 
Proper immunosuppressive therapy is essential for a successful kidney 
transplantation. The ideal protocol is to effectively prevent acute and chronic allograft 
rejection and also avoid the immunosuppressive drug related adverse effects. Elderly 
ESRD patients may have a lower risk for rejection compared to young patients (19-
22) due to immunosenescence, and be suitable for minimizing immunosuppressive 
drugs (23). A re-evaluation of current immunosuppressive regimes is warranted 
especially as the proportion of elderly ESRD patients has increased over the last 
decades. However, the calendar age may not be similar to the immunological T cell 
age. Previous research has demonstrated that the uremic environment present in 
ESRD patients induces premature T-cell ageing and a discrepancy of 15-20 years 
between the patient’s calendar age and immunological age of T cells was noted.  A 
more in-depth analysis of the impact of uremia-associated premature T-cell ageing 
in elderly ESRD patients is lacking but of significant interest as in these patients the 
highest impact of T-cell ageing on immune function may be expected. Therefore, a 
comprehensive assessment of T-cell immunity needs to be established in  elderly 
ESRD patients.   
T-cells can be characterized by several (ageing) parameters, including thymic 
output, phenotyping (assessing both T-cell numbers and differentiation status), 
telomere length, diversity of TCR repertoire and activation of TCR-induced signaling 
pathways.   
CMV has a substantial impact on the composition and function of circulating T cells. 
Recent studies have shown that CMV latency expands the number of circulating 
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CD8+ T cells significantly by almost twofold (24), promotes the emergence of 
highly differentiated T-cell subsets (25),  induces T cell telomere attrition (26), and 
contraction of the TCR Vβ-repertoire in immunocompetent individuals. This vast 
expansion of CMV specific T cells may exceed 4% of CD8+ T cells (27) and these 
anti-CMV T cells clones are stably maintained for 5 years (28).
The effects of ESRD on T cells mainly exist within elderly CMV seropositive 
patients compared with elderly CMV seropositive HI, as elderly patients had less 
thymic output, a reduction in numbers of naive and CM T cells, and T cells had 
shorter telomeres. Increased levels of oxidative stress and inflammatory cytokines 
caused by retention of uremic toxins (29, 30), together with cumulative exposure to 
antigens and environmental free radicals during ageing(31), contribute to the pro-
inflammatory environment and advanced ageing in elderly ESRD patients. Elevated 
concentrations of serum or plasma TNF-α are associated strongly with progressive 
loss of renal function (32) and this TNF-α-induced apoptosis may be an explanation 
of the loss of naive and CM in elderly ESRD patients (33, 34). In addition, CMV 
latency leads to a dramatic accumulation of CD28-  T cells in both elderly HI and 
patients. Higher frequencies of CD28- T cells are present within CD8+ T cells (up to 
20-30%) compared to CD4+ T cells in the peripheral blood (35-37). CD4+CD28- T cells 
are probably involved in destabilizing atherosclerotic plaques and are related with 
cardiovascular disease in ESRD patients (38). CD8+CD28- T cells  represent highly 
cytotoxic T cells producing IFN-γ but no IL-4 and very little IL-2 upon responding to 
CMV antigen (39). Both uremia and CMV accelerate the ageing process in elderly 
patients, however, since most differences of ageing parameters between elderly 
patients and elderly HI are observed within the CMV seropositive population but 
not CMV seronegative population, CMV infection is a driver of ageing in the elderly 
ESRD patients. Following a primary CMV infection, CMV becomes latent and 
keeps challenging the host immune system. Compared with immunocompetent HI, 
immunocompromised individuals, such as ESRD patients, are supposed to have 
more highly differentiated T cells responding to CMV virus to keep control over the 
virus. With increasing age, the CMV seronegative ESRD patients and HI converge 
in their T cell ageing characteristics when assessed by traditional ageing markers. 
We speculated ESRD may influence the ageing process in elderly patients in other 
aspects, then the new T cell ageing parameters were further tested in the elderly 
ESRD patients. 
A diverse TCR Vβ-repertoire is crucial for an effective T-cell mediated immune 
response. Naive T cells migrating from the thymus into the circulation possess the 
broadest TCR repertoire (40). The memory T cells that develop upon encountering 
of an antigen have a repertoire that is being skewed towards particular specificities 
(41). Ageing induces reduction of naive compartment and relatively expands memory 
compartment, it also caused the skewing of the TCR Vβ-repertoire composition in 
elderly population. The TCR Vβ-repertoire can be assessed using several approaches 
such as gene scan spectratyping (42), flow-cytometry (43-45), and next generation 
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sequencing (NGS) (46, 47). We used the multiplex DNA-based spectratyping which 
is a semi-quantitative assessment to have an overview of the TCR Vβ-repertoire 
in our patient population. Since elderly ESRD patients with CMV seropositivity had 
less thymic output and a reduction in numbers of naive and CM T cells compared 
with CMV seropositive HI, it was no surprise that we found CMV-seropositive ESRD 
patients  to have a skewed TCR Vβ-repertoire compared with CMV-seropositive HI. 
Interesting, the skewed TCR Vβ-repertoire is also observed in CMV-seronegative 
elderly ESRD patients when compared with CMV-seronegative elderly HI, whilst 
having similar numbers of naive T cells . This indicates TCR Vβ clonal selection, 
several clones may be expanded and some clones may have- shrunken  meanwhile, 
in  elderly ESRD patients. Then we used a flow cytometry-based approach to 
evaluate TCR Vβ-repertoire diversity, which results in a more accurate quantitative 
measurement, assessing percentages of TCR Vβ-families at the T-cell subset level 
obviating the need for cell sorting. We found ESRD to induce skewing already within 
naive T cells and but a skewed repertoire was mainly present in highly differentiated 
memory CD8+ T cells. ESRD did not affect one TCR Vβ-family in particular, indicative 
of expansions of different clonal origin, that may be induced by different underlying 
kidney diseases. Moreover, CMV latency induced a vast expansion of CMV-specific 
T cells, which may also alter the TCR Vβ-repertoire . This skewed TCR Vβ-repertoire 
composed of  selective TCR clones , causes a quick response against specific 
antigens (e.g. CMV),  but in the meantime, the narrowed TCR Vβ-repertoire diversity 
compromises the possibility to respond to a newly encountered antigen(48). 
Studying signaling pathways in immune cells has been a ‘hot topic’ in the last several 
years. The MAPK pathway including ERK and p38 is one of the major pathways 
induced upon TCR-stimulation(49). Recently, ERK activity through phosphorylation 
is reported to be associated with ageing. Elderly HI showed decreased TCR-induced 
ERK phosphorylation from naive CD4+ T cells compared with young HI (50). Low ERK 
activity impairs TCR-induced activation, increases sensitivity of cells to apoptosis 
and reduces cell proliferation (51). As expected, TCR-mediated phosphorylation 
of ERK in CD4+ T cells of young patients was in between young and old HI (52). 
This reduced ERK phosphorylation downregulates the early T-cell activation marker 
CD69 (52) and may be related to a defective activation of T cells in lymph nodes (53). 
Increased levels of DUSP6 might be one of the factors responsible for this defective 
phosphorylation of ERK (50). Inhibition of DUSP6 can restore TCR-induced ERK 
phosphorylation in elderly HI and ESRD patients. Increasing ERK phosphorylation 
could be a potential target to restore TCR-mediated immune responses and increase 
for example the vaccination efficiency. We found the baseline of p38 phosphorylation 
to be positively associated with the differentiation status. The canonical pathway 
of p38 phosphorylation is mediated by MAPK kinases (MKKs) upon triggering of 
the TCR (54). However, highly differentiated CD27-CD28-CD4+ T cells, accumulated 
in elderly HI, have an unique MKK-independent mechanism to phosphorylate p38 
via 5’ adenosine monophosphate activated protein kinase (AMPK) and transforming 
growth factor-β-activated protein kinase1 (TAK1)-binding protein 1 (TAB1) (55). 
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Sestrin increases the baseline of p38 phosphorylation of CD27-CD28-CD4+ T 
cells through AMPK pathway. Silencing of AMPK, TAB1 or sestrin enhances T-cell 
mediated immunity in elderly HI (56). Therefore, the uremia-mediated defect in TCR-
induced phosphorylation of ERK and high baseline phosphorylation of p38, may 
contribute to the impaired T-cell mediated immune response in ESRD patients.
CMV infection is one of the most common infections in the ESRD patients (57), which 
usually dramatically changes the T cells composition and function. Interestingly, 
our data reveal a considerable percentage (>50%) of CMV seronegative ESRD 
patients have a low frequency of CMV-specific T cells, which is in agreement with 
others(30%) (58). This emphasizes that the initial viral load of CMV is of importance, 
since low viral load may lead to CMV-specific cellular immunity to prevent the CMV 
viremia, but this may not suffice to induce adequate humoral immune responses 
(59, 60) or to maintain protective antibodies (61). CMV vaccination may have the 
similar effect to induce cellular response as a low viral load of CMV (62, 63). It may 
have little impact on the T-cell ageing parameters but protect ESRD patients from 
CMV infection. CMV vaccination could be essential to prevent excessive ageing in 
the elderly ESRD patients if they were vaccinated at an early age before ESRD and 
CMV infection. 
We have shown ESRD patients to have a prematurely aged T-cell mediated immune 
system by assessing several ageing parameters. Ageing and CMV latency may have 
an additional effect on this defective T-cell mediated immunity. We propose ESRD 
patients with a low number of naive T cells, high percentage of highly differentiated 
memory T cell subsets, T cells with short telomeres, skewed TCR Vβ-repertoire, 
low TCR-induced ERK phosphorylation and high baseline of p38 phosphorylation 
to represent the low risk group with respect to rejection and potential candidates for 
lowering immune suppressive drugs. How to define the threshold for each parameter 
requests a large cohort to be investigated. CMV vaccination at an early age before 
ESRD and CMV infection maybe a practical strategy to prevent the advanced ageing 
in the elderly ESRD patients. In fact, the allograft immune response is a complicated 
process, which may be influenced by the recipients immune system, quality of donor 
kidney, surgery procedure, dynamic effect of immunosuppressive drugs and so on. 
It might not be  possible to find one specific biomarker to correctly predict the clinical 
outcomes after renal transplantation such as acute and chronic rejections. However, 
a comprehensive and careful assessment of the T-cell immune state taking into 
account the different aspects as mentioned above can contribute to establish an 
immune profile. Based on those profiles, we would gain more knowledge about 
how to identify patients with low risk of rejection. Then it would be very interesting 
to investigate if those low risk patients could benefit from low immunosuppressive 
drugs treatment.
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CONCLUSIONS 
In this thesis, we demonstrated that the defective T cell immune system from ESRD 
patients can be evaluated in more depth  using  relatively new phenotypic and functional 
in addition to the traditional T-cell ageing parameters. A declined number of naive, 
more highly differentiated memory T cells, reduced telomere length, skewed TCR 
Vβ-repertoire, declined TCR-induced ERK phosphorylation and elevated baseline of 
p38 phosphorylation are important features of a defective T-cell mediated immunity 
in ESRD patients. Ageing and CMV infection accelerate this premature T-cell ageing 
process. In addition, we demonstrate the role of CMV-specific cellular immunity in 
preventing CMV infection after kidney transplantation. Comprised T-cell mediated 
immunity seems to be a double-edged sword  for ESRD patients. A defective T-cell 
mediated immune system in ESRD patients, especially elderly ESRD patients, may 
contribute to a lower vaccination efficacy, more severe infections but on the other 
hand reduce the risk for allograft rejection after transplantation. Overall, the work 
described in this thesis provides new insights for evaluating T cell immunity in ESRD 
patients. Those insights may allow identification of ESRD patients at low risk of a 
rejection and allow development of strategies for individualizing immunosuppressive 
regimes.
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De belangrijkste functie van de nier is het verwijderen van afvalstoffen en overtollig 
vloeistof uit het lichaam. Verschillende aandoeningen waaronder bijvoorbeeld hoge 
bloeddruk of suikerziekte kunnen leiden tot chronisch verlies van nierfunctie.  Het 
chronisch verlies van nierfunctie kan onderverdeeld worden in 5 stadia, op  basis van 
de overgebleven functie van de nier. Het laatste stadium wordt ook wel eindstadium 
nierfalen genoemd. De overgebleven nierfunctie is dan minder dan 10 procent van 
de normale nier capaciteit, wat betekent dat de nier niet meer goed  functioneert. 
Behandeling van patiënten met eindstadium nierfalen bestaat uit dialyse 
(hemodialyse or peritoneale dialyse) of niertransplantatie. De voorkeur gaat uit naar 
niertransplantatie vanwege het feit dat dit leidt tot een betere kwaliteit van leven en 
een hoger overlevingspercentage. Voor een succesvolle behandeling is er maar één 
nier nodig. Deze kan gedoneerd worden door een levende of overleden donor. In 
het algemeen, is het gebruik van een nier van een levende donor beter dan van een 
overleden donor. Voor een succesvolle niertransplantatie is het levenslang gebruik 
van afweer onderdrukkende medicijnen van belang om de kans op afstoting van de 
nier te minimaliseren en te blijven leven. Veel van deze medicijnen zijn gericht tegen 
T cellen, bepaalde cellen van ons afweersysteem, die een belangrijke rol spelen bij 
het behoud van het orgaan. Langdurig gebruik van deze afweer onderdrukkende 
medicijnen gaat echter gepaard met bijwerkingen zoals een verhoogde kans op 
infecties, ontwikkeling van kanker en veel van deze medicijnen zijn uiteindelijk weer 
toxisch voor de donornier. 
Bijna elke niertransplantatie ontvanger krijgt dezelfde afweer onderdrukkende 
medicatie voorgeschreven maar er zitten grote verschillen tussen de diverse 
ontvangers. Zo is de proportie oudere (>65 jaar) patiënten met eindstadium nierfalen 
sterk toegenomen in de afgelopen jaren. Met het toenemen van de leeftijd verandert 
echter ook ons T cel afweersysteem. Bovendien hebben wij recent laten zien dat 
verlies van nierfunctie gepaard gaat met een vervroegde veroudering van het T cel 
afweersysteem.  Het T cel afweersysteem van een jonge patiënt met eindstadium 
nierfalen is vergelijkbaar aan dat van een 15-20 jaar oudere gezond individu. Er is 
dus een discrepantie tussen de kalenderleeftijd en de immunologische leeftijd van T 
cellen. Om de juiste dosering/type afweer onderdrukkende medicatie vast te stellen 
voor de individuele patiënt is het in kaart brengen van factoren die mogelijk een rol 
spelen bij o.a. afstoting van een orgaan van belang. Een van deze factoren betreft 
een zo goed mogelijke karakterisatie van het T-cel gemedieerde afweersysteem.
Het voornaamste doel van dit proefschrift was dan ook om een beter begrip te 
hebben van de conditie van het T-cel gemedieerde afweersysteem van patiënten met 
eindstadium nierfalen vόόr transplantatie door zowel fenotypische als functionele 
eigenschappen te bestuderen met daarbij speciale aandacht voor de oudere 
nierpatiënt. 
In hoofdstuk 1, wordt het concept premature T cel veroudering geïntroduceerd en 
passeren de  verschillende traditionele en nieuwere (waaronder ook functionele) 
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parameters om de conditie van T cellen te bepalen in patiënten met eindstadium 
nierfalen, de revue. De traditionele parameters betreffen het bepalen van de 
functie van de thymus, T cel differentiatie status, telomeerlengte van T cellen. De 
functie van de thymus kan worden bestudeerd door de frequentie naïeve T-cellen 
die net uit de thymus komen en/of de hoeveelheid T cel receptor excisie cirkels 
te bepalen. Het bepalen van de T cel differentiatie status kan worden gedaan 
door naast het aantal antigen-onervaren (naïeve) en ervaren (geheugen) T 
cellen ook eigenschappen die verder onderscheid maken tussen minder en meer 
gedifferentieerde T cellen te bestuderen. Telomeren zijn repetitieve nucleotiden aan 
het einde van chromosomen, welke bij elke deling korter worden totdat de cel dood 
gaat of verouderd. Als nieuwe parameters zal ook diversiteit van het T cel receptor 
repertoire en belangrijke moleculen bij signaaloverdracht na activatie van de T cel 
receptor bestudeerd worden.  Verlies van nierfunctie, een cytomegalovirus (CMV) 
infectie en veroudering hebben allemaal invloed op de immunologische leeftijd van 
patiënten met eindstadium nierfalen, daarom dient rekening te worden gehouden 
met deze factoren bij het beoordelen van de conditie van het T-cel afweersysteem.
In hoofdstuk 2, werden de traditionele alsook een functionele T cel parameter 
bestudeerd in oudere nierpatiënten. Oudere nierpatiënten hadden een verder 
gevorderd verouderd T cel afweersysteem wanneer vergeleken met leeftijds-
gematchde gezonde individuen voor wat betreft de meeste traditionele parameters. 
Dit werd met name gezien wanneer de CMV seropositieve individuen werden 
vergeleken. De T-cel proliferatie capaciteit was niet verschillend tussen patiënten 
met eindstadium nierfalen en leeftijds- en CMV serostatus-gematchde gezonde 
individuen.  
In hoofdstuk 3 en 4 werd door middel van een aantal methoden de diversiteit van 
het T-cel receptor (TCR) repertoire bepaald in patiënten met eindstadium nierfalen 
en leeftijds- en CMV serostatus-gematchde gezonde controles. Een brede diversiteit 
is cruciaal voor het ontwikkelen van een effectieve T-cel gemedieerde respons. 
Patiënten met eindstadium nierfalen hadden een minder divers TCR repertoire 
dan leeftijds- en CMV serostatus-gematchde gezonde individuen. Een meer 
gedetailleerde analyse liet zien dat deze gereduceerde diversiteit al zichtbaar was 
in de naïeve T cellen door een toegenomen aantal expansies van bepaalde TCR 
receptor families. Echter ook de geheugen en met name de CD8+ T cellen hadden 
een minder divers TCR repertoire.  
Nadat de TCR een antigen tegenkomt, worden een aantal signalen in de cel 
doorgegeven door middel van activatie (o.a. fosforylatie) van aantal moleculen 
zodat de T cel verder geactiveerd raakt. Extracellular signal–regulated kinase (ERK) 
en p38 zijn twee cruciale moleculen voor deze TCR-gemedieerde activatie van T 
cellen. In hoofdstuk 5 lieten wij zien dat in patiënten met eindstadium nierfalen de 
TCR-gemedieerde ERK activatie verminderd was, terwijl het basis niveau van p38 
activatie juist was gestegen. Deze verminderde activatie van ERK werd waarschijnlijk 
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veroorzaakt door een hogere expressie van duale specifieke fosfatasen 6 (DUSP6). 
Remming van DUSP6 herstelde de activatie (fosforylatie) van ERK. Een CMV 
infectie is één van de meest voorkomende infecties in niertransplantatie patiënten 
en ook een factor die de kans op acute afstoting kan vergroten.
Ontvangers die geen CMV antilichamen hebben in het bloed  en een orgaan 
ontvangen van een donor welke een CMV infectie heeft doorgemaakt, maken deel 
uit van de hoog risico groep en hebben een grotere kans op het ontwikkelen van 
een CMV infectie na transplantatie. In een deel van deze patiënten is echter wel een 
cellulaire respons tegen CMV detecteerbaar.  In hoofdstuk 6 werd deze cellulaire 
respons gericht tegen CMV gekarakteriseerd en het belang voor het ontwikkelen van 
een CMV infectie na transplantatie bestudeerd. Patiënten zonder CMV-specifieke 
antilichamen maar met een lage, minder gedifferentieerde, CMV-specifieke cellulaire 
(T-cel) respons hebben minder kans op het ontwikkelen van een CMV-infectie na 
transplantatie dan wanneer deze niet meetbaar was. 
In feite is de reactie op een transplantaat een gecompliceerd proces, welke kan 
worden beïnvloed door het immuunsysteem van de ontvanger, de kwaliteit van de 
donornier, de chirurgische procedure, het dynamische effect van immunosuppressiva 
en enz. Het is misschien niet mogelijk om één specifieke biomarker te vinden die 
klinische uitkomstmaten na een niertransplantatie, zoals acute en chronische 
rejectie, correct kan voorspellen. Een uitgebreide en zorgvuldige beoordeling van 
de conditie van de T cel door bepaling van de hierboven genoemde aspecten kan 
echter bijdragen aan het vaststellen van een immunologisch profiel van patiënten (op 
verschillende tijdstippen). Gebaseerd op deze profielen zouden wij meer informatie 
kunnen inwinnen met betrekking tot het identificeren van patiënten met bijvoorbeeld 
een laagrisico op afstoting. Daarnaast zou het interessant zijn om te onderzoeken of 
deze laag risico patiënten profijt zouden hebben van een lagere dosis van  of andere 
afweer onderdrukkende medicijnen.
Concluderend, we hebben aangetoond dat een verzwakt T-cel afweersysteem 
van patiënten met eindstadium nierfalen kan worden aangetoond op basis van 
verschillende verouderingsparameters. Deze patiënten hebben minder naïeve 
T-cellen en meer gedifferentieerde geheugen T-cellen, kortere telomeren, een 
minder divers TCR repertoire, minder TCR–gemedieerde fosforylatie (activatie) van 
ERK en hogere p38 baseline activatie. Veroudering en CMV infectie versnellen deze 
vroegtijdige verouderingsprocessen. Daarnaast  laten wij de rol van CMV-specifieke 
cellulaire responsen in afwezigheid van CMV-specifieke antilichamen zien bij het 
verhinderen van een CMV infectie na niertransplantatie met een CMV positieve 
donornier. 
Een verzwakte T-cel gemedieerde afweer lijkt een tweesnijdend zwaard te zijn 
voor patiënten met eindstadium nierfalen. Verminderde T-cel gemedieerde afweer 
in patiënten met eindstadium nierfalen, in het bijzonder in ouderen, draagt bij aan 
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een lage vaccinatie effectiviteit en een verhoogd risico op infecties. Desondanks 
hebben deze patiënten een laag risico op het krijgen van een afstoting. Over het 
algemeen biedt het werk dat in dit proefschrift beschreven wordt nieuwe inzichten 
voor het evalueren van de T-cel afweer bij patiënten met eindstadium nierfalen. Deze 
inzichten kunnen bijdragen aan de ontwikkeling van een meer gepersonaliseerd 
afweer onderdrukkende regime na transplantatie en zo de lange termijn bijwerkingen 
van afweer onderdrukkende medicijnen minimaliseren.
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